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"The natural course of pregnancy in diabetes even in the insulin era
can be summarised in the word destruction. Maternal survival can
be assured, but if a non-intervention program is followed only one
diabetic pregnancy in three terminates in a live, surviving infant"
Priscilla White 1959
Abstract
Pregnancy in women with spontaneous autoimmune-induced insulin-dependent
diabetes mellitus (IDDM) is associated with a perinatal mortality rate (PNMR) 2-4
times higher than that for non-diabetic pregnancy. This is due to increased rates of
(1) fetal early growth delay, (2) congenital malformation, (3) prematurity due to
spontaneous pre-term labour, and (4) babies small for gestational age. The
mechanisms underlying these phenomena have not been precisely defined but
circumstantial evidence suggests that they may result primarily from embryonic
damage in the earliest stages of pregnancy. Since practical and ethical considerations
limit direct investigation of these areas in human subjects, this hypothesis has been
examined directly using the BioBreeding/Edinburgh (BB/E) rat,- which spontaneously
develops autoimmune-induced IDDM,- as a model for the human disorder.
Established IDDM in the BB/E rat was associated with severe disturbance in the
development of the pre-implantation embryo, as indicated by (1) a five fold increase in
the number of unfertilised oocytes, (2) a reduced percentage of expanded blastocysts,
and (3) a -20 % inner cell mass (ICM) cellular deficit in embryos which reached the
expanded blastocyst stage. Moreover, blastocysts removed from diabetic rats and
cultured in vitro for 24 h showed no sign of 'catch-up' growth of the ICM, although
under these conditions, the trophectoderm (TE) exhibited a 25 % cellular accretion.
Data obtained from pregnant Diabetes Prone (DP) BB/E rats during the pre-diabetic
period (when the maternal metabolic profile was normal), showed that the full
complement of IDDM susceptibility genes was not in itself, sufficient to disturb early
complement of IDDM susceptibility genes was not in itself, sufficient to disturb early
embryo development and/or give rise to an ICM cell deficit. In addition, experiments
involving the transfer of two-cell embryos showed that the oviductal/uterine
environment of a Diabetic DP-BB/E recipient could induce not only an ICM deficit
but also a TE cell accretion in embryos from Non-Diabetic Diabetes Resistant (DR)
BB/E donor rats. However, transfer of two-cell embryos from Diabetic DP- into
Non-Diabetic DR-BB/E mothers did not prevent the development of an ICM cellular
deficit or a TE cell accretion,- implying earlier damage to the germ cells.
Greatly improved metabolic control was achieved in Diabetic DP-BB/E rats before
and over the period of conception using sustained release insulin implants. This
resulted in a reduction in the number of unfertilised oocytes, an increase in the
percentage of expanded blastocysts but no change in ICM cellular deficit.
A sensitive and accurate quantitative RT-PCR method was developed and used to
determine the ratio of bcl-2 (a cell death agonist gene) to bax (a cell death antagonist
gene) expression in single blastocysts from Diabetic DP- and Non-Diabetic DR-BB/E
rats. Although the bcl-2 to bax ratio was not significantly increased in blastocysts
from diabetic rats, these data demonstrate for the first time that bax and bcl-2 mRNA
is present in the pre-implantation embryo.
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Pregnancy in women with insulin-dependent diabetes mellitus (IDDM) is associated
with a high incidence of fetuses exhibiting early growth delay and congenital
malformation, babies small for gestational age, and spontaneous pre-term labour. The
mechanisms underlying the teratogenic effect of maternal IDDM have not been
precisely defined. It is however, recognised that these complications tend to be
associated with each other (in both diabetic and non-diabetic pregnancy) and are not
only responsible for the excess perinatal morbidity and mortality still incurred by
women with IDDM, but are also associated with long-term morbidity in children born
to these mothers.
In vivo studies of the pathogenesis of diabetic embryopathy have involved animals
with chemically-induced diabetes and have largely focused on the period of
organogenesis. Studies of the pre-implantation period are less common.
The aim of the study was to elucidate the mechanism of the teratogenic effect of
IDDM by studying the interaction of maternal genetic background and metabolic
profile on pre-implantation embryo development using the spontaneously diabetic,
insulin-dependent BB rat as a model for human IDDM. In addition, the effect of the
degree of diabetic metabolic control achieved before and at various points after




1.1 Diabetes Mellitus - what is it?
Diabetes mellitus is a common clinical syndrome characterised by an elevated level of
glucose in the blood (hyperglycaemia) and in the urine (glycosuria) due to an absolute
or relative deficiency of insulin. There are two main categories of diabetes: primary
and secondary diabetes. Primary diabetes can be further divided into two main clinical
types: insulin-dependent diabetes mellitus (or Type 1 diabetes) and non-insulin-
dependent diabetes mellitus (or Type 2 diabetes). At clinical presentation, insulin-
dependent diabetes mellitus (IDDM) is characterised by a virtual disappearance of
pancreatic (3 cells and hence an absolute deficiency of endogenous insulin. Without
insulin replacement therapy patients die rapidly in ketoacidosis. In contrast, most
patients with non-insulin-dependent diabetes mellitus (NIDDM) have only a moderate
reduction in pancreatic P cell mass, a relative deficiency of endogenous insulin,
insignificant ketonaemia, and mild symptoms. Most NIDDM patients can survive for
long periods of time without insulin treatment.
Diabetes may also occur secondary to (i) another pathology, either in the pancreas
(for example pancreatitis or neoplastic disease) or in other endocrine glands where
there is excess production of hormonal antagonists of insulin (such as growth
hormone, thyroid hormone, Cortisol, catecholamines or glucagon), or (ii) pregnancy.
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Diabetes occurring for the first time during pregnancy is known as Gestational
Diabetes Mellitus (GDM). GDM is a controversial area and a common clinical
problem. Several studies such as the one by Metzger et al (1), have emphasised the
heterogeneity of GDM indicating that women with previously undetected NIDDM as
well as women in the pre-diabetic period of both IDDM and NIDDM can be involved.
The hormonal/metabolic adaptation to pregnancy results in increased resistance to the
action of insulin. Maintenance of normoglycaemia requires a greater secretion of
insulin and those with pre-diabetes may be unable to meet this demand. GDM is
present in about 2 % of all pregnancies and is typically a disorder of the second half of
pregnancy. For this reason, the problems associated with untreated GDM mainly
consist of babies large for gestational age (macrosomia) and late intra-uterine death.
Diabetes may also be found associated with genetic syndromes such as Down's,
Klinefelter's or Turner's syndrome.
Diabetes is a world-wide problem and the incidence of both types of primary diabetes
is increasing. However, the prevalence of both varies considerably in different parts
of the world. In Britain, the prevalence of diabetes is between 1 and 2 %, with a 0.4
% incidence rate for IDDM in Caucasians of European descent (2,3). In Europe and
North America the ratio of NIDDM : IDDM is approximately 7:3, but it is estimated
that almost 50 % of cases ofNIDDM remain undetected.
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1.1.1 Metabolic Consequences of Insulin Deficiency
Insulin has profound effects on the metabolism of carbohydrate, protein, fat and
electrolytes. These can be divided into anabolic and anticatabolic actions. The
balance of these effects in the fasting and post-prandial states is controlled by (i) a
variation in the relative circulating concentration of insulin (the only anabolic
hormone) and several catabolic hormones - glucagon, growth hormone, Cortisol,
catecholamines and thyroid hormones, and (ii) the fact that insulin exerts its
anticatabolic effects at a lower concentration than that required for its anabolic
actions.
Diabetes mellitus is characterised by hyperglycaemia due to an absolute (IDDM) or
relative (NIDDM) lack of insulin. In both types of diabetes this leads to decreased
anabolism and increased catabolism. The metabolic consequences of untreated
diabetes mellitus are shown in Figure 1.1. At first, hyperglycaemia is only evident
after a meal but as the disease progresses and insulin deficiency becomes more severe,
fasting hyperglycaemia develops. One of the first metabolic derangements caused by
a lack of insulin is the inhibition of glucose utilisation in muscle and adipose tissue.
Hepatic gluconeogenesis is also stimulated in the liver, releasing additional glucose
into the blood. Glucose is excreted in the urine when the blood glucose level exceeds
the reabsorptive capacity of the renal tubules (approximately 10 mmol/L). Glycosuria
gradually becomes more continuous and is associated with increased water loss
leading to polyuria and polydipsia, and eventually to dehydration. If hyperglycaemia
develops very slowly over a period of months or years as in NIDDM, the renal
threshold for glucose rises slowly and so glycosuria and the symptoms of diabetes
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may be slight for a prolonged period. This is the reason why so many cases remain
undetected until a late stage. Insulin deficiency also results in reduced protein
synthesis and increased protein breakdown, leading to a rise in circulating amino
acids. One-third to one-half of this is converted to glucose via gluconeogenesis which
further contributes to the hyperglycaemia.
The most profound effect of insulin deficiency is on fat metabolism - there is a
decrease in triglyceride synthesis and an increase in triglyceride breakdown (lipolysis).
Fatty acids are taken up by the liver and degraded through eight steps within the
mitochondria of the liver cells, each stage yielding one molecule of acetyl co-enzyme
A. Under normal circumstances, these molecules enter the Krebs cycle but in the
absence of insulin, more acetyl co-enzyme A is formed than can enter the cycle.
Instead, acetyl co-enzyme A is converted to aceto-acetic acid which is then reduced
to form P-hydroxybutyric acid and some decarboxylated to form acetone. These
ketone bodies are normally oxidised and utilised as metabolic fuel but when the rate of
production exceeds that of removal by peripheral tissues, hyperketonaemia results.
Ketone bodies are acids which dissociate almost completely at physiological pH,
releasing hydrogen ions into the blood and body fluids. The fall in pH can be
countered by buffers in the blood, in particular bicarbonate, but only to a certain
extent and so the pH of the blood and other body fluids continues to fall resulting in
acidosis. Elevation of blood P-hydroxybutyrate and acetoacetate concentration
produces additional problems for the kidney, already troubled by osmotic diuresis
caused by the hyperglycaemia. The ketone bodies are excreted in the urine but largely
at the expense of sodium and potassium ion loss. This aggravates the dehydration and
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further decreases the blood volume, leading to a decreased blood pressure and a
diminished glomerular filtration rate.
When there is a relative insulin deficiency as in NIDDM, there may be sufficient
circulating insulin to preserve its anticatabolic but not its anabolic effects. In these
circumstances lipolysis is not markedly accelerated and the concentration of ketone
bodies in the blood remains relatively normal despite severe hyperglycaemia. Patients
with IDDM however, have an absolute deficiency of endogenous insulin and without
insulin replacement therapy die rapidly in ketoacidosis.
1.1.2 Clinical Features of Diabetes
Table 1.1 shows the classical clinical features of the two main types of diabetes.
Table 1.1 Clinical features of IDDM and NIDDM
IDDM NIDDM
Age at onset < 40 years >50 years
Duration of symptoms Weeks Months to years
Body weight Normal or low Obese
Ketonuria Yes No
Rapid death without treatment Yes No
Autoantibodies Yes No
Diabetic complications at diagnosis No 10-20%
Family history of diabetes No Yes
Other autoimmune disease Yes No
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The difference between the two types is not distinct as overlap occurs particularly in
the age of onset, duration of symptoms and family history. For example, Maturity
Onset Diabetes in the Young (MODY) is an uncommon genetic syndrome with a
dominant mode of inheritance which results in a NIDDM-like disorder in young adults
(5), whilst some elderly patients can present with typical autoimmune IDDM. Since
the age of onset of NIDDM is usually after the age of 40, most of the women with
NIDDM are not of reproductive age. There are however some exceptions to this,
including: (i) the Pima Indians from Arizona in the USA; (ii) ethnic groups in Britain
such as the Asian Indians; and (iii) patients with MODY. These groups have high
prevalence rates for NIDDM and disease often develops at a young age, and so
women from these groups may have diabetes during their child-bearing years. In
these NIDDM pregnancies, the problems mainly consist of macrosomia and late intra¬
uterine death. These complications also occur in pregnant women with IDDM but
they may experience additional severe fetal morbidity and mortality not encountered
in NIDDM pregnancies.
1.1.3 Aetiology of Insulin-Dependent Diabetes Mellitus
Although the precise aetiology of IDDM is still uncertain, it is known that
environmental factors interact with genetic susceptibility to determine which of those
genetically predisposed actually develop clinical disease.
1.1.3.1 Genetic Factors
To date, 12 separate chromosome regions have been implicated in the development of
IDDM. These include the major histocompatibility complex (MHC) region on
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chromosome 6p21 (IDDM1) (6,3); the variable number tandem repeat (VNTR) (7) in
the insulin gene region (8,9,10,11) on chromosome 11 p 15 (IDDM2). Linkages were
also seen at chromosome 15q26 (IDDM3) (12), chromosome 11 q (IDDM4),
chromosome 6q (IDDM5) chromosome 18q (JDDM6) and the X chromosome (13)
In addition, a disease locus on chromosome 2 (IDDM7) has been mapped (14).
Two recent studies have used dense microsatellite maps (approximately 300 markers
at a spacing of 11 cM) and reconfirmed the major importance of IDDM1 but provided
limited, if any, support for IDDM2 (15,16). Both studies identified a new
susceptibility locus (IDDM4) in the vicinity of the FGF3 gene on the long arm of
chromosome 11. Davies at al (16) found linkage with another locus on the long arm
of chromosome 6, near the ESR marker. From these studies there seems no doubt
that IDDM is a polygenic disorder in humans, with the strongest effect at IDDM1 and
more minor effects seen at a number of other loci spread throughout the genome.
The identities of IDDM1 and IDDM2 are known but the other mutations remain to be
identified (17).
The MHC is responsible for encoding three HLA Class II molecules known as HLA-
DP, -DQ, and -DR. It has been shown that susceptibility to IDDM is directly related
to the amino acid at position 57 of the N-terminal B-l domain of the HLA-DQ beta
chain (18). Maximum susceptibility is associated with substitution of aspartic acid at
position 57 with either alanine, valine or serine (this is seen in more than 80 % of
IDDM patients), whereas almost complete resistance to the development of IDDM is
conferred by the inheritance of two alleles with aspartic acid at position 57. The
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HLA-DQ genes encode cell surface DQ molecules which present antigens to T cells.
The occurrence of both positive and protective DQ associations suggests that
different DQ molecular structures may influence disease susceptibility by their effects
on antigen binding or presentation. Thus, DQ polymorphisms may determine the
specificity and extent of an autoimmune response against pancreatic islet insulin-
secreting cells.
A major problem which confounds the interpretation of the genetics of autoimmune
diabetes is the problem of penetrance i.e. the degree to which a particular genotype is
actually expressed in the form of a clinical disease. This is illustrated by the relative
low concordance for IDDM between monogygotic twins (36 %) (19) which indicates
a role for environmental factors in the precipitation of disease. The most important




Dietary factors have been proposed as a possible explanation for the rising incidence
of IDDM in Europe and North America. Indirect evidence for this has come from
observations that (i) during periods of relative starvation, such as times of war, there
is a decrease in the incidence of IDDM (21, 22); (ii) when the diet is altered and
protein intake is increased (for example, in migrants from Western Samoa to
Auckland, New Zealand), there is an increased incidence of IDDM (23); (iii) in
Iceland, the unusually high incidence of IDDM in boys born in October, has been
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linked to the high nitrosamine content of meat traditionally consumed at Christmas
(24); and (iv) the mean incidence of childhood IDDM is correlated with the mean
consumption of unfermented cow's milk (25).
Helgason and colleagues reported that there was circumstantial evidence of a causal
relationship between IDDM in young Icelandic males and the consumption of
smoked/cured mutton by their parents at about the time of conception (24). This was
found to be linked to the high nitrosamine content of the smoked/cured mutton. This
hypothesis was tested in CD1 mice fed Icelandic nitrosamine-rich smoked/cured
mutton before mating, during pregnancy and to offspring from day 19 until 5 weeks of
age (26). Although the parent mice did not develop diabetes, over 16 % of the male
progeny and 4.2 % of the female progeny did. Upon histological examination, the
islet P cells were found to be morphologically damaged, but lymphocytic infiltration
was infrequent. When the mutton was fed to the parents for 10 days prior to
fertilisation, and the weanlings fed standard mouse diet, there was first a fall and then
a rise in plasma glucose in males at 3 weeks of age, and in females at 5-6 weeks of
age. Therefore, the diabetogenic effect of nitrosamine appeared to be mediated via
the parental germ cells rather than by a direct effect upon the fetal P cells.
In 1984 Borch-Johnsen and colleagues (27) suggested that the incidence of IDDM
was inversely proportional to the percentage of children breast-fed for less than 3
months. Subsequently it was shown that prolonged exclusive breast-feeding is
partially protective against the risk of subsequent diabetes imposed by being a first
degree relative of an IDDM patient (28). The reasons for this may be a delay in the
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introduction of a putative diabetogen into the weaning diet, or some protective moiety
in the human milk. As cow's milk is the predominant weaning food in high diabetes
incidence countries, it's involvement as a diabetogen has been studied. Other
investigators have shown that patients with IDDM have increased levels of IgA class
antibodies towards cow's milk proteins such as (3-lactoglobulin (29, 30) and bovine
serum albumin (BSA) (31). Analysis of the BSA molecule has identified a 17 amino
acid sequence known as ABBOS which differs markedly from the equivalent sequence
in man and other species and that antibodies to this region could cross-react with a (3
cell specific 69 kDa surface protein (P69) (32). P69 is not presented on the (3 cell
membrane and it is thought that it does not enter the repertoire of self-antigens
tolerated by the immune system. However, P69 can be induced on the (3 cell
membrane by the inflammatory cytokine gamma interferon which is secreted in
response to infection. It has been postulated that individuals with genetic
susceptibility to IDDM are capable of generating antibodies against the ABBOS
sequence and these antibodies are then able to cross-react with P69 on the (3 cells, but
only when P69 is expressed on the surface of the (3 cells, for example during an
infection (33).
These associations between early nutritional status and risk for IDDM must still be
regarded as speculative. It is unlikely that the introduction of cow's milk proteins is
the only trigger of autoimmunity against the P cell. More studies are needed including
large prospective intervention studies in high-risk groups, before advice to the general
population regarding a change in eating habits could be used for primary prevention.
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(ii) Viral Infections
Infections with many unrelated viruses have been associated with the pathogenesis of
IDDM. Viral infections may induce diabetes either by direct damage to the pancreatic
islets or by the induction of an autoimmune reaction. It is also possible that both
mechanisms may operate together. The complete nucleotide sequence of the
diabetogenic Coxsakie B virus (CBV4) has been compared to that of non-
diabetogenic strains and 25 nucleotide sequence differences were identified affecting
the amino acid changes of the viral coat proteins (34). Three recent papers suggest
that molecular mimicry exists between the protein P2-C of CBV4 and the |3 cell
enzyme glutamic acid decarboxylase (GAD). The T cell mediated immune-response
aimed at fighting the Coxsakie virus infection may also destroy the |3 cell (35,36,37).
Encephalomyocarditis (EMC) virus has two variants, a diabetogenic strain (strain D)
and a non-diabetogenic strain (strain B). There is a 14 nucleotide sequence difference
between the two strains, and it appears that only two amino acid changes may be
responsible for the diabetogenicity of EMC virus (38). The effects of EMC on the
pancreatic islets are similar to those of CBV, namely damage to the P cells and a
reduction in the production of insulin (39).
Rubella is the only known maternal infection which can induce diabetes in the
offspring. About one third of the long-term survivors of congenital rubella syndrome
(CRS) develop diabetes 5-20 years after the initial infection (40). Although diabetes
is the most common of the delayed manifestations of CRS, autoimmune thyroid
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disease (41), Addison's disease (41) and growth hormone deficiency (42) have also
been reported.
In the majority of cases, IDDM autoimmunity develops months, if not years before its
clinical onset and so a recent viral infection cannot be responsible for initiating (3 cell
autoimmunity. However, an infection may stimulate memory T cells reactive against
self antigens which have already been primed by an ongoing autoimmune process.
Although these studies point to a viral involvement in the pathogenesis of IDDM,
additional factors must also be required since only a small fraction of patients infected
with these viruses actually develop diabetes. Moreover, the introduction of mumps,
measles and polio vaccines decreased the incidence of these diseases but did not
change the incidence or age of onset of IDDM.
1.1.4 Pathogenesis of Insulin-Dependent Diabetes Mellitus
The pathogenesis of IDDM is associated with a series of chronic autoimmune
reactions against the pancreatic P cells. By the time a clinical diagnosis is made more
than 90 % of the P cell mass has been lost. However, there is an array of
autoantibodies against islet cell antigens which are detectable months, sometimes
years before the clinical onset of hyperglycaemia and insulin deficiency.
Islet cell antibodies (ICA) have been detected in 80 - 90 % of new-onset IDDM
patients. The presence of ICA in genetically predisposed individuals before the onset
of clinical disease supports the hypothesis that the autoimmune P cell destruction is a
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chronic and progressive process. The first autoantigen to be characterised was insulin
(43). Insulin auto-antibodies (IAA) (defined as antibodies present in individuals not
yet treated with insulin) occur in 40-50 % of IDDM patients and appear to inversely
correlate with the patient's age at onset of disease (44).
Glutamic acid decarboxylase (GAD) catalyses the synthesis of the inhibitor
neurotransmitter y-amino butyric acid (GABA) from glutamate. Autoantibodies
against the 65 kDa isoform of GAD (GAD65) appear to be the best markers for
IDDM. IDDM antibodies immunoprecipitate mainly GAD65 in 75 - 80 % of new
onset IDDM patients compared with 1 -2 % of healthy individuals (45,46). GAD65
autoantibodies are also found in another autoimmune disorder, the stiff-man syndrome
although two different epitopes are involved (47).
Another autoantigen was isolated when a human islet A.gtll expression library was
screened with sera from ICA positive first degree relatives of IDDM patients (32) and
named ICA 69. The number of potential IDDM autoantigens has increased as
molecular cloning techniques rapidly advance. However, the role of ICA in the
destruction of the {3 cells has not been clarified. An immune reaction to many of the
autoantigens may be secondary to the massive (3 cell damage associated with the
release of these intracellular molecules.
The sequence of events which leads to the destruction of the pancreatic (3 cell begins
with hyperexpression of Class I MHC antigens within the islets and on the vascular
endothelium, followed by insulitis. The invading infiltrate contains macrophages,
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helper and cytotoxic and suppressor T lymphocytes, natural killer cells and B
lymphocytes. The intense expression of Class I MHC antigens now extends to all
pancreatic cells - resulting in the specific destruction of the (3 cells, leaving the other
islet cells intact. Finally, an end-stage islet with no residual insulin is left as the
infiltrate regresses. The sequence of events leading to the destruction of the
pancreatic (3 cell in the human has been shown to be identical to that described in the
BB/E rat (48, 49, 50).
1.2 Pregnancy in women with Insulin-Dependent
Diabetes Mellitus
1.2.1 A Historical Overview
Before the discovery of insulin, few cases of pregnancy complicated by IDDM were
reported since most female patients of reproductive age died within one to two years
of disease onset. The first true case of diabetes in pregnancy was described in 1824
by Heinrich Gottlieb Bennewitz of Berlin (51). The patient, Fredrica Pape was a 22
year old who after several successful normal pregnancies was admitted to the Berlin
Infirmary at 36 weeks gestation with classic symptoms and signs of gestational
diabetes. She suffered an intrapartum fetal death and delivered a 12 lb. still-born
infant.
In the limited number of pregnancies reported in the pre-insulin era, both the perinatal
and maternal mortality rates were approximately 50 %, with half of the maternal
deaths occurring during pregnancy and the remainder during the following two years
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(52). In 1915 Elliott Joslin presented a paper to the Boston Medical and Surgical
Society in which he reported that almost every case of diabetes mellitus ended in
death from ketoacidosis and that this fatal outcome was accelerated by pregnancy
(53). It was emphasised by diabetologists and obstetricians alike that pregnancy
should be terminated if complicated by diabetes as the risks to mother and fetus were
too high.
With the discovery of insulin in 1921 by Banting and Best, life expectancy was
dramatically improved for all diabetic patients. In eight short months insulin had been
isolated and clinical trials begun. The first injection of insulin was administered on
January 11 1922 to Leonard Thompson, a 13 year old boy. He weighed only 64 lb and
had been kept alive on only 450 calories per day. Insulin treatment improved the
fertility of women with diabetes allowing women with more severe diabetes to
become pregnant. Between 1923 and 1927 the maternal survival rate continued to
improve but the perinatal mortality rate (PNMR) remained unchanged (54).
One of the most important pioneers in the treatment of diabetic pregnancy was Dr.
Priscilla White of the Joslin Clinic in Boston, USA. In 1928 she made several
important observations that revolutionised the treatment of diabetic pregnancy, she
concluded that (i) good control of diabetes was essential to fetal welfare and that the
high maternal blood glucose concentration was probably responsible for excessive
fetal growth, and (ii) "close and persistent supervision" of the patient by both the
diabetologist and obstetrician was the most important part of the treatment
programme (55). In 1932 she described the first three successful cases of diabetes
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complicating pregnancy which had been treated with insulin - all of the mothers
survived and delivered healthy live infants (56).
Over the 77 years since the discovery of insulin the PNMR has continued to decline
and the maternal mortality rate is now almost the same as that found in the non-
diabetic population. This improvement has resulted from the ability to achieve better
regulation of the maternal diabetes than was formerly possible following the
introduction of home glucose monitoring and more intensive insulin therapy.
However, even in "centres of excellence", the PNMR for diabetic pregnancy remains
approximately four times that for non-diabetic women (4-8 % vs 1-2 %) (57) and 15-
20 % of the infants born to mothers with IDDM experience neonatal morbidity severe
enough to require a stay of more than 10 days duration in intensive care (58, 59).
Thus today pregnancy complicated by maternal diabetes remains an important clinical
problem.
1.2.2 Classification of Diabetes in Pregnancy
Women whose pregnancies are complicated by diabetes can be broadly divided into
those who are known to have diabetes before pregnancy and those with diabetes
diagnosed for the first time during their pregnancy (known as gestational diabetes).
The White classification was designed by Dr. Priscilla White (56) to predict outcome
of pregnancy on the basis of severity of maternal diabetes. She recognised that long
duration of diabetes, particularly if complicated by vascular disease, had a
progressively adverse effect on maternal and fetal outcome. The most recently
revised White classes are shown in Table 1.2 (60).
17
Table 1.2 The White classification of Diabetic Pregnancy




Abnormal glucose tolerance test (GTT) - euglycaemia maintained
by diet / insulin
Diet alone, any duration or onset age




Relatively young onset (age 1-19 years) or relatively long duration
(10-19 years)
Very young onset (<10 years of age), very long duration (20 years
or more) or evidence of background retinopathy
Renal Disease
R Proliferative Retinopathy or vitreous haemorrhage
RF Renal Disease and Proliferative Retinopathy
H Atheriosclerotic heart disease
T Pregnancy after renal transplant
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Although this system has been used extensively for the last 50 years there is now
general agreement that a new system of classification needs to be introduced as it is
too complicated and some patients do not fit into any one of the classifications. A
system which is simple, addresses both the maternal and fetal issues and correlates
with fetal outcome is required. It must also take into account the type of diabetes and
the presence of maternal complications.
1.2.3 The Effect of Pregnancy on Maternal IDDM
1.2.3.1 Ketoacidosis
Ketoacidosis now only affects about 1 % of IDDM pregnancies but it remains one of
the most serious complications. It may occur particularly in association with
infections, hyperemesis gravidarum, treatment with p-sympathomimetric agents (used
to suppress uterine contractions), corticosteroid use and insulin pump failure (61).
Since pregnancy is marked by a relative insulin resistance, enhanced lipolysis and
ketogenesis, diabetic ketoacidosis may occur with minimal hyperglyacaemia.
Ketoacidosis results in a considerable loss of fluid and electrolytes, particularly
potassium. Treatment involves the administration of unmodified insulin by intra¬
muscular or intra-venous injection, fluid and potassium replacement and the
administration of antibiotics if an infection is present. If ketoacidosis does occur
during pregnancy the fetal loss can be as high as 20 %. It is essential that the
ketoacidosis is correctly rapidly in order to save the life of the fetus and the mother.
1.2.3.2 Pre-eclamspia
Diabetic pregnancies complicated with pre-eclampsia cause much concern because of
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poor perinatal outcome. In one study, pre-eclampsia complicated 13.6 % of IDDM
pregnancies and 5 % of non-diabetic pregnancies (62). The proportion of pregnancies
complicated with pre-eclampsia rises with increasing severity and duration of diabetes
according to the White classification. The perinatal mortality rate is 60 per 1000
livebirths for pre-eclamptic diabetic women, compared with 3.3 per 1000 livebirths for
normotensive diabetic women. The occurrence of pre-eclampsia does not seem to be
related to glycaemic control during pregnancy (62). Pre-eclampsia is difficult to
diagnose in diabetic women with nephropathy and hypertension: it has been estimated
that 30 % of diabetic women with nephropathy also have pre-eclampsia.
1.2.3.3 Hypoglycaemia
Hypoglycaemia is the most common untoward event in insulin-treated diabetes. The
first trimester is a period of glycaemic instability and hypoglycaemic reactions may be
more frequent and more severe. Therefore patients and physicians should not strive
for normoglycaemia at the expense of more frequent episodes of hypoglycaemia.
Hypoglycaemia may not only be detrimental to fetal development and contribute to
the progression of maternal retinopathy, but may also lead to serious injury and
impairment of cognitive function.
1.2.3.4 Vascular Disease
Disease of the small blood vessels (microangiopathy) is specific to diabetes and affects
all the small blood vessels in the body, but its effect is most destructive in three
particularly sensitive areas: the retina (causing 'diabetic retinopathy' which may result
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in blindness); the nerves (causing 'diabetic neuropathy' resulting in difficulty in
walking, chronic ulceration of the feet, bladder and bowel dysfunction); and the renal
glomerulus (causing 'diabetic nephropathy' and resulting in renal failure).
(i) Diabetic Retinopathy
Studies have shown that pregnancy can worsen proliferative retinopathy when
compared with progression of the disease over a 40 week period in non-pregnant
diabetic women (63). However, data from Denmark (64, 65) show that in women
with well-controlled IDDM, background retinopathy progresses to proliferative
retinopathy only occasionally and that most cases regress spontaneously after
delivery.
(ii) Diabetic Nephropathy
Overt diabetic nephropathy is present in 5 % IDDM pregnancies and a first trimester
finding of >300 mg / 24h proteinuria is associated with an adverse pregnancy
outcome. Creatinine clearance rate is used as a diagnostic indicator of kidney function
for pre-pregnancy counselling. A creatinine clearance rate of less than 50 ml/min
before pregnancy has been associated with high rates of pregnancy-induced
hypertension and fetal wasting (66). Fetal death is more common in hypertensive
mothers than in pregnancies in which blood pressure is normal, however, recent
developments in obstetric management and techniques have improved the outcome
quite considerably. Pre-pregnancy counselling must emphasise that (i) poor perinatal
outcome is predicted by proteinuria greater than 3 g/24 hours, a serum creatinine
>130 mmol/L or a mean arterial pressure >107 mmHg, and (ii) even though
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pregnancy may be successful, maternal long-term morbidity and mortality are high and
may compromise a diabetic mother's ability to raise her child.
(iii) Diabetic Neuropathy
There have been few studies in which the effects of pregnancy on the development of
progression of diabetic neuropathy has been examined. Autonomic neuropathy may
be troublesome in pregnancy with worsening postural hypotension, diminished
counter-regulatory hormonal responses (notably catecholamines, growth hormone,
Cortisol and glucagon) to hypoglycaemia, and deterioration of gastroparesis. Diabetic
gastroparesis contributes to nausea and vomiting, nutritional problems and difficulty
with glucose control (67).
1.2.4 Maternal Metabolic Adaptations to Pregnancy
1.2.4.1 Non-Diabetic Pregnancy
Metabolic adaptations to pregnancy are directed towards (i) ensuring appropriate
growth and development of the fetus, (ii) equipping the fetus with a store of energy to
see it through the immediate neonatal period, and (iii) establishing a maternal bank of
energy to ensure survival of the fetus, the neonate and the infant, should the supply of
dietary energy be inadequate during and after pregnancy (68).
During the first half of pregnancy there is an increased secretion of insulin in response
to glucose, minimal increase in total insulin resistance, and a rise in the number of
insulin receptors on adipocytes. This results in increased triglyceride synthesis and
secretion by the liver, which is then stored as fat.
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In late pregnancy however, the plasma concentration of insulin remains raised but the
number of insulin receptors returns to normal levels and so there is an increase in
insulin resistance (69, 70). This insulin resistance parallels the growth of the feto¬
placental unit (71) and there is a progressive rise in the ratio of plasma
immunoreactive insulin to plasma glucose, reaching a peak at 32 weeks gestation with
a gradual decline thereafter to non-pregnant levels post-partum (68). The result of
this insulin resistance is a reduction in fasting blood glucose levels (72) which appears
to be due to (i) a reduction in maternal gluconeogenesis and (ii) an increase in glucose
use by the growing fetus. The maternal metabolism copes with the outflow of glucose
to the fetus by switching to fat metabolism (73).
During pregnancy the ovary, placenta, anterior pituitary, pancreas and the fetal
adrenal cortex are all involved in bringing about hormonal changes which have a
profound effect on carbohydrate, fat and amino acid metabolism. The concentration
of human placental lactogen (HPL) rises steadily during the first and second
trimesters, reaching a peak in the last four weeks of pregnancy. Increased HPL
causes the mobilisation of lipids as free fatty acids which serve as a maternal energy
source thereby making glucose and amino acids available to the fetus (74). The
concentration of free Cortisol also progressively increase throughout pregnancy.
Cortisol stimulates endogenous glucose production, glycogen storage and decreases
glucose utilisation thereby reducing the effectiveness of insulin (75).
Thus, the biphasic metabolism of carbohydrate, fat and protein is used to spread the
energy cost and protein requirement of pregnancy over the whole of the gestation
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period. This is programmed by the placental steroid hormone balance which is
determined by the growth of the placenta. These placental hormones are responsible
for (i) conserving energy in early pregnancy, described as 'facilitated anabolism' by
Freinkel (71), and (ii) redirecting available energy to the fetus in late pregnancy,
'accentuated catabolism' (71).
1.2.4.2 Diabetic Pregnancy
The various derangements in metabolic fuels such as carbohydrates, amino acids,
lipids and ketones, characteristic of IDDM, have the potential to adversely affect the
development of the fetus. Poorly controlled maternal IDDM during the first
trimester, in particular during the first six weeks of pregnancy, has been associated
with a spectrum of developmental abnormalities ranging from spontaneous abortion to
congenital malformations and growth delay. In contrast, poor metabolic control
during the latter two thirds of gestation has mainly been associated with accelerated
fetal growth and a risk of large-for-gestational age babies.
The effect of increasing resistance to the action of insulin during pregnancy is
clinically expressed as (i) a substantial and progressive rise in the dose of insulin
required to maintain glycaemic control in women with established IDDM, and (ii) the
development of impaired glucose tolerance or frank gestational diabetes in some
apparently normal women with a (hitherto occult) deficit in pancreatic (3-cell secretory
reserve (76).
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In normal pregnancy the maternal blood glucose is maintained within a narrow range
(3-6 mmol/L) and the concentration of glucose in the fetal circulation is half the
maternal level. This means that stimulation of the fetal (3-cells is usually minimal.
Any deterioration in regulation of the maternal metabolism (as occurs in diabetes)
results in the premature over-stimulation of the fetal P-cells with major consequences
for fetal well-being (see Figure 1.2). Therefore the aim of intensive treatment in
IDDM pregnancy is to maintain maternal normoglycaemia. This goal is not often
achieved in practice because the insulin delivery systems currently available for
treating diabetic patients are not glucose-responsive.
1.2.5 The Placenta in IDDM Pregnancy
Studies of placentae from women with IDDM have shown focal syncytial necrosis,
dilation of syncytial endoplasmic reticulum, a normal or increased number of syncytial
pinocytotic vesicles, an increased number of syncytial secretory droplets, focal
basement membrane thickening and evidence of cytotrophoblast proliferation (77).
The placentae of these women also have decreased utero-placental blood flow (78),
and it has been speculated that the diameter of the uterine vessels supplying the
placenta is slightly reduced, thereby restricting the access of blood to the fetal-
placental unit (80). As described above, the histological structure of placentae of
IDDM pregnancy shows numerous changes, including increased villous branching and
an increased fetal-maternal exchange area (80, 81), in addition to a significant increase
in the density of microvilli on the free surface of the villous syncytiotrophoblast (82).
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However, there is no correlation between the degree and extent of the abnormalities
noted in placentae from women with IDDM and the severity or duration of the
maternal diabetic state (77). The authors were unable to show that the placental
changes were any less marked in patients with well-controlled diabetes than in
placentae from women with poor metabolic control (77). The mechanism controlling
villous vascularisation and the cause of the abnormalities is still unknown, but it is
thought that some component(s) of the diabetic state must play a pathogenic role.
In the rat with streptozotocin (STZ)-induced diabetes, similar morphological changes
in placental histology have been reported. In particular, distorted placental
morphology (83) and a decreased placental blood flow (84, 85, 86). In addition,
changes in the capacity to transfer nutrients from mother to fetus have been
demonstrated in the chorioallantoic placenta of rats with STZ-induced diabetes (87,
88). However, the mechanisms underlying the damaging effects of IDDM on the
development and function of the placenta remain obscure.
1.2.6 Causes of Fetal and Neonatal Mortality and Morbidity
in Established IDDM Pregnancy
1.2.6.1 Early Pregnancy
(i) Early spontaneous abortion
Spontaneous abortion is defined as death of the embryo or fetus before 20 weeks
gestation. It has been shown that women with poorly controlled IDDM in the
preconception period and early pregnancy have increased rates of spontaneous
abortion (89, 90). Midovnik and colleagues (91) showed that women who later had
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spontaneous abortion had significantly elevated HbAlc levels at 8 weeks gestation but
no elevation of either glycosylated albumin (reflecting mean blood glucose levels in
the preceding 2-4 weeks) or glycosylated total protein. They concluded that
spontaneous abortion was related to poor glycaemic control around the time of
conception rather than control immediately before the actual abortion.
(ii) Early Growth Delay
Studies from Copenhagen have examined fetal growth in IDDM pregnancy using
ultrasound scanning to measure crown-rump length accurately and have reported a
high incidence of small fetuses in the first trimester of pregnancy which was
associated with an increased risk of subsequent fetal malformation (92) and
spontaneous abortion (93). Fog-Pedersen et al (94) have presented data supporting
their view that EGD results from the metabolic disturbance associated with IDDM,
particularly if metabolic control was poor around the time of conception, and that
EGD is associated with poorer psychomotor development post-natally (95).
EGD in fetuses from IDDM pregnancies has been confirmed in three other centres
(96, 97, 98). However, one centre has reported that the phenomenon of EGD
disappears when the time of conception is determined more accurately (99).
(iii) Congenital Malformation
IDDM pregnancy is associated with an increased risk of fetal maldevelopment, the
mechanism of which has not been precisely defined. Congenital malformations are
now the most common cause of neonatal death. Most studies have demonstrated a 3-
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4 fold increase in major congenital malformations in infants of diabetic mothers (100,
101, 71, 102). No organ system is exempt and almost any congenital malformation
can occur. Cardiac anomalies affect approximately 4 % of IDDM pregnancies and
include ventricular septal defects, complex lesions of the great vessels, and coarctation
of the aorta (103). Many infants of IDDM mothers have a thickened interventricular
septum and enlarged left or right ventricular wall which can lead to left ventricular
outflow obstruction and cardiac failure. Most infants are asymtomatic but some
develop congestive cardiac failure in the neonatal period.
IDDM pregnancy also carries an especially high risk for neural tube defects: 19.5 per
1000 pregnancies compared to 2 per 1000 for normal pregnancies (104). A rarer
complication (0.5 % of IDDM pregnancies) is the caudal regression syndrome (sacral
agenesis, phocomelic embryopathy) which is a continuum of malformations ranging
from agenesis of the lumbosacral spine to sirenomelia with fusion of the lower
extremities. This syndrome although very rare, is the type of malformation most
closely linked to IDDM pregnancy.
1.2.6.2 Late Pregnancy
(i) Intra-Uterine Growth Retardation
Approximately 5-10% of infants born to IDDM mothers are small, undernourished
and growth retarded rather than macrosomic. Intra-uterine growth retardation
(IUGR) is generally accepted as birth weight below the 10th centile in accordance
with the gestational age for infants in the same community (105). Predisposing
factors for IUGR include poor maternal renal function, poor metabolic control during
28
organogenesis, pre-eclampsia and chronic hypertension (106). Babies born with
IUGR may be susceptible to immediate medical problems such as hypoglycaemia.
Other recognisable features of IUGR include asymmetrical organ growth,
polycythaemia, impaired gluconeogenesis, depleted glycogen and fat stores, delay of
skeletal growth and a higher incidence of asphyxia (107).
(ii) Macrosomia
It is well established that fetal macrosomia in diabetic pregnancy is associated with
high perinatal morbidity and mortality rates. The term 'macrosomia' refers to a
neonatal birth weight of more than 4500 g. Macrosomia occurs in 25-42 % of
pregnancies in diabetic women compared with 8-14 % in control populations (108).
These fetuses are at a higher risk for unexplained death in utero, birth trauma,
hypertrophic cardiomyopathy, vascular thrombosis and neonatal hypoglycaemia (108).
In a study of 21 macrosomic infants Fee and Weil (109) found hyperplasia and
hypertrophy of most tissues - resulting in an overall increase in body weight of 141 %
compared with controls. They found an increase in heart (174 %), liver (179 %), lung
(127 %), adrenal glands (158 %), pancreas (110 %) and spleen (127 %), with the
brain and kidney unaffected.
Despite improvements in glycaemic control in IDDM pregnancy, rates of macrosomia
still vary between 20 and 50 % (110, 111) and may signal the importance of other
factors predisposing to fetal macrosomia such as maternal weight, maternal weight
gain during pregnancy, parity and genetic factors (112).
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(iii) Intra-Uterine Death
Late intra-uterine death or unexplained stillbirth has been a very important contributor
to high perinatal mortality in diabetic pregnancy. Between 1946 and 1952 the rate of
unexplained stillbirth was reported to be 27 %, falling to 15 % between 1953 and
1955 (113). In the 1960's an attempt was made to reduce the incidence of sudden
unexplained stillbirth by adopting a policy of premature delivery by elective caesarean
section at 36 weeks gestation. This reduced the number of stillbirths but increased the
number of neonatal deaths due to respiratory distress syndrome as these babies are
often more immature than their actual gestational age. Unexplained stillbirth has
become less common in recent years, since the introduction of stricter diabetic control
during pregnancy and more sophisticated fetal monitoring. However, it still occurs at
a rate four times that for non-diabetic patients and can happen with alarming swiftness
despite a previously normal fetal cardiotocograph. Factors known to be associated
with sudden fetal death include a pregnancy at more than 36 weeks gestation, a
mother with long-term diabetes and vascular disease, poor diabetic control, pre¬
eclampsia, ketoacidosis, polyhydrominos and a macrosomic infant (114, 115).
1.2.6.3 Neonatal Period
(i) Respiratory Distress Syndrome
Respiratory distress syndrome (RDS) is defined as an acute restrictive pulmonary
disease which develops shortly after birth in susceptible premature infants. It is
principally due to pulmonary surfactant deficiency and often leads to progressive
ventilatory failure (116). An increased risk of RDS in infants born to IDDM mothers
was initially reported by Gellis and Hsia (117). Before the introduction of neonatal
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intensive care in the 1950's and 1960's RDS was the most common cause of neonatal
death. Since then, however, the emphasis on improved maternal metabolic control
and prolongation of the pregnancy beyond 38 weeks gestation, RDS has become
much less common (118). In addition to prematurity, other risk factors for RDS
include fetal sex - RDS develops more frequently in males (119); and mode of
delivery - higher incidence of RDS in babies born by caesarean section; (120).
(ii) Hypoglycaemia
Neonatal hypoglycemia is a very important complication because of its frequency and
potential to cause long term mental handicap particularly if hypoglycaemia is
prolonged (121). It may be associated with reduced myocardial cointractivity so that
congestive heart failure develops. Once the umbilical cord has been cut the glucose
source for the infant is withdrawn and the excess insulin circulating in the baby's blood
quickly rids the plasma of the remaining glucose and so blood glucose levels may drop
precipitously during the first hour or two of life. It is essential therefore, that the
blood glucose of these babies is monitored frequently and they are fed high-
carbohydrate, high-calorie feeds in an effort to prevent hypoglycaemia.
(iii) Hypocalcaemia and Hypomagnesaemia
Hypocalcaemia (serum calcium less than 1.7 mmol/1) occurs in approximately 25-50
% of all infants born to IDDM women and its incidence appears to be directly related
to the severity of maternal diabetes. Hypomagnesaemia can occur in 70-80 % of
these babies and seems to be unrelated to maternal diabetes control.
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Infants of IDDM mothers often exhibit transient functional hypoparathyroidism at
birth, leading in some, to neonatal hypocalcaemia (122). This functional
hypoparathyroidism may be due to a state of magnesium deficiency, which in itself is
secondary to maternal hypomagnesaemia created by the increase in urinary
magnesium excretion that exists in IDDM (123) and low maternal and fetal levels of
magnesium may lead to delayed development of fetal parathyroid gland function
which is a condition frequently found in hypocalcaemic infants.
(iv) Jaundice
Pathological hyperbilirubinaemia (serum bilirubin above 200 pmol/L) is frequent in
infants of IDDM mothers. Its incidence is related to macrosomia with 70 % of all
macrosomic infants affected compared with 47 % of those not macrosomic. The
actual cause of bilirubinaemia is unclear, but polycythaemic babies are more likely to
have a serum bilirubin above 170 pmol/L than non-polycythaemic babies. The
increased bruising and trauma at birth commonly associated with macrosomic infants
contributes to increased bilirubin production and therefore to jaundice.
Hyperbilirubinaemia remains a common problem and strict control of diabetes during
pregnancy may be the best way to reduce its incidence.
1.2.7 The Metabolic Basis of Fetal and Neonatal Mortality and
Morbidity in Established IDDM Pregnancy
Although the precise mechanism(s) of early embryopathy remains uncertain, clinical
and experimental evidence suggests that poor maternal diabetic control during the
period of organogenesis (from 2-10 weeks gestation) may result in an increased rate
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of congenital malformation (71). While the risk of anomalous development can be
reduced by establishing meticulous metabolic control prior to the period of
organogenesis (124, 125), most women with IDDM continue to incur an increased
risk of malformations in their offspring because of the inherent difficulties in achieving
good enough metabolic regulation with the unresponsive insulin-delivery systems
currently in use. Miller and associates (126) showed that when the HbAlc value at
the 14th week of pregnancy was 6.9 % there were no greater risk of congenital
malformations, if the HbAlc was 7.0-8.5 % (indicating fair diabetes control) the
incidence of malformation was 5.1 %, but when the HbAlc was greater than 8.6 %
(indicating poor control) the incidence of malformation increased to 22.4 %. This
result was later confirmed by Ylinen et al (127) and Reid et al (128). However,
Hanson and colleagues (90) reported that the individual HbAlc value cannot be used
to accurately predict fetal malformation since in their study more than 50 % women
who had HbAlc values of +8 SD or more above the control mean value had infants
without malformations.
The use of HbAlc to assess glycaemic control in pregnancy is limited for the
following reasons: (i) episodes of hypo- and hyperglycaemia can result in a mean
value which seems quite acceptable, (ii) the influx of new young red blood cells into
the circulation is increased in pregnancy leading to a misleadingly low HbAlc value,
(iii) increased maternal blood volume in pregnancy which can also lead to a
misleadingly low HbAlc value. The value of HbAlc is primarily in the pre-pregnancy
period and in the very earliest stage of pregnancy. Otherwise, accurate and frequent
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blood glucose measurements are mandatory during pregnancy to assess metabolic
control.
Most of the evidence for the link between diabetes and early embryopathy has come
from animal studies. Using whole rat embryos cultured in high glucose concentration
during day 9.5-11.5 of gestation Sadler et al (129) showed that these embryos
developed growth retardation, anomalies of fusion of neural folds, microencephaly,
malformations of the eyes, vasculature and heart. Freinkel (130) later showed that
this did not happen when other hexoses such as fructose, inositol, sorbitol or
galactose were substituted - indicating the specificity of glucose.
Freinkel et al (131) showed that ketones and glucose together can be synergistic in
their teratogenic effects. If used together in smaller doses they could cause a greater
malformation rate than if used singly in larger doses. They termed this effect 'fuel-
mediated teratogenesis'. These studies suggest that malformations in IDDM
pregnancy result from the combined impact of several metabolic abnormalities.
Factors other than glucose reported to cause malformations in vitro include ketones
(132, 133, 134, 131) and serum fractions that inhibit somatomedin activity (131, 135,
136). In vitro studies of embryogenesis revealed that deficiency of myoinositol (137,
138), abnormalities of arachidonic acid and prostaglandin metabolism (139, 140, 141)
and over-production of oxygen radicals (142) may mediate the embryotoxic effects of
hyperglycaemia. These animals studies and others, indicate that the aetiology of
diabetic embryopathy is complex and involves more than just hyperglycaemia.
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In the non-diabetic population spontaneous abortion is multifactorial whereby up to
60 % are due to chromosomal abnormalities (143) and the remainder to maternal
vascular, immunological and idiopathic factors. It is not known whether an increase
in spontaneous abortion rates in diabetic women with poor glycaemic control is due
directly to an increase in blood glucose or if some other pathology is responsible.
Most authors speculate however, that the increased risk of spontaneous abortion is
due to an increased rate of malformation incompatible with embryonic or fetal life.
Evidence has accumulated in the last 20 years to support the original Jorgen Pedersen
hypothesis (101) that many of the pathophysiological events found in the infant of the
IDDM mother may be attributed to fetal hyperinsulinaemia secondary to inadequate
maternal metabolic control. The Pedersen hypothesis states that maternal
hyperglycaemia results in increased delivery of glucose to the fetus, which experiences
premature maturation of pancreatic insulin secretion. The resulting fetal
hyperinsulinaemia causes overgrowth of the fetus, particularly in insulin-sensitive
tissues such as the liver, subcutaneous fat, striated and cardiac muscle. This
hypothesis was modified (71) to include the synergistic effect of other fuels such as
amino acids and lipids. However, the impact of maternal hyperglycaemia on the
developing fetus is not simply restricted to fetal overgrowth as shown in Figure 1.2.
Insulin and insulin-like growth factors are the main regulating hormones affecting fetal
growth. Insulin is present in the pancreatic islets at 8-10 weeks gestation but is not
secreted into the circulation until 20 weeks when the insulin response to glucose
becomes evident (144). Approximately 80 % of the maternal glucose level will be
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found in the fetus and the endogenous glucose level in the fetal circulation will
regulate the glucose responsiveness of the fetal (3 cells (145).
The precise cause of intra-uterine death is unknown but sustained fetal
hyperglycaemia in the sheep is associated with stimulation of fetal oxygen
consumption, increased fetal uptake of substrates namely glucose and lactate, and
placental lactate production and can result in fetal hypoxaemia resulting in metabolic
acidosis and fetal death (146). Chronic fetal hypoxaemia stimulates extramedullary
haematopoeisis resulting in fetal polycythaemia and an increase in platelet aggregation
which may predispose the fetus to intravascular thrombosis (147). The additional
haemoglobin synthesised requires elemental iron, but the placental transport of iron is
relatively limited owing to vascular disease affecting placental blood flow (78) this
results in fetal iron deficiency. Alterations in iron metabolism may contribute to some
of the neonatal morbidity in infants born to IDDM mothers, since tissue iron
deficiency is known to adversely affect the development of the brain, liver, gastro¬
intestinal tract, heart and skeletal muscle. Intra-uterine growth retardation may also
result from fetal hypoxaemia caused by reduced uterine blood flow which may be
caused by pre-eclampsia, poor metabolic control, vascular disease or ketoacidosis.
There is evidence that maternal hyperglycaemia and fetal hyperinsulinaemia are
involved in the process of delaying fetal lung maturation. High glucose and insulin
can inhibit fetal lung maturation directly in a dose dependent manner (148, 149).
Type II pneumocytes in the lung have insulin receptors which play a role in their
uptake of glucose and it has been suggested that hyperglycaemia/ hyperinsulinaemia
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may lead to down regulation of glucose receptors in the fetal lung resulting in reduced
glucose availability for the synthesis of surface-active phospholipids (150). After
birth, the down-regulated receptors limit glucose uptake and phosphatidylcholine
synthesis which contributes to the development of RDS.
Fetal hyperinsulinaemia may also result in neonatal hypoglycaemia during the first few
hours of life. Infants of IDDM women are unable to respond to the hypoglycaemia by
releasing glucagon from the a cells of the pancreas to mobilise glycogen (151). They
are also relatively glucagon resistant, requiring ten times the usual amount of
glucagon to cause glycogen to be released and broken down into glucose.
1.2.8 Long-term Morbidity in Infants of Diabetic Mothers
1.2.8.1 Neuropsychological Development
The relationship between maternal ketonuria and impaired intellectual development of
the offspring was first described by Churchill in 1969 (121). It has been reported that
moderate hypoglycaemia in the neonatal period can have serious neuro-developmental
consequences (152, 153). They report that the number of days on which moderate
hypoglycaemia occurred was strongly related to a reduction in mental and motor
scores at 18 months of age. Five or more separate days of hypoglycaemia increased
the risk of impairment by a factor of 3.5.
Studies from Copenhagen involved 90 children born to diabetic mothers between
1980 and 1983 who were tested and examined at 4-5 years of age. The study also
included a group of low birth weight children born to non-diabetic mothers and a
38
matched control group. They reported that children born to mothers with well
controlled IDDM still incurred an increased risk of impaired psychomotor
development which is comparable to that seen in low-birth weight children.
Psychomotor retardation was evident in 23 out of 34 children who had demonstrated
early intra-uterine growth retardation as assessed by ultrasound, their poor cognitive
function suggests neurological immaturity (95, 154).
1.2.8.2 Development of Diabetes
There is a high risk of developing IDDM in the offspring of parents whose own
IDDM was diagnosed before the age of 11 (155). The risk is reduced by two-thirds
in the offspring of parents whose IDDM was diagnosed later in life. In addition,
regardless of the mother's age at diagnosis of IDDM, a child born after the mother is
25 years old has half the risk of developing IDDM of a child born to that mother at a
younger age. The mechanisms through which maternal age reduces the risk of IDDM
are unknown. Increased maternal age is associated with diminished fertility, increased
spontaneous abortions and trisomic anomalies and a higher risk of complications that
result from growth retardation, which presumably results from placental
complications. Fetuses of older mothers may be exposed to different hormonal and
immunological characteristics which may play an important role in the development of
(3 cell function.
The children of diabetic fathers are three times more likely to develop IDDM than
those born to diabetic mothers. Buschard and colleagues (156) suggested that
maternal hyperglycaemia may protect the child against development of diabetes in
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later life by promoting earlier maturation of fetal/neonatal (3 cells. Using Diabetes-
Prone (DP) BB rats Buschard and colleagues stimulated the immature neonatal [3 cells
in the first 6 days of life by administering various secretagogues - glucose, arginine,
glucagon and tolbutamide, - with the intention of rendering them mature, increasing
antigen expression, inducing tolerance and reducing the incidence of IDDM in these
offspring (156). The data showed that neonatal treatment of DP-BB rats with
combinations of either glucose and glucagon, or glucose and arginine resulted in a fall
in the incidence of IDDM from 65 % in untreated controls to 23 % and 20 %
respectively in the two treated groups.
1.2.9 Overall Conclusion
In no other group of babies, (except perhaps those born prematurely to normal
mothers) has the perinatal mortality rate improved so dramatically over the past 25
years as in the infants of diabetic mothers. The main factors responsible for the fall in
PNMR are strict control of maternal blood glucose concentration during pregnancy
(157 158) and the centralisation of cases (159). Improving metabolic control during
pregnancy has resulted in a lower risk of stillbirth allowing later delivery, which along
with advances in neonatal management has led to a fall in the neonatal death rate,
particularly from RDS.
However even today the PNMR for diabetic pregnancy remains approximately four
times that for non-diabetic women (4-8% vs 1-2%) (57). The main causes of the high
PNMR in women with IDDM are prematurity resulting from either spontaneous pre¬
term labour or elective early delivery performed to avoid late intra-uterine death;
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intra-uterine death, fetal early growth delay; infants small for gestational age; and
malformation. The mechanisms underlying the teratogenic effect of IDDM, the
initiation of pre-term labour, and the development of infants small for gestational age
remain obscure and good metabolic control during pregnancy has not abolished these
problems. It is however, well recognised that these complications tend to be
associated with each other (in both diabetic and non-diabetic pregnancy) and to occur
particularly in mothers with IDDM who also have clinically-evident microangiopathy
and/or pre-eclampsia and/or early growth delay. Thirty to sixty percent of all
perinatal deaths and a substantial proportion of the excess neonatal morbidity in
IDDM pregnancy are now due to malformation. In addition, there is increasing
concern about long term morbidity in the children born to mothers with IDDM.
Elucidation of the teratogenic effect of diabetes requires the study of the
immunological and metabolic environment at conception, implantation and during
organogenesis. Direct study of the early human embryo in IDDM pregnancies is
impossible for practical and ethical reasons and so appropriate animal models provide
a direct approach for studying disturbances in early IDDM pregnancy.
1.3 Animal Models of Insulin-Dependent Diabetes
Mellitus
An appropriate animal model for human IDDM should include a definable genetic
susceptibility linked to the MHC, evidence of both cell mediated and humoral
immunity, possible initiation by environmental factors and the pathological hallmark
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should include selective (3 cell destruction accompanied by insulitis in early stages
(160). The current animal models for diabetes can be separated into two groups (i)
chemically-induced and (ii) spontaneous models.
1.3.1 Chemically-Induced Animal Models
1.3.1.1 Alloxan-Induced Diabetes
The (3 cell toxicity of alloxan was discovered in 1943 while testing the nephrotoxicity
of uric acid derivatives in rats and rabbits (161, 162). Alloxan toxicity is dose-
dependent and the drug passes the placenta readily although no diabetes has been
detected in the offspring. Administration of alloxan is most effective when
administered by intravenous injection in a dose of 40-45 mg/kg/body weight. It
produces irreversible functional (3 cell damage within minutes and structural damage
within hours in most rodents, dogs, cats, rabbits, monkeys, cattle, birds and fish.
Alloxan is rapidly taken up by the (3 cells and has a direct effect on membrane
permeability (163, 164). Alloxan interferes with the generation of glucose-derived
energy in islets by inhibiting the glycolytic flux and pyruvate oxidation (165).
Malaisse and colleagues (166) concluded that that the mechanism of alloxan toxicity
was probably due to free radical formation. Alloxan is rapidly reduced within the cell
to dialuric acid which autoreoxidises to alloxan and the superoxide radicals arising
from this alloxan-dialuric acid cycle decompose spontaneously or through catalysis by
the enzyme superoxide dismutase. Thus, hydrogen peroxide is formed which reacts
with the superoxide to form, in the presence of iron ions, hydroxyl radicals, which are
extremely reactive oxidising agents damaging various cellular components (167).
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1.3.1.2 Streptozotocin-Induced Diabetes
The diabetogenic properties of streptozotocin (STZ) were first discovered by
Rakieten, Rakieten and Nadkarni (168) during the testing of potential antibiotics from
the bacterium Streptomyces achromogenes. STZ consists of a 1-methyl-1-nitrosourea
moiety linked to carbon 2 of D-glucose. The glucose moiety is an essential
component which specifically directs it to the P cell. Once inside the cell, STZ
spontaneously decomposes to form an isocyanate compound and a
methyldiazohydroxide (169), which further decomposes to form a carbonium ion.
This highly reactive ion is able to alkylate various cellular components, including
DNA - leading to lesions which are removed by excision repair. Part of this repair
process involves the activation of the enzyme poly (ADP-ribose) synthetase to form
poly (ADP-ribose) using NAD as a substrate (170, 171). In the P cell this enzyme is
overactivated and NAD is critically depleted leading to cessation of cell function and
cell death (172). Non-lethal but unrepaired DNA lesions may lead to abnormal gene
expression and result in altered cellular function such as decreased or inappropriate
insulin secretion. Moreover, the high tumour frequency in islets which is a
phenomenon associated with STZ-induced diabetes is thought to be due to inhibition
of DNA repair mechanisms resulting in abnormal DNA recombination with the
formation of a tumour-inducing gene (173). The treatment of islets with
nicotinamide, the precursor of NAD prevents depletion of NAD and protects against
the diabetogenic effect of STZ (174).
Various forms of diabetes can be induced with STZ depending on the dose and the
protocol employed to administer it.
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1.3.1.2.1 Low-Dose STZ-Induced Diabetes
One important difference between alloxan and STZ is that only STZ in repeated small
doses produces in susceptible species a delayed insulitis-related diabetes (175). Five
consecutive subdiabetogenic doses (40 mg/kg/body weight) of STZ produce a
delayed but progressive increase in blood glucose and islet infiltration with
lymphocytes and macrophages, accompanied by P cell necrosis and hyperinsulinaemia
(175). Interpretation of these experiments has also to take into account the fact that
STZ has independent deleterious effects on the host defence system (176). These
effects include failure of lymphocytes to release mediators involved in the recruitment
of T cells, depressed numbers and functions of T cells, low phagocytic activity of
macrophages and a reduced bone marrow function (177, 178, 179). This model was
mainly used to study the components and progression of the pancreatic infiltrate in the
early stages of P-cell destruction before the discovery of spontaneous autoimmune
animal models.
The susceptibility or resistance to low dose STZ treatment involves at least three gene
groups (180). One is responsible for the sex determined propensity to insulitis, since
males are more sensitive to insulitits than females. Castration abolishes the sex related
difference and testosterone sensitises castrated males as well as females (181, 182,
183). The reported age difference in susceptibility may also be related to changes in
sex hormone levels with age. A second gene is located on the MHC of mice, H-2 and
influences the development of hyperglycaemia, and the third gene is located outside
the MHC and controls the susceptibility to diabetes in an opposite direction to the
MHC-linked gene.
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1.3.1.2.2 High-Dose STZ-Induced Diabetes
One single large dose (i.e. 50-60 mg/kg/body weight) given intravenously or
intraperitoneal^ causes specific, acute degeneration of (3 cells of the pancreas and
chronic hyperglycaemia. Some ketonaemia and ketonuria may accompany severe
hyperglycaemia and wasting in animals with STZ-induced diabetes lethal ketoacidosis
is relatively uncommon.
1.3.2 Spontaneous Autoimmune-Induced Animal Models
1.3.2.1 Non Obese Diabetic (NOD) Mouse
The non obese diabetic (NOD) mouse was derived in Japan from a cataract-prone
female mouse displaying severe glycosuria. The NOD mouse spontaneously develops
an insulin-dependent diabetes mellitus that has many immunological and pathological
similarities to human insulin-dependent diabetes. After brother-sister mating for over
20 generations an inbred strain was established in 1980 (184). Most mice of both
sexes develop insulitis after 9 weeks of age. Conversely, the occurrence of overt
diabetes is different depending on the sex : in the female the incidence rises gradually
with age to approximately 80 %, in male mice however, diabetes occurs only rarely,
the cumulative incidence at 30 weeks being less than 20 % (185).
1.3.2.1.1 Pathogenesis of IDDM
The autoimmune nature of the disease is suggested by lymphocytic infiltration of islets
of Langerhans, preceding the destruction of insulin-producing (3 cells (186). Diabetes
in the NOD mouse is immune-mediated since T cell deficient mice do not develop
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hyperglycaemia and have very little lymphocytic infiltration. Immunosupressive
measures such as irradiation, bone marrow transplant and treatment with cyclosporin
A prevent hyperglycaemia and insulitis. P cell deterioration in the NOD mouse can be
prevented or attenuated by nicotinamide, scavengers of free radicals and inhibitors of
poly-ADP-ribose synthetase. Therefore, the destruction of pancreatic islets shows
some similarities to those of chemical cytotoxins. In addition, retrovirus-like particles
are seen in the islets of NOD mice which is also the case in multiple-dose
streptozotocin-induced diabetic animals.
Lymphocytes are localised in the periductular capillary spaces with a clear basement
membrane boundary, without overt contact with the P cells. Later on, only the P cells
are affected while the A, D and PP cells remain intact. The cellular infiltrate consists
initially of macrophages and CD4+ T cells. Recruitment of CD8+ T cells occurs later
coinciding with the intra-islet infiltration and overt diabetes (187). Unlike the BB rat
which displays pronounced lymphopenia, NOD mice exhibit varying levels of
moderate lymphocyte decline. The onset of diabetes is manifested by the presence of
glucose in the urine and increasing levels of glucose in the blood. As the disease
progresses the animals develop polyuria, polydypsia and muscle wasting but ketosis is
variable and diabetic animals can survive for prolonged periods without insulin
replacement therapy.
1.3.2.1.2 Humoral Immune Response
Humoral antibody changes such as the presence of islet cell surface antibodies (ICSA)
islet cell cytoplasmic antibodies (ICA) and anti-GAD autoantibodies have been
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detected in the sera of pre-diabetic NOD mice (188, 189), indicating the role of
humoral immunity concomitant to cell mediated immunity.
High doses of cyclophosphamide (Cy) injected intraperitoneally induces variable
diabetes incidence in NOD mice within 1 month of the injection. It has been proposed
that Cy acts by targeting the regulatory/suppressor cells (190). Although this diabetes
is drug induced the basic mechanism is autoimmune since macrophages and T cells are
involved (191).
1.3.2.1.3 Genetics of the NOD mouse
In the NOD mouse IDDM is a polygenic trait (192, 193, 194) with the major locus
Iddl located in the MHC region on chromosome 17. Originally the action of Iddl was
believed to be recessive, but it has now been shown that the action of NOD MHC is
dominant with reduced penetrance (194). The MHC genes responsible for disease
susceptibility include Class II genes encoding for the I-A and I-E molecules. The
NOD mouse has a unique Abg7 gene which encodes for a rare I-A®7 molecule required
for the disease. A deletion mutation in the promoter region of the gene encoding the
Ea chain causes a lack of I-E expression, a null phenotype that is also essential for the
development of the disease.
In addition to Class II alleles, there is some evidence that ClassI and II loci have some
influence on disease development. Non-MHC genes are also essential but not
sufficient in themselves for the development of diabetes, and at least 14 other loci
contribute to the development of disease (192, 193, 194). All these genes have a
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dominant mode of action with varying degrees of penetrance. These loci are Idd2 (on
chromosome 9), Idd3 and IddlO (on chromosome 3), Idd4 (on chromosome 11), Idd5
(on chromosome 1), Idd6 (on chromosome 6), Idd7 (on chromosome 7), Idd8 and
Iddl2 (on chromosome 14), Idd9 and Iddll (on chromosome 4), Iddl3 (on
chromosome 2), Iddl4 (on chromosome 13), and IDD15 (on chromosome 5) (195).
1.3.2.2 BioBreeding (BB) Rat
1.3.2.2.1 Introduction
The spontaneous autoimmune diabetic BB Wistar rat was first discovered in 1974 by
Drs. Reginald and Clifford Chappel at the BioBreeding Laboratories, Ontario,
Canada. The syndrome appeared in a commercial outbred colony of Wistar-derived
albino rats and is thought to have been due to a spontaneous mutation. The diabetic
animals were inbred to create the Diabetes Prone (DP) BB rat strain and animals from
this group were subsequently supplied to establish separate breeding colonies in a
number of locations including Worcester, Philadelphia and Edinburgh. Animals that
failed to develop diabetes were also inbred to become a control line for non-diabetic
BB rats - now designated as Diabetes Resistant (DR) BB rats. Since BB rats
distributed to different centres show variations in the incidence of diabetes, it was
suggested that each laboratory adopt a supplementary designation such as BB/W
selected by Like and associates to designate their colony by its location in Worcester,
Massachusetts (196).
Attractive features of the BB rat as a model for IDDM include a long (approximately
3 month) silent pre-diabetic period which can be used to investigate possible
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intervention and primary prevention strategies; involvement of both genetic and
immune factors in its aetiology; the absence of obesity; and the occurrence of
functional and structural changes in the retina, kidneys and nerves of established
diabetic animals. There are several dissimilarities from human IDDM in that islet
cytoplasmic antibodies are only found in man; lymphopenia is only found in BB rats;
BB rats are inbred and there is a higher incidence of diabetes in BB rats (30-90 %)
than in humans (197).
The main problem encountered using the BB rat strain is that they are very
susceptible to developing pulmonary and other infections by common varieties of
bacteria, mycoplasma and viruses (198). It has therefore been necessary to develop
facilities in which the rats are 'germ-free' using barriers to prevent such infections.
There are also problems in breeding and maintaining spontaneously diabetic animals.
1.3.2.2.2 Clinical Features
The onset of diabetes in the DP-BB rat is abrupt and acute with the peak age at onset
96 days of age (range 60-120 days) in 50-80 % of an inbred colony. Diabetes
develops in both sexes at a similar incidence in this model (199, 200). Clinical
symptoms at onset include polyuria, polydipsia and severe weight loss and lethargy
(201). At onset, hyperglycaemia is associated with undetectable circulating insulin
and a high incidence of severe ketoacidosis along with hyperglucagonaemia,
hyperketonaemia, hyperlipidaemia and uraemia. Ketoacidosis develops in virtually all
diabetic rats and spontaneous remission is very rare. There are many similarities to
human IDDM including a total dependence on insulin therapy for survival and the fact
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that DP-BB rats develop IDDM at an age roughly comparable to that in diabetic
patients where the highest incidence is 10-30 years old (197).
1.3.2.2.3 Aetiology of IDDM
As in human IDDM, the development of diabetes in the DP-BB rat, requires both
genetic predisposition and environmental factors.
1.3.2.2.3.1 Genetic Factors
Diabetes in the DP-BB rat is inherited by an autosomal recessive transmission with
approximately 50 % penetrance (200, 201). A strong association with IDDM and
class II MHC genotype has been reported in the human (202) and the BB rat (203,
204, 205). The rat MHC is known as RT1 and consists of a number of class I gene
loci (RT1A, RT1C, RT1E) flanking two class II gene loci, RT1B and RT1D
(homologues of the human HLA-DQ and HLA-DR). The TNF-a and P loci are
located between the class II loci and the telomeric class I loci which is also seen in the
human and the mouse MHC (206). Susceptibility to diabetes in DP rats is linked to
the class II region of the MHC and two non-MHC genes (204), one of which induces
a severe T cell lymphopenia. Genetic studies crossing DP-BB rats with non-diabetic
rat strains have shown that only rats expressing the RT1U haplotype develop IDDM
(203) and all Diabetes-Prone BB rat lines (to date) have been shown to type as RT1U
(207, 208). Furthermore, only the class II subregion of the RT1U complex appears to
be necessary for disease expression (209). This is similar to human IDDM where only
one copy of the permissive class II allele is sufficient to confer susceptibility.
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Lymphopenia precedes clinical manifestations and involves primary and secondary
lymphoid tissues and affects all subsets of T cells. Lymphopenia is controlled by a
single autosomal recessive gene (lyp) (204) which maps close to the neuropeptide Y
(Npy) gene on chromosome 4 (210). It is characterised by a marked decrease in the
number of T lymphocytes in the peripheral blood, lymph nodes and spleen. While all
T subsets are diminished, the cytotoxic supressor T cell subset (OX8+) is most
affected (211). In addition, the RT6 differentiation alloantigen is absent in rats with
lymphopenia (212, 213). The RT6 alloantigenic system is found on chromosome 1
and consists of at least two alleles - the RT6a gene encodes the RT6.1 alloantigen and
the RT6b gene encodes RT6.2 (214, 215). The surface expression of RT6
alloantigens is restricted to T cells in the rat. It is a maturational antigen and is
expressed on most but not all mature T cells in the rat, approximately 50 % of W3/25+
(CD4) and 70 % of OX8+ (CD8) peripheral T cells express RT6 (216, 217).
Biochemical analysis of peripheral T lymphocytes of DP-BB/W rats failed to detect
RT6 protein (218). More recent reports have demonstrated that the RT6a gene is
present, transcribed and translated in DP-BB/W rat lymphocytes (219). They also
show evidence of an intact phosphatidylinositol linkage of the protein to the cell
surface and that the RT6.1 antigen is correctly processed and folded in the lymph
node cells, therefore the lack of RT6+ T cells in DP-BB/W rats is unlikely to be
caused by defects in RT6 gene expression per se. It is possible that defects in RT6
gene regulation or premature death of the T cell lineage may be responsible.
Elimination of RT6+ T cells by treating in DR- BB rats with polyinoinic: polycytidylic
acid and an antibody against RT6 renders 50-100 % of the resistant subline
susceptible to IDDM (220).
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Unlike any other BB rat colony, in which only the DP-BB rats have lymphopenia,
both of the BB/Edinburgh rat sublines (i.e. DP-BB/E and DR-BB/E) display profound
lymphopenia and there is no difference between them in the severity of the phenotype
(221). The DR-BB/E line has an apparently normal, potentially diabetogenic RT1U
haplotype at the MHC and therefore it seems likely that although the RT1U haplotype
and homozygosity for lymphopenia are necessary for the development of diabetes,
these factors alone are not sufficient to create a permissive genotype in the DR-BB/E
line (221). This suggests that there is an additional polymorphism required for the
development of IDDM in the DP lines. One candidate gene is the pancreatic
lymphocytic infiltration (Pli) allelism (222, 223). In the DP-BB rat this is
characterised by the appearance of clusters of lymphocytes around the small ductules
and venules of the pancreas (224). However, more detailed analysis of this gene
polymorphism is required before the exact nature of the differences between BB/E
and other BB colonies can be understood.
1.3.2.2.3.2 Environmental Factors
In human IDDM there is a relatively low concordance for IDDM between
monogygotic twins (36 %) (19). A similar situation exists in the BB rat where only
50-60 % of animals in DP litters develop diabetes. This indicates a role for
environmental factors in the precipitation of disease in both the human and the BB rat.
(i) Diet
Diet is a crucial factor influencing the penetrance of the diabetogenic phenotype in BB
rats. Elliot and Martin (225) reported that feeding DP-BB/W rats a mixture of amino
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acids in place of intact proteins significantly decreased the incidence of IDDM. The
addition of 1 % skimmed milk powder to the amino acid mixture diet increased the
risk for diabetes in the offspring, particularly when it was fed to mother and pups
during the weaning period (226).
Further studies, reviewed by Scott (227), have shown that wheat and milk proteins
have the strongest diabetogenic effect. These compounds have been designated
'initiators' of disease, since they are capable of triggering the events which result in P
cell destruction but only in genetically susceptible animals. Other dietary constituents
have been designated 'modifiers' since they appear to be able to modify the course of
diabetes once it has been initiated. These compounds include vitamin E (an
antioxidant) and lard, which reduces and increases the incidence of IDDM
respectively. Diets either based on hydrolysed caesin, or deficient in essential fatty
acids can reduce the incidence of diabetes and delay the age at onset (228, 229, 230).
The mechanisms responsible for these effects are not known, whether the decrease in
frequency of diabetes is secondary to the removal of a specific dietary protein or
whether it is a non-specific effect of removing fibres, lectins, viral or bacterial toxins
which may be present in the chow remains to be determined. None of the diets affect
the lymphopenia and tend to have the greatest effect when introduced before the age
of 4 weeks.
(ii) Viral and Non-Viral Infections
Certain viruses can influence the expression of IDDM in BB rats. A common rat
parvovirus, Kilham's rat virus (KRV) has been identified as a viral trigger of IDDM in
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BB rats (231). This microbial agent appears to promote diabetes by acting on cells of
the immune system rather than on islet (3 cells directly, and it has been suggested that
the virus may act on effector cells or regulatory T cells to promote an autoimmune
response. DR-BB/W rats housed in viral antibody-free facilities remain free of
spontaneous diabetes but if infected with KRV can become diabetic (232). Recently,
Ellerman and colleagues (233) demonstrated that KRV infection could induce
autoimmune diabetes in three unrelated strains of rats: DR-BB/W rats, PVG.RTlu
rats and LEW1.WR1 rats and they propose that for a rat strain to be susceptible to
KRV-induced autoimmune diabetes it must possess beta cell specific autoreactive T
cells as part of its peripheral T cell receptor repertoire.
Other observations however, have revealed that the environmental influence of
microbial agents on IDDM can be protective against disease development (234).
Thus some viral infections introduced into colonies of diabetes prone BB rats
previously maintained in a pathogen-free environment resulted in a reduction in the
incidence of diabetes. For example, experimentally induced infection with lymphocytic
choriomenigitis virus (LCMV) was found to decrease the frequency of IDDM in DP-
BB/W rats (234).
Bacterial and fungal preparations have also been found to exert a protective effect
against diabetes development in BB rats, these include streptococcal extract OK432
(235), and complete Freud's adjuvant (CFA) comprised of killed mycobacterium
tuberculosis in oil emulsion (236).
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(iii) Stress
The immune system's response to acute infection and chronic disease can be modified
by environmental stress. Studies have shown that environmental stress such as
restraint, rotation, crowding and resocialisation may modify the age of onset of
diabetes in the DP-BBAV rat (237).
1.3.2.2.4 Pathogenesis of IDDM
Sequential pancreatic biopsies in individual animals together with cohort analysis have
permitted the cellular sequence of events leading to (3 cell destruction to be delineated
(49, 50, 238). The first change occurs prior to any cellular infiltration and consists of
increased expression of MHC class I molecules on the vascular endothelium and on
islet cells. The next event occurs 2-3 weeks before the onset of IDDM when there is
a marked recruitment and accumulation of a population of macrophages identified by
the monoclonal antibody (EDI). These EDI macrophages are quite distinct from the
resident population of ED2-positive tissue macrophages. These recruited cells
proceed to infiltrate the pancreatic islets. Approximately 10 days before the onset of
IDDM there is an infiltration of the islets by other activated effector cells including
CD4+ and CD8+ T cells, natural killer (NK) cells and B cells appear (239). At this
time the expression of MHC class II molecules is restricted to the infiltrating
immunocytes and is never seen on the islet insulin-secreting cells. At the onset of
IDDM, the insulin secreting cells have virtually disappeared but occasionally MHC
class II antigens are expressed on the few remaining cells which contain insulin.
Finally when all insulin-containing cells have been destroyed the infiltrate disappears.
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Diabetes Prone BB rats show abnormal glucose tolerance and symptoms a few days
before IDDM onset at approximately 60-120 days of age in 50-60 % of an inbred
colony. Immediately after the development of hyperglycaemia there is pronounced
insulitis with the lymphocyte infiltration (201). Insulitits precedes the onset of overt
diabetes by several days and disappears soon after leaving shrunken end-stage islets
devoid of P cells and composed almost entirely of cells containing glucagon (A cells),
somatostatin (D cells) and pancreatic polypeptide (PP cells) (240). As in human
IDDM autoantibodies reacting against various tissues and proteins are present in the
BB rat, both in the pre-diabetic period and at diagnosis of diabetes. These include
antibodies to gastric parietal, smooth muscle and thyroid cells as well as to
lymphocytes, islet cell surface antibodies (ICSA), a 64 kDa islet cell protein and
insulin (IAA) (241, 242, 243). Islet cell cytoplasmic antibodies (ICA) and antibodies
to pituitary, adrenal and ovary cells have not been found in the BB rat and no
mononuclear infiltration is seen in these tissues.
Cytokines are critically involved in regulating several aspects of IDDM, including the
pathogenesis of the disease. This is true for human IDDM as well as spontaneous
autoimmune IDDM in the DP-BB rat. Cytokines are fundamental mediators of T cell
regulatory and effector functions and they have been shown to be critical for the
development and maintenance of pancreatic P cell directed autoimmunity. It has been
suggested that in IDDM cytokines serve as chemoattractants, generators of cytotoxic
Thl type responses, and pancreatic P cell toxins (244). Evidence for this comes
mainly from in vitro studies in which interleukin-1 (IL-1), tumour necrosis factor-a
(TNF-a), and y-interferon (y-IFN) were found to be p cell cytotoxic (245). Several
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investigators have proposed that the expression of autoimmunity in BB rats depends
on a balance between populations of regulatory and effector T cells, i.e. between the
Thland Th2 subsets of the CD4+ T cell population (246, 244). Thl subsets mediate
proimflammatory reactions and secrete IFN-y and IL-2, whereas Th2 subsets secrete
IL-4 and IL10 and can down-regulate a Thl immune response. In the BB rat, IFN-y
and IL-12 play a major role in the expression of insulitis and thyroiditis and it has been
suggested that Thl lymphocytes predominate over Th2 lymphocytes in these
inflammatory lesions (247, 248). However, it appears that the prevention of diabetes
by insulin treatment is not associated with an alteration in the cytokine gene profile of
islet infiltrating cells (247).
1.3.2.2.5 Vascular Disease in the BB rat with long-term IDDM
The development of widespread microvascular disease is one of the most significant
long-term consequences of human IDDM, and it results in serious morbidity such as
blindness, gangrene and renal failure. These microvascular alterations are
characterised by a thickening of the basement membranes, deposition of extracellular
matrix and scarring. These changes are also seen in the BB rat with established long-
term IDDM. The exact mechanisms underlying these complications are unknown and
the use of the BB rat has enabled the link between hyperglycaemia and vascular
disease to be studied in more detail.
(i) Retinopathy
Diabetic retinopathy is an important cause of blindness in the world and research has
been difficult owing to the limitations imposed by the use of human tissue. Although
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the classical clinical features of diabetic retinopathy are not seen on opthalmoscopy in
BB rats, retinal pathology has been described (249, 250). Retinal pathology includes
pericyte degeneration and loss, endothelial cell degeneration, capillary basement
membrane (CBM) thickening, microthrombi and retinal pigment eptheliopathy.
Retinal CBM thickening can be prevented in galactosaemic animals by aldose-
reductase inhibitor therapy suggesting that augmented polyol pathway activity may
play in the development of this pathology (251).
(ii) Nephropathy
Severe nephropathy as seen in human IDDM is not found in BB rats, but proteinuria
and thickening of the glomerular basement membrane (GBM) and of the mesangium,
occur after a few months of diabetes. The development of proteinuria and GBM
thickening are correlated and are related to the degree of hyperglycaemia (252).
Treatment with insulin reduces proteinuria and slows down the progression of GBM
thickening (253).
(iii) Neuropathy
The first morphological change in the somatic nerves of the diabetic rat occurs
approximately 3 weeks after diabetes onset and is seen as localised swellings of the
large axons at the nodes of Ranvier (254). There is a reduction in nerve conduction
velocity and decreased amplitude of evoked muscle potentials - indicating a loss of
functioning motor units. At this stage the structural and functional abnormalities are
reversible by insulin treatment or administration of aldose reductase inhibitors.
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Without treatment, nerve conductivity falls and there is marked axonal atrophy and
loss of myelinated fibres develops (255).
1.3.2.2.6 The BB rat as a model for human IDDM pregnancy
Although insulin therapy has resulted in a dramatic improvement in the outcome of
pregnancy complicated by maternal IDDM, today, even in developed countries, the
perinatal mortality and morbidity rates in these countries remains at least twice that
for pregnancies in non-diabetic women. This is due to continuing high rates of (i)
poor fetal growth in early pregnancy, (ii) spontaneous premature labour, (iii)
congenital malformation, and (iv) low birth weight babies. The cause of these
problems remains obscure. Since the development of effective preventive strategies
depends on elucidation of their pathogenesis, these represent critically important areas
for research.
It is very difficult to study these areas in human pregnancy, however the
spontaneously diabetic insulin-dependent BB rat provides the opportunity to study the
interaction of genetics and the fetal environment in utero in determining the outcome
of IDDM pregnancy and the long-term development of the offspring of the diabetic
mother.
The first studies of diabetic pregnancy in the BB rat by Brownscheidle and colleagues
(256, 257) reported high rates of perinatal mortality and congenital malformation,
particularly neural tube and skeletal defects. It has also been shown that Diabetic DP-
BB/E rats maintained on continuous insulin therapy have a higher rate of fetal
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resorption than non-diabetic DR rats and malformations such as sacral dysgenesis,
exencephaly and omphalocoele have been described (258). In addition, these Diabetic
DP-BB/E rat pregnancies were often characterised by low birth weight pups and large
placentae (259).
Thus, pregnancy in the diabetic DP-BB rat is associated with many of the problems
seen in human IDDM pregnancy, - namely a high PNMR and congenital
malformation, which suggest that it is a valid model to study the pathogenesis of
IDDM-induced embryopathy (259).
1.3.3 Concluding Remarks on Appropriate Animal Models
for Human IDDM
Although some ketonaemia and ketonuria may accompany severe hyperglycaemia and
wasting in animals with STZ-induced diabetes, lethal ketoacidosis is relatively
uncommon and these animals are able to survive for variable periods of time
(weeks/months) without insulin replacement therapy. In contrast, in properly inbred
colonies of BB rats animals developing spontaneous, autoimmune-induced diabetes
will usually die rapidly (within 1-2 days) in severe ketoacidosis if treatment with
insulin is withheld.
This difference in clinical expression of disease reflects disparity in the degree of
insulin deficiency in these two animal models of human IDDM. Thus animals with
high-dose STZ-induced diabetes commonly retain a significant number of viable
insulin-secreting (3-cells along with a capacity for some regeneration (260) and this
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results in a low level of circulating insulin at diagnosis of disease. This endogenous
insulin is sufficient to exert an anti-catabolic effect (which prevents the development
of lethal ketoacidosis) but insufficient to maintain an effective anabolic function: hence
the severe hyperglycaemia, dehydration and wasting.
On the other hand, in BB rats no circulating endogenous insulin is detectable at
diagnosis of diabetes. This means that these diabetic animals are totally dependent on
rapid treatment with exogenous insulin to survive. They are therefore properly
designated as having Insulin-Dependent Diabetes Mellitus (IDDM) comparable to the
human disorder.
1.4 Development of the Pre- and Early Post-Implantation Embryo
Ovulation occurs in response to a surge in the level of luteinising hormone (LH)
produced by the pituitary gland. After LH stimulation, the oocyte undergoes nuclear
maturation when it loses its membrane (a process known as germinal vesicle
breakdown) and the chromosomes assemble on the spindle and move towards the
periphery of the cell where the first meiotic division takes place. One set of
chromosomes surrounded by a small amount of cytoplasm is extruded as the first
polar body, whereas the other set remains at metaphase II. The oocyte remains
arrested at metaphase II until fertilisation triggers the second meiotic division and
extrusion of the second polar body. Nuclear membranes form around the maternal
and paternal chromosomes forming separate haploid male and female pronuclei. The
pronuclei do not fuse but the membranes break down and the chromosomes assemble
on the spindle and the first cleavage takes place soon after. The first cleavage
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(beginning of the 2-cell stage) separates the embryo into two blastomeres
approximately the same size, and irrespective of the species, takes place between 11
and 20 hours after fertilisation.
The initial cleavage divisions are equal, asynchronous and without any particular
orientation. The blastomeres of early 8-cell embryos are spherical, evenly coated with
microvilli and can easily be dissociated because cellular interactions are weak. During
the 8-cell stage, cells start to flatten upon each other so that their boundaries can no
longer be seen with an optical microscope. The major molecule involved in this cell
flattening is the calcium-dependent cell adhesion molecule uvomorulin (also known as
L-CAM or E-cadherin). Simultaneously with this flattening process, cytoplasmic and
surface components become asymmetrically distributed (or polarised) - these two
processes are known collectively as compaction. From the subsequent mitotic
division (stage 16 in the mouse) this polarity is sufficient to produce two daughter
cells which are identical when the division plane corresponds to the polar axis and
different when the division separates the basolateral section of the cytoplasm (non-
polar cytoplasm) of the outermost section (polar cytoplasm). The relative frequency
of divisions according to the polar axis therefore determines the number of polar and
non-polar cells in the subsequent division. At this stage the embryo is known as a
morula. Tight junctional seals are formed in the trophectoderm and the blastocoele
expands as a result of fluid accumulation induced by a water transport system and a
basolaterally located Na+K+ATPase enzyme. Expansion of the blastocoele generates a
blastocyst containing two progressively determined cell populations - the
trophectoderm and the inner cell mass. The trophectoderm has all the features of a
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true epithelium with apical junctional complexes forming a complete permeability seal
against the outside environment, and generates cells that populate the placental
structures such as the ectoplacental cone, trophoblast giant cells and the chorion. The
trophectoderm (TE) overlaying the inner cell mass (ICM) is known as the polar TE,
and the cells surrounding the blastocyst caivity constitute the mural TE. In contrast,
the ICM cells generate the entire embryo and the amnion, the yolk sac, the allantois
and mesodermal components of the placenta.
During the 5th and 6th day of development (for the mouse and rat, respectively) the
blastocyst hatches from the zona pellucida and is ready for implantation. The walls of
the uterus become tightly opposed so that the uterine lumen is more or less occluded.
The blastocyst first adheres by its abembryonic pole (the mural TE furthest away from
the ICM) to the anti-mesometrial uterine wall. Blastocyst attachment induces the
formation of a uterine crypt and stimulates the uterine stroma to form a spongy mass
of cells known as decidual tissue. There is a rapid increase in the permeability of local
capillaries causing the uterine stroma to become swollen and oedematous. The
stromal cells proliferate, increase in size and establish numerous tight junctional
complexes with neighbouring cells. Degeneration of the epithelium allows the
trophoblast cells, which phagocytose the moribund epithelial cells, to invade the
deciduum.
During the post-implantation development, the trophectoderm becomes regionally
specialised with respect to morphology (51). The mural TE replicate their DNA
without cell division giving rise to trophoblast giant cells which invade the uterus
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during implantation. The rest of the TE grows to form the ectoplacental cone and the
extra-embryonic ectoderm which both contribute to the formation of the placenta.
Some cells from the primitive endoderm migrate over the whole inner surface of the
mural TE - they become the parietal endoderm. The remaining primitive endoderm
cells form the visceral endoderm which covers the elongating egg cylinder containing
the epiblast.
By 6 days after fertilisation (in the mouse) an internal cavity has formed inside the
epiblast, which becomes cup-shaped. The embryo proper develops from this curved
layer of epithelium. At 6V2 days, the gastrulation begins with the formation of the
primitive streak. The streak starts as a localised thickening at a point on the
circumference of the cup - this is the future dorsal side of the embryo. Proliferating
epiblast cells migrate through the primitive streak and spread out laterally and
anteriorly between the ectoderm and the visceral endoderm to form a mesodermal
layer which will give rise to the gut. The development of extra-embryonic structures
involves the production of extra-embryonic mesoderm at the end of the primitive
streak. This eventually contributes to the amnion, the visceral yolk sac and the
allantois and chorion, which are important components of the placenta.
During the final stages of gastrulation (approximately 8V2 days in the mouse)
organogenesis commences in the anterior part of the embryo with the formation of the
heart, the cranial neural folds and the appearance of somites. Between 8V2 and 9/4
days the mouse embryo undergoes a complicated change in conformation in which it
'turns' so that it becomes entirely enclosed in the protective amnion and amniotic
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fluid. The visceral yolk sac, a major source of nutrition, surrounds the amnion and the
allantois connects the embryo to the placenta.
1.5 Apoptosis and Pre-Implantation Embryo Development
Cell death can occur by one of two distinct processes, necrosis or programmed cell
death through apoptosis. Necrosis is usually associated with injury, and results in
cellular swelling and rupture of the plasma and internal membranes. True
programmed cell death (PCD) is genetically programmed, and requires the activation
of specific genes involved in the execution of cell death. Apoptosis is triggered by
external or internal stimuli, the process can be divided into four phases (389). The
first phases may occur in response to an external trigger delivered through surface
receptors (e.g. fas ligand and CD40 ligand), or may originate inside the cell from the
action of a drug, toxin, or radiation (284). The next phase involves detection of this
signal and transduction of the signal. The activation or signalling phase encompasses
a great variety of signal transduction pathways including tyrosine kinases, steroid
receptors, ceramide, inositol phosphates and cytokine receptors. The death effector
phase is the third part of the cell death mechanism and includes the cysteine proteases
that are activated during apoptosis. The fourth phase is the post-mortem phase, in
which the cell's chromatin condenses and its DNA is degraded into oligonucleosome
chains (seen as DNA 'laddering' on gel electophoresis) (284). Depending on their
ratio, Bcl-2 and similar proteins can inhibit the action of the proteases, either by
blocking their activation or by preventing them from reaching their targets. Other
proteins implicated in the regulation of apoptosis include tumour suppressor protein
p53 which triggers apoptosis in cells with damaged DNA, and c-Myc which can
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inhibit apoptosis in the presence of factors such as insulin-like growth factor-I, insulin
and epidermal growth factor (390).
Developmentally regulated cell death is widespread in embryogenesis (288) and
occurs by apoptosis in both vertebrate and invertebrate species. It is a widespread
feature in blastocysts of many mammals such as the cow (289); Rhesus monkey (290);
mouse (2291) and the human (268). The significance of these dead cells is not folly
understood, but it has been suggested that the primary function is to allow for the
removal of redundant or defective cells from the blastocyst (288), or the elimination
of ICM cells retaining the potential to form TE (291). Other suggestions include lack
of survival factors in vitro or in vivo, and chromosomal abnormalities (387). In
mouse blastocysts it has been recently reported that embryonic cells have a death-by-
default mechanism that requires constant suppression by 'survival' factors produced
both by the embryo and the maternal reproductive tract (388). However, the role of
cell death in blastocyst development is unknown and the precise molecular






Chemicals for molecular biology were obtained from BDH Chemicals Ltd., Poole, UK
unless otherwise stated, and were of analytical quality. All molecular biology
solutions were prepared in reverse osmosis distilled water (Elgastat Prima) and
solutions for RNA work were prepared in autoclaved distilled water treated with 0.1
% diethyl pyrocarbonate (DEPC) (Sigma). Chemicals used to prepare rat embryo
culture media were obtained from Sigma and were of tissue culture grade. Sterile
water used to prepare cell culture media was obtained from Baxter Healthcare Ltd
(Norfolk, England).
2.1.2 Animals
2.1.2.1 BB/Edinburgh (BB/E) Rats
A breeding colony of BB Wistar rats was established in Edinburgh in 1982 from a
small nucleus of animals (3 male and 4 female) donated by Dr. P. Thibert from the
original outbred BB rat colony in Ottawa. The BB/E colony consists of two sublines
created by selectively breeding for and against diabetes. These two lines have now
been through more than 30 generations of strict brother-sister mating on site thus
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meeting the international criterion for designation as an inbred line, and have had their
inbred status confirmed by skin allograft experiments.
In the high incidence Diabetes Prone mainline (DP-BB/E) the incidence of IDDM is
50-60 % and the mean (± SD) age at onset is 96 (± 18) days of age. In the Diabetes
Resistant subline (DR-BB/E) the incidence of diabetes is zero. The lymphoid status
of the two lines has been characterised in detail using FACS analysis and it has been
shown that the BB/E colony is unique in that both lines are identical in all the
immunological parameters examined (221). This makes the DR-BB/E subline an
exceptionally good control strain for studies of the effect of diabetes on any parameter
selected.
2.1.2.2 Non-BB Wistar Han Rats
Adult Wistar Han rats (out-bred on site for 5 years) were obtained from our breeding
facility.
All animals were maintained at 20°C on a 12 hour light/12 hour dark cycle and
allowed free access to food and water. BB/E rats were fed rat and mouse Number 1
Expanded Feed and Wistar Han rats CRM rat and mouse Breeder and Grower Diet,
both from Special Diet Services (Witham, UK).
2.1.2.3 Diagnostic Criteria for IDDM in the BB/E rat
All animals are weighed twice weekly from 40 days of age. If they fail to gain weight
or lose weight they are tested for glycosuria (Multistix SG reagent strips, Bayer
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Diagnostics). If glycosuria is detected, the blood glucose concentration is measured
(ExacTech blood glucose meter, Medisense) on a blood sample obtained by tail
tipping without anaesthesia. In the Edinburgh BB rat colony a blood glucose
concentration of >18 mmol/L is invariably associated with loss of weight, ketonuria,
undetectable circulating endogenous insulin (J Freeman, RM Lindsay, JD Baird, J
Foster, CR Elcombe, DJ Harrison, H Wolf and CR Wolf, unpublished observations)
and the permanent need for daily treatment with insulin to ensure survival. These
parameters constitute our criteria for classifying an animal as having autoimmune-
induced insulin-dependent diabetes mellitus (IDDM).
2.1.2.4 Treatment and Management of Diabetes in the BB/E rat
(i) Conventional Insulin Therapy
Diabetic DP-BB/E rats were maintained by conventional insulin therapy i.e. a single
subcutaneous injection of long acting insulin (Bovine Ultratard U40, Novo Nordisk,
Denmark) each morning. The dosage of insulin (usually 2.0-2.6 units per day) was
adjusted for each animal according to blood glucose measurements, glycosuria and
body weight. This treatment allows the animals to be generally healthy, maintain
normal body weights and live a normal lifespan but does not achieve normoglycaemia.
(ii) Sustained Release Insulin Implants
A separate group of Diabetic DP-BB/E rats with IDDM were maintained on
Linplant®or LinBit™ sustained release insulin implants (SRIIs). These implants are
small rods of insulin (7 mm long with a diameter of 2 mm) consisting of 14 %
powdered bovine insulin compressed under high pressure into a pellet with 86 %
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palmitic acid (Linplant SRIIs) or 5 % insulin with 95 % palmitic acid (LinBit SRIIs).
Following implantation (using a local anaesthetic, trocar and cannula) erosion of the
implant begins at once and the effect of the released insulin on the blood glucose level
can be detected within 1 h of implantation. The insulin is released at a steady rate and
approximately 2 units of bovine insulin is delivered per Linplant SRII or 0.4 units of
bovine insulin per LinBit SRII, per 24 h per implant for >40 days. The recommended
sites for implantation are subcutaneously in the dorsal neck region or the sternal area
and the recommended dose for young female rats (weighing approximately 220 g) is
Vi Linplant implant or two lower dose LinBit implants.
2.1.2.5 Assessment of Metabolic Control
Irrespective of the method of treatment it was important to assess the degree of
metabolic control for each individual animal. Whole blood samples (20 pi) were
taken either daily or on alternate days, by tail tipping without anaesthesia and the
concentration of blood glucose was measured using a glucose meter (ExacTech,
Medisense). In addition, urine samples were monitored regularly for the presence of
glucose and ketone bodies (Multistix). Plasma samples were also collected
intermittently by removing approximately 1.5 ml of whole blood by tail tipping into
heparinised eppendorf tubes. Plasma and whole blood were separated by
centrifugation using an bench top centrifuge (Eppendorf) at 10,000 x g for 5 min.
The plasma was stored at -20°C before being sent to Dr. Linda Ashworth (University
of Newcastle Upon Tyne) to measure the concentration of various plasma
metabolites. The remaining red blood cells were washed with 0.9 % sodium chloride
and stored at 4°C and used to determine the percentage of glycosylated haemoglobin
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by Dr. Mark Lindsay (Western General Hospital, Edinburgh) using the Pierce
Glyco.Test II (Pierce Chemical Co. Illinois, USA).
2.2 Methods
2.2.1 Preparation of Embryo Culture Media
2.2.1.1 Nutrient Mixture (Ham's) F10
Nutrient Mixture (Ham's) F10 (Gibco BRL) was supplemented with 0.1 % bovine
serum albumin Fraction V (Sigma), 100 U/ml penicillin and 100 pg/ml streptomycin
(Sigma). The medium was filter sterilised through a 0.22 pm bottle top filter (Falcon)
into sterile glass bottles and stored at 4°C.
2.2.1.2 M2 and M16 Media
M2 (263) and Ml6 (264) embryo culture media were prepared from concentrated
stock solutions of the component chemicals (Table 2.1). All stock solutions were
filter sterilised through a 0.22 pm bottle top filter and stored at 4°C. Stock solutions
A, D and E were stored for up to three months, and stock solutions B and C were
changed every other week. To prepare the 1 x solutions of M2 and Ml6, the
appropriate amounts of stock solutions (Table 2.2) were added to a conical flask and
sterile distilled water was added to a volume of 50 ml. The Ml6 medium was gassed
with 5 % C02 in air for 5 min to adjust the pH to 7.4. If required, 200 mg bovine
serum albumin (Fraction V) (Sigma) was added and allowed to slowly dissolve. The
media were then filter sterilised through a 0.22 pm bottle top filter (Falcon) into
sterile glass bottles and stored at 4°C for up to 1 week.
71
Table 2.1 : M2 and M16 culture media stock solutions
Stock A Component g/100 ml








Stock B Component g /100 ml
(10 x concentration) Sodium bicarbonate 2.101
Phenol red 0.010
Stock C Component g/10 ml
(100 x concentration) Sodium pyruvate 0.036
Stock D Component g/10 ml
(100 x concentration) Calcium chloride 0.252
Stock E Component g/10 ml
(10 x concentration) Phenol Red 0.010
Hepes (Gibco BRL) 75 ml
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Table 2.2 : Preparation of M2 and M16 from concentrated stock
solutions
Stock M2 (50 ml) M16 (50 ml)
A (x 10) 5.0 ml 5.0 ml
B (x 10) 0.8 ml 5.0 ml
C (x 100) 0.5 ml 0 .5 ml
D (x 100) 0.5 ml 0.5 ml
E (x 100) 4.2 ml -
Sterile distilled water 39.0 ml 39.0 ml
2.2.1.3 Minimal Essential Medium (Eagle's)
The incomplete MEM medium (alpha modification) was prepared by dissolving the
powdered media (Sigma) in 800 ml of sterile water, the pH was adjusted to 7.4 by
adding 29.7 ml sodium bicarbonate (Gibco BRL) and the total volume was adjusted
to 1 litre with water. The medium was filter sterilised in to sterile glass bottles and
stored at 4°C. Complete alpha MEM medium was prepared from 435 ml of
incomplete medium, 50 ml fetal bovine serum (Advanced Protein Products), 10 mM
Hepes (Sigma), 100 U/ml penicillin and 100 yig/ml streptomycin (Sigma) and 5 x 10 5
M 2-mercaptoethanol.
2.2.1.4 Uterine Cell Conditioned Media
Pregnant diabetic and non-diabetic BB/E rats were killed on day 4.5 of gestation.
Uterine cell conditioned media were prepared using the method described by Clark et
al (265) and Lea et al (266). Uterine cells were harvested by scraping the walls of the
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endometrium and passing the cells through a 60-mesh stainless steel screen (Sigma) to
obtain a single cell suspension. The uterine cells from each uterus were incubated in
0.5 ml a-MEM for 48 hours in a humidified atmosphere of 5 % C02 at 37°C. After
incubation the cell suspensions were centrifuged at 2772 x g and the supernatant was
removed, filtered (0.22 pm sterile filter, Sigma) and pooled with other supernatants
from either diabetic or non-diabetic rats (4 supernatants per pool).
2.2.2 Embryo Collection
Pregnancy was confirmed the morning after mating by the presence of a sperm
positive vaginal smear and was designated day 0.5 of gestation. Pregnant rats were
killed by cervical dislocation on day 4.5 of gestation and the uterine horns
immediately removed. Embryos were gently flushed from the excised uteri with pre-
warmed Nutrient Mixture (Ham's) F10.
2.2.3 Morphological Analysis
Embryos from each individual pregnancy were transferred to an inverted microscope
and classified as having reached a recognisable developmental stage, namely morula,
early blastocyst with a nascent blastocoele and expanded blastocyst with a clearly
demarcated trophectoderm (TE) and inner cell mass (ICM) (267).
The remaining structures could not be classified into one of these categories but were
characterised by the following features: (1) having the form of a flattened disc rather
than a sphere, (2) cell cytoplasm with a granular appearance, and (3) a reduced
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Figure 2.1
Photograph of a typical example of an unfertilised oocyte from a Non-Diabetic
DR-BBE/E rat
75
number of irregular shaped cells with much reduced cell-to-cell contact. This latter
feature was demonstrated by the fact that when the zona pellucida was removed the
'embryo' separated into single cells. Figure 2.1 shows a typical example displaying
these features. Structures with similar features were described by Hardy et al (268)
and classified as 'abnormal embryos'. However, since I identified similar structures in
Non-Diabetic non-pregnant females which had not been mated with male rats, and in
Diabetic and Non-Diabetic females mated with vasectomised male rats proven sterile,
the conclusion was that in our experimental situation these abnormal structures were
in fact unfertilised oocytes.
The number and percentage of (i) embryos at each developmental stage and (ii)
unfertilised oocytes was determined and recorded separately for each individual
pregnancy.
2.2.4 Differential Staining of Trophectoderm and Inner
Cell Mass
The number of trophectoderm and inner cell mass cells was determined in expanded
blastocysts using a dual fluorochrome differential staining technique originally
described by Handyside and Hunter (269) and established in our laboratory by Dr.
Richard Lea. Blastocysts were subjected to a 15 min incubation in 0.4 % pronase
(Boehringer Mannheim, UK) in M2 medium containing 10 mg/ml BSA (Sigma) at
37°C, 5 % C02. The denuded blastocysts were washed four times in BSA-free M2
and incubated in 4 mM picrylsulfonic acid (trinitrobenzenesulfonic acid, Sigma) in
BSA-free M16 with 1 % polyvinylpyrrolidone (Calbiochem, La Jolla, CA) for 30 min
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on ice. After further washing in BSA-free M2, the blastocysts were incubated with 10
pg/ml rabbit anti-dinitrophenyl-bovine serum albumin complex polyclonal antibody
(ICN Biomedicals) in BSA-free M2 for 30 min at 37°C, 5 % C02. After a final
washing step the blastocysts were incubated in 10 % whole guinea pig serum (Sigma)
as a source of complement in BSA-free M2 containing 10 pg/ml propidium iodide
(Sigma) and 20 pg/ml bisbenzimide (Sigma) for 30 min 37°C, 5 % CO2. This
sequential treatment results in the anti-DNP-BSA antibody binding to the
trinitrophenol groups on the surface of the trophectoderm cells. In the presence of
complement, the TE cells are partially lysed allowing access of propidium iodide
(which is excluded from viable cells) and bisbenzimide to the TE cell nuclei. The ICM
remains intact due to the tight junctional seal of the trophectoderm and is labelled
with bisbenzimide alone. Under conditions of UV light excitation the different
fluorescent spectrum of each dye results in the ICM staining blue and the TE staining
red/pink. The differentially stained blastocysts were individually mounted on
microscope slides in a small amount of medium in the centre of a silicone ring with a
coverslip on top and incubated at room temperature in a dark box for 20 min. The
number of ICM and TE cells were counted directly under a Leitz Orthoplan
fluorescence microscope fitted with a Leitz A filter, after gently pressing the edges of
the coverslip to convert the blastocyst into a two-dimensional form to facilitate
accurate cell counting.
2.2.5 Blastocyst Culture
Expanded blastocysts flushed from the uterine horns of Diabetic and Non-Diabetic
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BB/E rats on day 4.5 of pregnancy were cultured in vitro in Nutrient Mixture (Ham's)
F10 medium supplemented with 0.1 % BSA, 100 U/ml penicillin and 100 pg/ml
streptomycin for 24 h at 37°C, 5 % C02. After culture, blastocysts were re-examined
on an inverted microscope, washed with BSA-free M2 medium and differentially
stained as described in section 2.2.4.
2.2.6 Blastocyst Culture in Uterine Cell Conditioned Media
Expanded blastocysts flushed from Diabetic DP-BB/E rats, Non-Diabetic DR-BB/E
rats and Wistar Han rats were transferred into multi-well dishes (Nunc) containing
200 pi of either Diabetic DP- or Non-Diabetic DR-BB/E rat uterine cell conditioned
media. Between 5 and 10 blastocysts were transferred to each well. The final volume
in each well was increased to 400 pi with the addition of 200 pi Nutient Mixture
(Ham's) F10. Blastocysts were cultured for 24 h at 37°C, 5 % C02. After incubation
the number of trophectoderm and inner cell mass cells was determined using the dual
fluorochrome method described in section 2.2.4.
2.2.7 Total Cell Counts in Early Pre-implantation Embryos
Using a giemsa staining procedure modified from the method of Tarkowski (270) the
total cell number in morulae and early blastocysts was determined. Embryos were
flushed from the uterus of Diabetic DP- and Non-Diabetic DR-BB/E rats at 90 h post
coitum (assuming fertilisation to have occurred in the middle of the dark period
preceeding the discovery of the vaginal copulation plug). The embryos were washed
twice in 1 x PBS, followed by a 10 min wash in hypotonic (1 %) sodium citrate
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(BDH). The embryos were then incubated in freshly prepared acid : alcohol fixative
(ethanol: acetic acid, 3:1 v:v) for 30 min at room temperature. Single embryos were
placed in a drop of fixative on a clean glass microscope slide and before the fixative
could evaporate, a small drop of 60 % acetic acid was added to separate the
individual cells of the embryo. The slides were left to air dry before being stained for
20 sec in 4 % giemsa stain (Gurr, BDH). Finally, slides were washed in distilled water
and air dried before counting the number of individual cells in each embryo under a
light microscope.
2.2.8 Embryo Transfer Procedure
2.2.8.1 Recovery of 2-cell embryos
The standard procedure is to transfer 2-cell embryos to the oviduct on day 0.5 of
pseudopregnancy (where day 0.5 is day of vaginal plug, indicative of mating the
previous night). This procedure ensures that the embryos are at the blastocyst stage
at the time the uterus is receptive for implantation, which is day 4.5 in the rat.
Donor females (at 1.5 days gestation) were killed by cervical dislocation and the uteri
and ovaries quickly removed and placed into a petri dish containing pre-warmed M2
medium (containing 400 mg/ml BSA). The ovary was removed from one horn and
under the dissecting microscope the excess fat was trimmed away and the oviduct
separated from the ovary and uterus. The end of a flushing needle was inserted into
the opening of the oviduct, the infundibulum, and the edge of the infundibulum was
held with forceps while 0.5 ml of M2 medium was gently flushed through the oviduct
into a 4-well multidish. Embryos were recovered from the second oviduct in the same
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way and held in 500 pi of M2 medium at 37°C, 5 % C02 until recipient females were
ready for transfer.
2.2.8.2 Anaesthesia
A Hypnorm/Hypnovel cocktail was prepared by mixing 1 part of Hypnorm (Janssen
Animal Health, Buckinghamshire,UK; containing 0.315 mg/ml fentanyl citrate and 10
mg/ml fluanisone), 1 part of Hynovel (Hoffman La Roche, Nutley, NJ; containing 5
mg/ml midazolam) and 2 parts of sterile water.
Recipient pseudopregnant females (at day 0.5 of pseudopregnancy) were weighed and
anaesthesia (0.33 ml per 100 g of body weight) administered by intraperitoneal
injection. The rat was then placed in a 37°C heat box until fully anaesnethetised.
2.2.8.3 Loading of the transfer pipette
Transfer pipettes were prepared from glass capillary pipettes, pulled to a fine tip. The
transfer pipettes were first loaded with a small amount of light paraffin oil (BDH)
followed by a small air bubble and a small amount of M2 medium containing 400
mg/ml BSA. Then, a second air bubble was drawn into the pipette followed by the
embryos in a minimal volume of M2 containing 400 mg/ml BSA.
2.2.8.4 Transfer of 2-cell embryos
Once the recipient female was fully anaesnethetised, a small area on her left hand side
was shaved, swabbed with 70 % ethanol and a small transverse incision was made in
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the skin. Once the fat pad had been located through the body wall, an incision
through the abdominal muscle was made and the ovary fat pad was pulled out
bringing the ovary, oviduct and uterus with it. Using a dissecting microscope the
infiindibulum was located and 5-10 pi drops of 1 % epinephrine (Sigma) were placed
on some of the small capillaries of the ovarian bursa to prevent localised bleeding
once the bursa was cut. With forceps and scissors, a small hole was made in the bursa
and the transfer pipette containing the embryos was inserted through the hole and into
the infundibulum, and the embryos were expelled into the ampulla of the oviduct. The
ovary and uterus were carefully placed back into the body and the abdominal muscles
were sutured. Finally, the skin incision was closed with 9 mm wound clips (Autoclips,
Becton Dickinson and Co., Parsiappany, NJ).
2.2.8.5 Post-operative care
The rat was placed on a cotton wool mat in a cage with free access to food and water
and the cage put in a warm place. A post-operative analgesic, Nubain (DuPont
Pharmaceuticals Ltd, UK; containing Nalbuphine hydrochloride, 10 mg/ml) was
prepared by adding 0.2 ml Nubain to 0.8 ml sterile water and a dose of 0.2 ml given
subcutaneously.
2.2.9 Reverse-Transcriptase Polymerase Chain Reaction
2.2.9.1 Tissue collection and RNA extraction
Pregnant rats were killed by cervical dislocation on day 4.5 of gestation and the
uterine horns immediately removed. Pre-implantation embryos were gently flushed
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from the excised uteri with pre-warmed Nutrient Mixture (Ham's) F10. Single
embryos, in 5 pi of medium, were flash frozen in liquid nitrogen and stored at -70°C.
Total RNA was isolated using the method originally described by Chomczynski and
Sacchi (271) and later modified for pre-implantation embryos by Sharkey et al (272),
in which frozen tissue is homogenised with 100 pi buffer containing 4 Mguanidinium
thiocyanate (Fluka), 25 mM sodium citrate pH 7.0, 0.5 % sarcosyl and 0.1 M 2-
mercaptoethanol. RNA precipitation was assisted with the addition of glycogen at a
final concentration of 20 pg/ml (273).
The pH was lowered by the addition of 0.5 ml 2 M sodium acetate pH 4 and the
lysate was extracted in phenol:chloroform with 20 pi buffer saturated phenol (Fisher
Scientific) and 20 pi chloroform-isoamylalcohol (49:1, v:v) (Fisons Scientific). The
tubes were placed on ice for 15 min and centrifiiged at 10,000 x g at 4°C for 20 min.
The aqueous phase was removed and mixed with 100 pi isopropanol and the RNA
was precipitated at -20°C. The RNA was recovered by centrifugation, dried and
resuspended in 30 pi of homogenisation buffer and then precipitated with 1 volume
(30 pi) of isopropanol at -20°C for 1 hour. Finally, the RNA was centrifuged at
10,000 x g at 4°C for 20 min, the pellet washed in 75 % ethanol, dried and dissolved
in 5 pi DEPC-treated water and stored at -20°C.
2.2.9.2 cDNA Synthesis
In a sterile RNase-free, microcentrifuge tube, 1 pi of 0.1 mM random hexamer
primers (Pharmacia) was added to half (i.e. 2.5 pi) of the total RNA prepared from a
single embryo and the volume was adjusted to 10 pi with DEPC-treated water. The
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tube containing RNA and primers was heated to 70°C for 5 min, cooled to 25°C and
centrifiiged briefly to collect the liquid to the bottom of the tube. A reaction mix was
prepared containing 4 pi avian myoblastosis virus (AMV)-reverse transcriptase buffer
(containing 250 mM Tris HC1 pH 8.8, 250 mM potassium chloride, 50 mM
magnesium chloride, 50 mM DL-dithiothreitol and 2.5 mM spermidine), 2 pi dNTP
mix (10 mM), 0.5 pi RNA guard (Pharmacia), 3 pi DEPC-treated water and 2 pi
AMV-reverse transcriptase (Promega). The reaction mix was added to the RNA and
primers. The reactions were incubated at 37°C for 60 min, followed by 95°C for 5
min and 25°C for 1 min. cDNA was also synthesised from 1 pg of ovary-derived
RNA using the same method as described above.
Negative controls were prepared in which (1) the RNA was replaced with water, to
check for contamination of primers, magnesium chloride and buffers, and (2) a culture
medium control with added glycogen (and no embryos), which were extracted,
reverse transcribed and amplified in exactly the same way as the embryo RT reactions.
2.2.9.3 Design of oligonucleotide primers for PCR
The sequence of the external and internal primers for bax, bcl-2 and /3-actin genes are
shown in Table 2.3. The primers were based on available sequence data for the genes
of interest /3-actin (274), bcl-2 (275), bax (276).
The primers were designed according to the following constraints namely: (i) between
20-30 nucleotides in length with a balanced G/C and A/T content; (ii) not have






























































minimum homology with other members of the bcl-2 gene family, and (v) include an
intron in the amplicon for discrimination of products from genomic DNA.
Oligonucleotide primers for all genes were synthesised by Oswel (Southampton, UK).
Lyophilised primers were dissolved in sterile water to give a concentration of 100 pM
and 50 pi aliquots were stored at -20°C.
2.2.9.4 cDNA Amplification
One-tenth aliquots (i.e. 2 pi) of embryo cDNA were amplified in the presence of lOx
PCR buffer (containing 50 mM Tris-HCl (pH 9.1), 16 mM ammonium sulphate and
150 pg/ml bovine serum albumin), 200 pM of dNTP mix (50 mM dATP, 50 mM
dGTP, 50 mM dTTP, 50 mM dCTP), 1 pM of each primer and 0.5U Taq polymerase
(Helena Biosciences, Newcastle Upon Tyne). Magnesium chloride was added to give
a final concentration of 1 mM, 1.7 mM and 2.5 mM for P-actin, bax and bcl-2
respectively. Reactions were overlaid with 30 pi of light mineral oil (Sigma) to
prevent evaporation and placed in a Hybaid Omnigene PCR machine.
After 33, 30 or 20 cycles of PCR (for bax, bcl-2 and P-actin primers respectively)
using the external primer pair, 1 pi of the first round reaction was transferred into a
fresh tube containing the internal primer pair. PCR mix was added (as decribed
above, with the exception that the magnesium chloride concentration was reduced to
1 mM). The reactions were amplified for further 33, 30 or 20 cycles for bax, bcl-2
and P-actin internal primers respectively.
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The cycling conditions were 3 min at 94°C for one cycle, followed by 94°C for 1 min,
n°C for 1 min and 72°C for 2 min for 33, 30 or 20 cycles depending on the primers
used, and the last cycle concluded with a 10 min extension time at 72°C. n°C was the
annealing temperature for each pair of primers as described below : bax and bcl-2 53
and 55°C; and (3-actin 58 and 64°C (external and internal primers respectively).
2.2.9.5 Verification of PCR products
2.2.9.5.1 Agarose gel electrophoresis
Agarose gels (2 %) were prepared in 1 x TAE buffer (40 mM Tris acetate and 1 mM
EDTA). Agarose (Gibco BRL) was dissolved in TAE buffer and ethidium bromide
was added to a final concentration of 0.5 pg/ml. The PCR samples were mixed with
gel loading buffer (0.25 % bromophenol blue, 0.25 % xylene cyanol FF and 30 %
glycerol in water) and loaded into the wells. Since the expected sizes of the PCR
products were 300-700 bp the size marker was Bluescript plasmid DNA (Stratagene)
which had been digested with Sau3A, creating marker band sizes of 1000, 737, 341,
258, 222, 105 and 78 bp. A voltage of 10 V/cm was applied to the gel for 1-1.5 h.
2.2.9.5.2 DNA Sequencing
Sequencing was performed using an ABI Prism™ 377 DNA Sequencer (Perkin Elmer)
using the Taq DyeDeoxy™ Terminator cycle sequencing kit. The Taq polymerase,
Ampli Taq® DNA polymerase, FS, was developed especially for fluorescent cycle
sequencing with dye labelled primers and terminators. The kit also contains
deoxyinosine triphosphate (dITP) in place of dGTP to minimise band compressions
which often occur in GC-rich areas of sequences.
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(i) Preparation of sequencing gel
A 36 cm 4 % acrylamide gel (BioRad) containing 29:1 ratio of acrylamide to
bisacrylamide and 8 M urea was made in IX TBE (tris-borate-20mM EDTA buffer
pH 8.3), and poured using 0.2 mm spacers and combs.
(ii) Preparation of cDNA
A reaction was set up for each set of primers consisting of 100 ng of purified PCR
product, 3.2 pmole primers and 8 pi of Terminator Ready Reaction mix (containing
A-, C-, G-, and T-Dye Terminators, dITP, dATP, dCTP, dTTP, Tris-hydrochloride
pH 9), magnesium chloride, thermal stable pyrophosphatase and Ampli Taq® DNA
Polymerase, FS). The reaction volume was adjusted to 10 pi with sterile distilled
water, overlaid with 35 pi of mineral and amplified using a Hybaid Omnigene PCR
machine for 25 cycles of 30 sec at 96°C, 15 sec at 50°C and 4 min at 60°C. The
reactions were placed on ice following amplification and 1 pi 3 M sodium acetate (pH
4.6) and 20 pi 95 % ethanol were added to precipitate the cDNA. The pelleted
cDNA was resuspended in 6 pi of loading buffer (deionised formamide containing 25
mM EDTA (pH 8) and 50 mg/ml blue dextran in a ratio of 5:1 formamide to
EDTA/blue dextran). The samples were denatured at 90°C for 2 min and placed on
ice. A 1.5 pi aliquot of each sample was loaded onto a pre-warmed 4 % acrylamide
gel and run at 1.68 kV, 50 mA and 150 W for 7 h at a constant temperature of 51°C.
2.2.10 Preparation of Internal Standards
2.2.10.1 cDNA Amplification
One quarter of the ovary RT reaction was amplified for 30 cycles using the external
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primer pair for each gene. Immediately after PCR, a 10 pi aliquot was
electrophoresed on a 2 % agarose gel and the amount of product estimated by eye
after ethidium bromide staining.
2.2.10.2 Ligation and cloning of PCR products
An aliquot of 2 pi of PCR product was added to 1 pi ligation buffer (containing 60
mM Tris-HCl pH 7.5, 60 mM magnesium chloride, 50 mM sodium chloride, 1 mg/ml
bovine serum albumin, 70 mM P-mercaptoethanol, 1 mM ATP, 20 mM
dithiothreteitol and 10 mM spermidine) and 2 pi pCR2.1 vector at 25 ng/pl
(Invitrogen) to give a molar ratio of 1:1. The volume was adjusted to 9 pi with sterile
water and 1 pi T4 ligase (40 Weiss units) was added. The ligation reactions were
incubated at 14°C overnight.
2.2.10.3 Preparation of Solutions for Transformation
(i) Ampicillin
A 100 mg/ml stock solution was prepared by dissolving 1 g of ampicillin (Sigma) in
10 ml of deionised water. The antibiotic was filter sterilised through a 0.2 pm filter
unit and 500 pi aliquots were stored at -20°C.
(ii) LB (Luria-Bertani) Medium and Agar
To prepare 1 litre of LB broth, 10 g of bacto-tryptone (Difco Laboratories), 5 g
bacto-yeast extract (Difco Laboratories) and 10 g sodium chloride (BDH) were
dissolved in 950 ml of deionised water. The pH of the solution was adjusted to 7.0
with sodium hydroxide and the volume was increased to 1 litre with deionised water.
88
The solution was autoclaved for 20 min at 15 lb./square inch and allowed to cool to
55°C. Ampicillin was added to give a final concentration of 100 pg/ml.
LB agar plates were prepared as described above but 15 g/1 agar (Difco Laboratories)
was added before autoclaving. The agar was cooled to 55°C and ampicillin was
added to a final concentration of 100 pg/ml. The agar was then poured into 10 cm
plates allowed to set and the plates were stored at 4°C for < 1 month.
(iii) 5-bromo-4-chloro-3 indolyl-P-D-galactoside (X-Gal)
A 40 mg/ml stock solution was prepared by dissolving 400 mg X-Gal (Sigma) in 10
ml dimethylformamide. Aliquots of 500 pi were stored at -20°C protected from light.
(iv) Isopropyl-P-D-thiogalactopyranoside (IPTG)
A 100 mM stock solution was prepared by dissolving 238 mg IPTG in 10 ml
deionised water. The solution was then filter sterilised and stored in 1 ml aliquots at
-20°C.
(v) X-Gal / IPTG LB agar plates
To previously prepared LB agar plates containing 100 pg/ml ampicillin, 40 pi of the
X-Gal stock solution and 40 pi of the IPTG stock solution were spread evenly over
the surface of the agar. The plates were incubated at 37°C for 20-30 min to allow the




SOC medium (100 ml) was prepared by dissolving 2 g bacto-tryptone (Difco
Laboratories), 0.5g bacto-yeast extract (Difco Laboratories), 1 ml of 1M sodium
chloride and 0.25 ml potassium chloride in 97 ml of deionised water. A 1 ml aliquot
of 2 M Mg2+ stock solution (1 M magnesium chloride, 1 M magnesium sulphate) and
1 ml of sterile 2 M glucose stock solution were added to give a final concentration of
20 mM. The complete medium was filter sterilised through a 0.2 pm filter unit and
stored at room temperature.
2.2.10.4 Transformation by heat shock
One 50 pi vial of frozen TOP lOF'competent Escherichia coli bacteria (Invitrogen)
per ligation reaction was thawed on ice. A 2 pi aliquot of 0.5 M p-mercaptoethanol
was added to each vial of competent cells and mixed gently. Two pi of ligation
reaction were added to each vial and incubated for 30 min on ice. The cells were heat
shocked for exactly 30 sec in a 42°C waterbath and placed on ice for a further 2 min.
To each vial, 250 pi of SOC medium were added and the vials were incubated at
37°C for 1 h before aliquots of 50 pi and 200 pi were spread on separate LB agar
plates containing 100 pg/ml ampicillin, 0.1 M IPTG and 40 pg/ml X-Gal. Plates were
inverted and incubated at 37°C overnight.
2.2.10.5 Plasmid minipreparation
A minimum number of 10 white colonies were picked from the above LB plates and
used to inoculate 3 ml of LB medium (containing 100 pg/ml ampicillin) which was
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then cultured overnight (12-16 h) at 37°C in a shaking incubator. After incubation
1.5 ml of each culture were lysed in alkali, and protein and denatured bacterial
chromosomal DNA precipitated with potassium acetate (pH 4.8), using a modification
of the methods originally published by Birnboin and Doly (277) and Ish-Horowicz and
Burke (278), as described by Sambrook, Fritsch and Manniatis (279). The plasmid
DNA was purified by phenol:chloroform extraction and precipitation. An equal
volume of phenol:chloroform:isoamylalcohol (25:24:1, v/v/v) was added and the
tubes were vortexed for 30 sec followed by centrifugation at 12,000 x g for 5 min.
The upper aqueous phase was transferred to a fresh tube and an equal volume of
chloroform:isoamylalcohol (24:1, v/v) was added. The tubes were vortexed briefly
and centrifuged at 12,000 x g for 2 min. The upper aqueous phase was removed and
transferred into a fresh tube and 2.5 volumes of ice-cold 100 % ethanol was added to
precipitate the DNA for 5 min. Finally the tubes were centrifuged at 12,000 x g for 5
min, rinsed with ice-cold 75 % ethanol and the pellet was allowed to air dry.
The plasmid DNA was resuspended in 50 pi of TE buffer containing RNAse A
(Sigma) to a final concentration of 2 pg/ml, and stored at -20°C.
2.2.10.6 Selection for recombinant plasmids
Plasmids prepared in section 2.2.10.5 were digested with appropriate restriction
enzymes to confirm they contained the (3-actin, bax and bcl-2 insert. The digested
plasmid DNA was separated by agarose gel electrophoresis as described in section
2.2.9.5.1.
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(i) Native pActPCR2.1 plasmids
In a 20 pi reaction, 2 pg of pActPCR2.1 were digested at 37°C for lh with BglI
(Boehringer Manheim) (10 units of enzyme per reaction). Digestion of plasmid
pCR2.1 containing the (3-actin insert yielded three fragments of 2241, 932 and 1474
bp or 2241, 285, 2121 bp (depending on the orientation of the insert). Vector
(PCR2.1) which did not contain the insert yielded only two fragments of 2241 and
1659 bp after enzyme digestion.
(ii) Native pBcl-2PCR2.1 plasmids
In a 20 pi reaction, 2 pg of pBcl-2PCR2.1 plasmid was digested at 37°C for lh with
BglI (Boehringer Manheim) (10 units of enzyme per reaction). Digestion of plasmid
pCR2.1 containing the bcl-2 insert yielded three fragments of 2241, 533 and 1544 bp
or 2241, 365, 1722 bp (depending on the orientation of the insert). Vector which did
not contain the insert yielded only two fragments of 2241 and 1659 bp after enzyme
digestion.
(iii) Native pBaxPCR2.1 plasmids
In a 20 pi reaction, 2 pg of pBaxPCR2.1 plasmid was digested at 37°C for lh with
BamHl (Boehringer Manheim, Lewes, UK) (10 units of enzyme per reaction).
Digestion of plasmid pCR2.1 containing the bax insert yielded two fragments of 3979
and 414 bp or 4275 and 118 bp (depending on the orientation of the insert). Vector
which did not contain the insert yielded only one fragment of 3939 bp after enzyme
digestion.
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2.2.10.7 Mutation of pActPCR2.1, pBaxPCR2.1 and
pBcl-2PCR2.1 Plasmids
(i) PActPCR2.1
In a 20 pi reaction, 2 pg of pActPCR2 1 were digested at 60°C for lh with BstEll
(Boehringer Manheim, Lewes, UK) (10 units of enzyme per reaction) for which a site
existed in the insert but not in the pCR2.1 sequence. The 3'-recessed termini of the
BstEll site were then filled by adding the Klenow fragment ofE.coli DNA polymerase
I (Boehringer Mannheim) (2 units per reaction) in the presence of 1 mM dNTPs.
Enzyme activity was inactivated by adding an equal volume of TE buffer (pH 7.6) and
extracting the DNA with phenol:chloroform:isoamylalcohol (as described in section
2.2.10.5). The DNA was dissolved in 20 pi TE buffer. A 20 pi aliquot (i.e. 0.2 pg)
of the plasmid was then recircularised at 16°C overnight with T4 DNA ligase
(Boehringer Manheim) (1 unit per reaction) before transformation.
(ii) pBcl-2PCR2.1
In a 20 pi reaction, 2 pg of pBcl-2PCR2.1 were digested with Nrul (Boehringer
Manheim) (10 units of enzyme per reaction) at 37°C for lh, for which a site existed in
the inserted amplicon but not in the pCR2.1 sequence. Enzyme activity was
inactivated by adding an equal volume of TE buffer (pH 7.6) and extracting the DNA
with phenol:chloroform:isoamylalcohol (as described in section 2.2.10.5). One pg of
commercial Xbal linker (Boehringer Manheim) d(CTCTAGAG) was ligated to 1 pg
of the linearised recombinant plasmid with 1 unit of T4 DNA ligase and ATP (final




In a 20 pi reaction, 2 pg of pBaxPCR2.1 were digested at 37°C for 1 h with NheI
(Boehringer Manheim) (10 units of enzyme per reaction) for which a site existed in
the inserted amplicon but not in the pCR2.1 sequence. The 3'-recessed termini of the
Nhel site were then filled by adding the Klenow fragment ofE.coli DNA polymerase I
(Boehringer Mannheim) (2 units per reaction) in the presence of 1 mM dNTPs.
Enzyme activity was inactivated by adding an equal volume of TE buffer (pH 7.6) and
extracting the solution with phenol:chloroform:isoamylalcohol (see section 2.2.10.5).
The DNA was dissolved in 20 pi TE buffer. A 20 pi aliquot (i.e. 0.2 pg) of the
plasmid was then recircularised at 16°C overnight with T4 DNA ligase (Boehringer
Manheim) (1 unit per reaction) before transformation.
2.2.10.8 Transformation by electroporation
The DNA in each ligation reaction was precipitated by adding potassium acetate pH
8.0 to a concentration of 0.25 M and 2.5 volumes of ethanol at -20°C for 2 h. DNA
was pelleted at 12,000 x g at 4°C for 2 min and the pellets were washed with cold
70% ethanol and air dried before being dissolved in 5 pi sterile distilled water. A 50
pi aliquot of XL-1 Blue E.coli competent cells (Stratagene) were thawed on ice and a
2 pi aliquot recircularised recombinant plasmid was electroporated into the XL-1 Blue
cells with a discharge of 2.5 KV at 25 microfarads on a Bio-Rad Gene Pulser.
Immediately after completion of the pulse, 300 pi of SOC medium was added and
each reaction was incubated at 37°C for 1 h on a shaking incubator. After incubation
aliquots of 20 pi, 50 pi and 100 pi were spread onto LB agar plates containing 100
pg/ml ampicillin. The plates were inverted and incubated overnight at 37°C.
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The following day, 12 transformants were selected and grown in 3 ml of LB medium
containing 100 pg/ml ampicillin overnight at 37°C. Plasmid DNA was isolated as
described in section 2.2.10.5.
2.2.10.9 Selection for Mutated pActPCR2.1, pBaxPCR2.1 and
pBcl-2PCR2.1 Plasmids
In 20 pi reactions, 2 pg of mutated recombinant plasmid DNA were digested with
appropriate restriction enzymes to distinguish between native and mutated
recombinant plasmid DNA. pActMutPCR2.1 DNA was digested with BstEll and
BamHl at 60° and 37°C (respectively) for lh at each temperature. pBcl-2MutPCR2.1
DNA was digested with Xbal at 37°C for 1 h, and pBaxMutPCR2.1 DNA was
digested with NheI and Hindlll at 37°C for 1 h. Digested plasmid DNA was
separated by agarose gel electrophoresis as described in section 2.2.9.5.1.
2.2.10.10 Synthetic mRNA synthesis
For each gene of interest 25 pg of pActMutPCR2.1, pBcl-2MutPCR2.1
pBaxMutPCR2.1 DNA were digested with Hindlll at 37°C for 2 hours. Hindlll was
chosen because it only cuts the plasmid once (upstream of the T7 promoter) and did
not cut any of the inserts. An aliquot of the digestion was analysed by agarose gel
electrophoresis to check complete digestion. The linearised template was purified by
extraction with phenol:chloroform:isoamylalcohol as described in section 2.2.10.5.
The DNA was dissolved in 25 pi RNase-free TE buffer pH 7.6 at a concentration of 1
Fg/pl-
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The DNA was further purified by proteinase K treatment to remove the RNase added
during the plasmid minipreparation. 0.1 volume of 10 x proteinase K buffer (500 mM
sodium chloride, 50 mM EDTA (pH 8) and 100 mM Tris chloride pH 8) and 0.1
volume of 5 % SDS was added to the recombinant plasmids. Proteinase K was added
to a final concentration of 100 pg/ml. The reactions were incubated at 37°C for 1
hour. After the incubation, the DNA was purified by extraction with
phenol:chloroform:isoamylalcohol (see section 2.2.10.5) and the DNA was dissolved
in 25 pi RNase-free TE buffer pH 7.6 at a concentration of 1 pg/pl.
Five pg of purified pActMutPCR2.1, pBcl-2MutPCR2.1 pBaxMutPCR2.1 DNA were
added to a transcription mix containing 20 pi transcription buffer (Promega), 10 pi of
100 mM DTT, 2.5 pi RNase inhibitor RNasin (1 unit/pl; Promega), 20 pi rNTPs at
2.5 mM each, 35 pi DEPC-treated sterile water and 2 pi T7 RNA polymerase
(Promega). A transcription reaction was set up for each recombinant plasmid. The
transcription reactions were incubated at 38°C for 2 hours and the DNA template was
digested by incubation with RNase-free DNase (0.1 unit/pl; Promega) for 30 min at
37°C. The synthesised RNA was extracted with phenol:chloroform:isoamylalcohol
(see section 2.2.10.5) and the RNA pellets were vacuum dried, dissolved in 30 pi
DEPC-treated sterile water and accurately quantified by spectrophotometry at 260
nm. A precise dilution series of synthetic mRNA standards ranging from 1 ng/pl to 1
fg/pl in 500 pi total volumes were prepared and the dilutions stored at -70°C in




In a sterile RNase-free microcentrifuge tube, 1 pi of 0.1 mM random hexamer primers
(Pharmacia), 6.8 pg synthetic (B-actin mRNA, 3.4 fg synthetic bax mRNA, 3.4 fg
synthetic bcl-2 mRNA was added to 2.5 pi of the RNA prepared from a single
embryo and the volume was adjusted to 10 pi with DEPC-treated water. The RNAs
were denatured at 70°C for 5 min, cooled to 25°C and kept on ice. A reaction mix
was prepared containing 4 pi AMV-reverse transcriptase buffer, 2 pi dNTP mix (10
mM), 0.5 pi RNA guard (Pharmacia), 3 pi DEPC-treated water and 2 pi AMV-
reverse transcriptase (Promega) and added to the RNA and primers. cDNA was
synthesised at 37°C for 60 min. The reaction stopped by denaturing at 95°C for 5
min.
2.2.11.2 cDNA Amplification
A 1 pi aliquot of newly synthesised embryo and standard cDNA was amplified in a
total volume of 25 pi containing lOx PCR buffer (Helena Biosciences, Newcastle
Upon Tyne), 200 pM of dNTP mix, 1 pM of each primer and 0.5U Taq polymerase
(Helena Biosciences). Magnesium chloride was added to give a final concentration of
1 mM, 1.7 mM and 2.5 mM for (3-actin, bax and bcl-2 reactions respectively.
Reactions were overlaid with 30 pi of light mineral oil (Sigma) to prevent evaporation
and placed in a Hybaid Omnigene PCR machine.
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The cycling conditions were 3 min at 94°C and 70°C for 2 min for one cycle, followed
by 94°C for 1 min, rfC for 1 min and 72°C for 2 min for 20 cycles and the last cycle
concluded with a 10 min extension time at 72°C. Where n°C was the annealing
temperature for the external pair of primers, namely 53°C for bax and bcl-2; and
58°C for (3-actin primers.
A phosphorylation reaction was set up for each of the forward internal primers. Two-
hundred pmoles of primer were added to a micro-centrifuge tube containing 2 pi T4
polynucleotide kinase (10 U/pl) (Boehringer Mannheim), 10 pmoles [y32-P]dATP
(Amersham) and lOx concentrated phosphorylation buffer (containing 500 mM tris-
HC1, 100 mM magnesium chloride, 1 mM EDTA, 50 mM dithiothreitol, 1 mM
spermidine, pH 8.2) (Boehringer Mannheim). The reaction was incubated at 37°C for
1-1.5 h.
The [y32-P]dATP-labelled forward internal primers were then added to their respective
PCR mixes (as described in section 2.2 .9.4), and 9.2 pi of this mix was added to PCR
tubes containing 0.8 pi of a 1:50 dilution of the first round PCR reaction, to give a
total reaction volume of 10 pi. The reactions were subjected to 27, 27 or 25 cycles of
amplification at 55°C, 54°C and 64°C for bax, bcl-2 and (3-actin primers respectively.
2.2.11.3 Polyacrylamide Gel Electrophoresis
(i) Preparation of polyacrylamide gel
Two glass plates and spacers were washed thoroughly in warm detergent (7X-PF
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phosphate-free detergent) (ICN Flow), rinsed with tap water and then distilled water.
The plates were cleaned with acetone and allowed to air dry. The smaller plate was
treated with silicone solution by pouring a small quantity of Repelcote (BDH) onto
the plate and wiping it over the surface of the plate with a tissue. The plate was then
rinsed with distilled water and dried. The plates were assembled by inserting the two
0.4 mm spacers between the plates and securing them with tape along the sides and
the bottom of the plates. For 50 ml of a casting solution of 4 % acrylamide, 8 ml of
SequaGel™ concentrate (containing a ratio of 19:1 acrylamide:bisacrylamide, and 7.3
M urea), 37 ml SequaGel™ diluent (containing 7.3 M urea) and 5 ml of SequaGel™
buffer (containing 50 % urea in 1 x TBE buffer) were mixed together. A 350 pi
aliquot of 10 % (w:v) ammonium persulphate (Amresco, Ohio) was added followed
by 15 pi of TEMED (Sigma). The solution was poured immediately into a 50 ml
syringe and injected slowly between the two plates. A comb was inserted and the gel
was left in a horizontal position for approximately 1 h to polymerise.
Once polymerisation of the gel was complete, the tape was taken off and the comb
carefully removed. The plates were transferred to a vertical gel electrophoresis
apparatus (BRL Life Technologies). The top and bottom reservoirs were filled with
lx TBE buffer and the apparatus was connected to the power supply and pre-run for
20 min at 35 W.
(ii) Preparation of cDNA
To the [y32-P]-labelled PCR samples, 20 pi of loading buffer (deionised formamide
containing 25 mM EDTA (pH 8) and 50 mg/ml blue dextran in a ratio of 5:1
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formamide to EDTA/blue dextran) was added and the samples were denatured for 2
min at 90°C and placed on ice. A 3 pi aliquot of each sample was loaded onto the
pre-electrophoresed 4 % acrylamide gel using a sequencing pipette (Sigma) and run
for 2 hours at a constant power of 35 W.
(iii) Autoradiography
After electrophoresis the two plates were separated leaving the gel attached to the
bottom plate and a piece of Whatman number 1 filter paper was placed on top of the
gel. Gentle pressure was applied to the paper so that the gel became firmly attached
to it. The excess gel was cut off and the paper was peeled away from the plate
bringing the gel with it. The gel was then covered with a piece of saran wrap and
dried in a vacuum dryer (Bio Rad) at 80°C for 1 h. After drying the saran wrap was
removed and the gel was exposed to x-ray film (Kodak Scientific Imaging film) for
16-24 hours at room temperature or at -70°C (depending on the signal intensity on
the gel). The film was developed in an automatic developer.
2.2.11.4 Phosphorimage Analysis
Quantification of RT-PCR products in the polyacrylamide gels was performed by
means of a Phosphorlmager (Molecular Dynamics). The intensity of the cDNA bands
(measured in arbitrary units) from target template (i.e. embryo) and standard template
was obtained for each of the three genes. The ratio of embryo absorbance/standard
absorbance was determined, and since the number of copies of standard synthetic
mRNA added to the initial RT reaction was known, the number of copies of target




3.1 Experiment I: Defining the Development of the Early
Embryo in the Diabetic BB/E rat
Introduction
Recent studies of the effect of diabetes on early pre-implantation embryo development
have involved NOD mice (280, 281) and STZ-diabetic rats and mice (282, 283).
Neither of these animal models are analagous to diabetic patients with IDDM in that
they are not dependent on insulin treatment to survive and indeed were not treated
with insulin in these reported experiments. The following experiments were carried
out to define the development of early pre-implantation embryos in BB/E rats with
IDDM. In particular, to identify any disturbances in the development of the pre-
implantation embryo which might be a presage of the pathology seen later in
pregnancy in this animal, such as low birth weight pups and malformations (260).
This study also provided the opportunity to observe early pregnancy in the Diabetes




All female DP-BB/E rats used for this study had established IDDM and were
maintained on daily injections of long-acting insulin. One group of female DP-BB/E
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rats (n = 79) were mated overnight with established insulin dependent Diabetic DP-
BB/E male rats, and a second group of female Diabetic DP-BB/E rats (n = 38) were
mated overnight with Non-Diabetic DR-BB/E males.
(ii) Non-Diabetic Pregnancies
Non-Diabetic DR-BB/E female rats (n = 73) were mated overnight with Non-Diabetic
DR-BB/E male rats. A second group of Non-Diabetic DR-BB/E females (n = 17)
were mated with Diabetic DP-BB/E male rats with established IDDM.
(iii) Wistar Han Pregnancies
Female outbred Wistar Han rats (n = 40) were mated overnight with outbred Wistar
Han males.
All male rats used for these studies were of proven fertility. Embryos were collected
from each individual pregnancy (see Methods section 2.2.1), transferred to an
inverted microscope and classified as having reached a recognisable developmental
stage, namely morula, early blastocyst with a nascent blastocoele and expanded
blastocyst with a clearly demarcated trophectoderm (TE) and inner cell mass (ICM).
The number and percentage of (i) embryos at each developmental stage and (ii)
unfertilised oocytes was determined and recorded for each pregnancy.
Results
Table 3.1 shows the number of morulae, early blastocysts, expanded blastocysts and
unfertilised oocytes recovered from each type of pregnancy at 4.5 days gestation.
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All of the BB/E rats had significantly fewer embryos per pregnancy than Wistar Han
rats (P < 0.0001), which may be explained as strain differences between outbred
Wistar Han and inbred BB/E rats.Diabetic DP- rats had fewer embryos per pregnancy
than Non-Diabetic DR-BB/E rats but this difference only reached statistical
significance for the Diabetic DP mother x Diabetic DP father group, when compared
to both types of Non-Diabetic DR-BB/E pregnancies (P < 0.05). Significance was
probably lost in the Diabetic DP mother x Non-Diabetic DR father group because (i)
it was a much smaller group compared with the other Diabetic pregnancy group (38
vs 79 pregnancies), and (ii) there was greater variation within the smaller group.
When the number of unfertilised oocytes was added to the total embryo number in
each pregnancy, the mean number all structures per pregnancy was not significantly
different for any of the BB/E pregnancies, indicating that all BB/E groups had
approximately the same ovulation rate.
Diabetic DP-BB/E pregnancies had fewer expanded blastocysts and more unfertilised
oocytes per pregnancy than Non-Diabetic DR-BB/E pregnancies. This effect
appeared to be a function of maternal diabetes with no input from the father, since (i)
pregnancies in which both parents had established diabetes had the same low number
of expanded blastocysts and high number of unfertilised oocytes as diabetic
pregnancies where only the mother had diabetes - showing no evidence of a
synergistic effect when both parents had established diabetes, and (ii) all non-diabetic
pregnancies had the same morphological distribution of embryos irrespective of the

































Morulae Early Expanded Unfertilised
Blastocysts Blastocysts Oocyte
Figure 3.1:
Mean ± SEM percentage of embryos at each morphological stage of development
recovered from 40 Wistar Han (light bars), 73 Non-Diabetic DR-BB/E (grey bars),
and 79 Diabetic DP-BB/E (black bars) rats on day 4.5 ofpregnancy.
Significant differences in the percentage ofembryos at each developmental stage is
indicated by * (as assessed by the Student's t-test)
Morulae: not significantly different
Early Blastocysts: P < 0.01 for Diabetic DP vs Wistar Han and P < 0.001 for Non-
Diabetic DR vs Wistar Han
Expanded Blastocysts: P < 0.0001 for both Diabetic DP- vs Non-Diabetic DR-BB/E
and Wistar Han rats
Unfertilised Oocytes: P < 0.0001 for both Diabetic DP- vs Non-Diabetic DR-BB/E
and Wistar Han rats
NB. Statistical differences between the percentage of expanded blastocysts per Diabetic DP
and Non-Diabetic DR-BB/E pregnancies remain significant when calculations exclude the
number of unfertilised oocytes.
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Figure 3.1 depicts the data from Table 3.1 expressed as the mean percentage of
embryos in each developmental category for the Diabetic and Non-Diabetic groups.
Having already established that the paternal metabolic status has no effect on the
morphological distribution of embryos at the pre-implantation stage, only pregnancies
in which both parents have the same metabolic status (i.e. Diabetic mother, Diabetic
father pregnancies; and Non-Diabetic DR mother, Non-Diabetic DR father
pregnancies) have been compared with Wistar Han pregnancies for simplicity. The
percentage of morulae per pregnancy did not differ significantly between the three
groups of animals. The percentage of early blastocysts was significantly greater in
BB/E rat pregnancies (both Diabetic DP and Non-Diabetic DR) than Wistar Han
pregnancies at 4.5 days gestation (P < 0.01 for Diabetic DP-BB/E vs Wistar Han; and
P < 0.001 for Non-Diabetic DR-BB/E vs Wistar Han). Diabetic DP- and Non-
Diabetic DR-BB/E pregnancies did not differ significantly in this regard. The
percentage of embryos reaching expanded blastocyst stage did not differ significantly
in Wistar Han and Non-Diabetic DR-BB/E pregnancies. However, significantly fewer
embryos reached the expanded blastocyst stage in Diabetic DP-BB/E than Non-
Diabetic DR-BB/E and Wistar Han pregnancies (P < 0.0001 for both differences) and
the percentage of unfertilised oocytes was significantly higher in Diabetic than both
groups ofNon-Diabetic pregnancies (P < 0.0001 for both differences).
Figure 3.2A shows that in the 73 Non-Diabetic DR- BB/E pregnancies the number of
expanded blastocysts per pregnancy is normally distributed at day 4.5 of gestation and
there are only 3 pregnancies without expanded blastocysts. In contrast, the




























Number of expanded blastocysts per pregnancy
Figure 3.2B:
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Number of expanded blastocysts per pregnancy
Figure 3.2:
Distribution of the number of expanded blastocysts in each pregnancy. Non-Diabetic
DR-BB/E rat pregnancies (n = 73) are indicated by hatched bars (Fig. 3.2A); Diabetic
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Number of expanded blastocysts per pregnancy
Figure 3.3:
The relationship between the number of expanded blastocysts and unfertilised oocytes
in individual Non-Diabetic DR- and Diabetic DP-BB/E rat pregnancies. Each dot (•)
represents a single pregnancy with one or more unfertilised oocyte. The right-hand
axis indicates the number of unfertilised oocytes in each individual pregnancy. The
bars represent the same data shown in Figure 3.2A and B.
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markedly disturbed (Figure 3.2B) with 16 out of 79 pregnancies having no expanded
blastocysts at all. Moreover, two thirds (67 %) of Non-Diabetic DR-BB/E
pregnancies had 5 or more expanded blastocysts per pregnancy compared with just
under half (46 %) of the Diabetic DP pregnancies.
Further analysis (Figure 3.3A) shows that although unfertilised oocytes occurred in
Non-Diabetic DR-BB/E pregnancies they were few in number and randomly
distributed. Diabetic DP pregnancies were very different, firstly, there were more
pregnancies with unfertilised oocytes; secondly, they were not randomly distributed
but were clustered in pregnancies with few or no expanded blastocysts; and thirdly,
there were some apparently normal pregnancies with no unfertilised oocytes (Figure
3.3B). There was no significant difference between diabetic mothers with and without
unfertilised oocytes with respect to age at pregnancy (130.3 ± 4.5 days vs 132 ± 2.1
days, respectively), duration of diabetes (41 ± 4.6 days vs 43 ± 2.3 days, respectively)
or blood glucose concentration measured at 10.00 hours on the day that the embryos
were retrieved - using an ExacTech meter, the majority being > 20 mmol/L.
3.1.2 Expanded Blastocyst Cell Lineage Analysis
Blastocysts from these apparently 'normal' Diabetic DP-BB/E pregnancies were
analysed more closely using the dual fluorochrome staining method described above




A: Micrograph of a three-dimensional BB/E rat blastocyst differentially stained by
immunofluorescence to show the Inner Cell Mass cells (blue) and the Trophectoderm
cells (pink)





Figure 3.4A is a photograph of a healthy expanded blastocyst stained (as described in
Methods section 2.2.3) to show the clearly polarised inner cell mass (blue) and
surrounding trophectoderm (red). Figure 3.4B shows the same blastocyst after slight
pressure has been applied to facilitate cell counting.
Table 3.2 shows ICM and TE cell numbers in expanded blastocysts with apparently
normal morphology isolated from Diabetic DP- and Non-Diabetic DR-BB/E rats on
day 4.5 of pregnancy. The number of cells in the ICM was significantly less in
blastocysts from Diabetic DP- compared with Non-Diabetic DR-BB/E rats (P <
0.0001); this represents a -20 % ICM cellular deficit. In contrast, there was no
difference in the number of TE cells in blastocysts from Diabetic DP- and Non-
Diabetic DR-BB/E rats.
Table 3.2 : ICM and TE cell number in blastocysts from Diabetic DP and





Inner Cell Mass Trophectoderm
Diabetic 57 8.35 ±0.34 * 20.09 ±0.42
Non-Diabetic 43 10.40 ±0.25 20.23 ±0.41
% increase / decrease -19.7 -0.7
* P < 0.0001 : significantly less than blastocysts from Non-Diabetic DR-BB/E rats
(Student's t test). Data expressed as mean ± SEM.
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Figure 3.5:
A. Differentially stained BB/E rat blastocyst showing dead cells and fragmented
nuclei, the appearances being characteristic of apoptosis in the ICM
B: Dead cells located at the edge of the ICM
C: Dead ICM cells on the outer edge of the blastocyst TE
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Closer examination of stained blastocysts revealed that cells with fragmented nuclei
were seen in blastocysts from both Diabetic DP and Non-Diabetic DR rats. Although
this technique did not allow accurate quantitation, it appeared that cells with
fragmented nuclei were observed more often in the ICM than in the TE (Figure 3.5A).
At high magnification (x 500) these cells showed the features characteristic of
apoptosis such as cell surface blebbing, nuclear condensation and fragmentation, and
finally splitting of the cell itself into multiple membrane bound 'apoptotic bodies',
some of which contained nuclear fragments (285). Dead cells were often seen at the
edge of the ICM (Figure 3.5B) and in some cases appeared to be in process of
extrusion (Figure 3 .5C).
3.1.2.1 Effect of Paternal Metabolic Status on Blastocyst Cell
Number
Since there is evidence that paternal genes can influence the development of early
embryos and blastocysts (286) Diabetic DP-BB/E rat pregnancies were generated by
mating Diabetic (DP-BB/E) females with Non-Diabetic (DR-BB/E) males. Similarly,
Non-Diabetic pregnancies were generated by mating Non-Diabetic (DR-BB/E)
females with Diabetic (DP-BB/E) males. Embryos were recovered on day 4.5 of
pregnancy as described above, the expanded blastocysts were differentially stained
and the number of TE and ICM cells in each blastocyst counted.
As shown in Table 3.3, blastocysts from Diabetic DP pregnancies where the father is
Non-Diabetic (DR-BB/E) exhibited the same -20 % deficit in the number ICM cells as
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that previously observed in blastocysts from Diabetic DP pregnancies where both
parents were diabetic. The number of TE cells remained unaffected.
\
Table 3.3 : Effect of paternal metabolic status on ICM and TE cell number in
blastocysts from Diabetic DP- and Non-Diabetic DR-BB/E rats on
day 4.5 of pregnancy
Type of Pregnancy Number of
Blastocysts
Cell Lineage
Inner Cell Mass Trophectoderm
Diabetic (DP) mother x
Non-Diabetic (DR) father
57 8.00 ±0.30 * 19.61 +0.38
Non-Diabetic (DR) mother
x Diabetic (DP) father
21 10.48 + 0.43 18.62±0.55
% increase/decrease -23.6 +5
* P < 0.0001 : significantly less than blastocysts from Non-Diabetic DR-BB/E rats
(Student's t test) Data expressed as mean ± SEM.
3.1.2.2 Effect of 24h Culture on Blastocyst Cell Number
To investigate whether these blastocysts with an ICM cellular deficit were capable of
restorative 'catch-up' growth when removed from the maternal diabetic environment,
blastocysts were flushed from Diabetic DP- and Non-Diabetic DR-BB/E pregnancies
(generated from Diabetic DP- and Non-Diabetic DR-BB/E males, respectively) and
cultured in vitro for 24 hours in Nutrient Mix (Ham's) F10 growth medium
supplemented with 0.1 % BSA.
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Table 3.4 shows that although proliferation of both the ICM and TE cells occurred in
blastocysts from Diabetic DP- and Non-Diabetic DR-BB/E rats during the culture
period, this was insufficient to restore the ICM cell number to that observed in
blastocysts from Non-Diabetic DR rats. Thus, an ICM cellular deficit of -18 % (P <
0.001) remained which was approximately the same as that found in vivo at day 4.5 of
gestation. In contrast, in vitro culture resulted in a 25 % increase in the number of
TE cells in blastocysts from Diabetic DP rats compared to those from Non-Diabetic
DR-BB/E rats (P < 0.0001).
Table 3.4 : ICM and TE cell number in blastocysts from Diabetic DP- and
Non-Diabetic DR-BB/E rats after 24 h in vitro culture.
Type of Pregnancy Number of
Blastocysts
Cell Lineage
Inner Cell Mass Trophectoderm
Diabetic (DP)mother x
Non-Diabetic (DP) father
33 10.61 ±0.54* 37.88 ±1.47#
Non-Diabetic (DR) mother
x Diabetic (DR) father
40 12.93 ±0.50 30.18 ±0.94
% increase/decrease -17.9 +25.5
Data expressed as mean cell number ± SEM
* P < 0.001 : significantly less than blastocysts from Non-Diabetic DR rats
# P < 0.0001 : significantly more than blastocysts from Non-Diabetic DR rats
(Student's t test)
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In addition, a group of pregnancies were generated from (a) Diabetic DP- females and
Non-Diabetic DR-BB/E males, and (b) Non-Diabetic DR- females and Diabetic DP-
BB/E males, to determine whether the TE cellular accretion observed after 24h in
vitro culture could be related to paternal or maternal metabolic status. The results,
shown in Table 3.5 demonstrate that the TE cell accretion is entirely due to the
presence of established diabetes in the mother, and that blastocysts from pregnancies
where the mother is Non-Diabetic (and the father is Diabetic), develop normally.
Table 3.5 : Effect of paternal metabolic status on ICM and TE cell number in
blastocysts from Diabetic DP- and Non-Diabetic DR-BB/E rats
after 24 h in vitro culture.
Type of Pregnancy Number of
Blastocysts
Cell Lineage
Inner Cell Mass Trophectoderm
Diabetic (DP) mother x
Non-Diabetic (DR) father
33 10.52 ±0.55* 37.67 ± 1.18 #
Non-Diabetic (DR) mother
x Diabetic (DP) father
32 12.28 ±0.34 31.38 ± 1.01
% increase/decrease - 14.3 ±20.0
Data expressed as mean cell number ± SEM
* P < 0.01 : significantly less than blastocysts from Non-Diabetic DR rats
# P < 0.0001 : significantly more than blastocysts from Non-Diabetic DR rats
(Student's t test)
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Blastocysts from Diabetic DP pregnancies (with Non-Diabetic DR fathers) showed an
ICM cellular deficit of -14 % which was not significantly different from the deficit of-
18 % observed in the previous group of Diabetic DP pregnancies which had Diabetic
DP fathers. The ICM cell deficit was however, significantly different from blastocysts
from Non-Diabetic DR pregnancies (P < 0.01). In addition, there was a 20 %
increase in TE cell number in blastocysts from Diabetic DP pregnancies (with Non-
Diabetic DR fathers) compared to those from Non-Diabetic DR pregnancies (P <
0.0001).
3.1.2.3 Effect of 24h Culture in Conditioned Media
In an attempt to mimic the intra-uterine milieu more closely, uterine cell conditioned
media were prepared by scraping uterine cells from the lining of the uterus of
pregnant Diabetic DP- and Non-Diabetic DR-BB/E rats on day 4.5 of gestation, and
allowing the uterine cells to condition the growth medium for 48 hours. During the
incubation period the uterine cells release cytokines and growth factors into the
medium and supernatants from these cultures were used as an incubation medium for
24h culture of blastocysts (see Methods section 2.2.6).
In this study, blastocysts were removed from Diabetic DP- and Non-Diabetic DR-
BB/E pregnancies (both generated from Non-Diabetic DR-BB/E male rats) on day
4.5 of gestation. The number of inner cell mass and trophectoderm cells was
determined in the blastocysts and the results are shown in Tables 3.6 and 3.7
respectively.
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Table 3.6 : Number of ICM cells in blastocysts from Diabetic DP- and Non-





ICM cell number in blastocysts from :
Non-Diabetic Pregnancies Diabetic Pregnancies
Non-Diabetic (DR) 16.85 ±0.14 14.06 ±0.50 *
(n = 33) (n = 33)
Diabetic (DP) 17.06 + 0.50 13.43 ±0.52 *
(n = 32) (n = 37)
Alpha MEM alone 16.07 ±0.41 14.33 ±0.39#
(n = 39) (n = 36)
Significantly less than blastocysts from Non-Diabetic DR-BB/E rats (by Student's t
test) where * P < 0.0001 # P < 0.01 and n is the number of stained blastocysts
When blastocysts from Diabetic DP mothers were removed from the diabetic intra¬
uterine environment and cultured in conditioned media prepared from Non-Diabetic
DR rats, they did not show any sign of ICM 'catch up' growth and they still
developed a TE cell accretion. Moreover, when blastocysts from Non-Diabetic DR
rats were cultured in conditioned media prepared from Diabetic DP rats, they did not
develop an ICM cellular deficit or a TE cell accretion.
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Table 3.7 : Number of TE cells in blastocysts from Diabetic DP- and Non-





TE cell number in blastocysts from :
Non-Diabetic Pregnancies Diabetic Pregnancies
Non-Diabetic (DR) 43.55 + 1.32 47.24 + 1.23 #
(n = 33) (n = 33)
Diabetic (DP) 35.72+ 1.33 43.78 ± 1.30 *
(n = 32) (n = 37)
Alpha MEM alone 37.90+ 1.26 42.81 ± 1.46#
o\mII (n = 36)
Significantly more than blastocysts from Non-Diabetic DR-BB/E rats (by Student's t
test) where * P < 0.0001, and # P < 0.05 and n is the number of stained blastocysts
Comparing blastocysts obtained from Diabetic DP rats with those from Non-Diabetic
DR rats the data suggest that regardless of the culture medium used, blastocysts from
Diabetic DP rats invariably exhibited an ICM cellular deficit and a TE cellular
accretion. Furthermore, these differences were greatest when conditioned media
prepared from Diabetic DP rats were used as the incubation medium : the ICM cell
deficit after culture in Non-Diabetic DR and Diabetic DP conditioned media was
-16.55 % and -21.28 % respectively; and the TE cell accretion in Non-Diabetic DR
media and Diabetic DP conditioned media was +8.47 % and +22.56 % respectively.
Thus blastocysts from Diabetic DP mothers were unable to restore their ICM cell
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number to normal even when conditioned medium prepared from Non-Diabetic DR
uterine cells was used as the culture medium.
3.1.2.4 Total Cell Counts in Early Embryos
Morulae and early blastocysts were flushed from Diabetic DP and Non-Diabetic DR
pregnancies at approximately 90 h post coitum (p.c.). The total cell number was
determined using a giemsa staining method (see 2.2.7 Methods section). The results
presented in Table 3.8 show that the mean total cell number per morula or early
blastocyst was not significantly different for Diabetic DP- and Non-Diabetic DR-BB/E
rat pregnancies.
These results suggest that the ICM cellular deficit develops between the early
blastocyst and the expanded blastocyst stage, - a period of approximately 6-8 hours.
Table 3.8 : Total cell number in morulae and early blastocysts from Diabetic
DP- and Non-Diabetic DR-BB/E rats at 90 h p.c
Pregnancy Type
Mean total cell number per embryo
(i) Morulae (ii) Early Blastocysts
Diabetic DP 14.1 ±0.62 19.0 ±0.57
(DP mother x DR father) (n - 27) (n = 29)
Non-Diabetic DR 14.0 ±0.29 18.2 ±0.6
(DR mother x DR father) (n = 30) (n = 29)
Where n is the number of stained embryos
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Conclusions from Experiment I
These results demonstrate that pregnancy in the DP-BB/E rat with established IDDM
is associated with a severe disturbance in embryo development, which can be detected
as early as the pre-implantation stage. This was indicated by (i) a five fold increase in
the number of unfertilised oocytes, (ii) a reduced percentage of expanded blastocysts,
and (iii) a -20 % ICM cellular deficit in embryos which reached the expanded
blastocyst stage.
Although there is evidence that paternal genes exert an influence on the development
of the pre-implantation embryo and the formation of the blastocyst (285), the
occurrence of unfertilised oocytes could not be correlated with any particular male
rat(s). Moreover, the ICM cellular deficit appeared to be solely a function of maternal
diabetes with no input from the father, since Non-Diabetic DR pregnancies with
Diabetic DP fathers were normal in respect to the number of unfertilised oocytes and
expanded blastocysts, and ICM cell number.
The mean total cell number per morula or early blastocyst was not significantly
different for Diabetic DP- and Non-Diabetic DR-BB/E rat pregnancies at 90 h p.c.
These results suggest that the ICM cellular deficit develops between the early
blastocyst and the expanded blastocyst stage, - a period of approximately 6-8 hours.
Blastocysts from Diabetic DP-BB/E mothers failed to show any sign of 'catch up'
growth in the ICM after 24 h in culture media or conditioned media prepared from
uterine cells. Under these conditions however, a TE cellular accretion occurred.
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Since it is the inner cell mass which forms all of the fetal germ layers, whilst the
trophectoderm forms the placenta and the extraembryonic membranes (286), it is
tempting to speculate that these phenomena are a presage of the characteristic
combination of fetal growth delay and large placentae which are a feature of both
BB/E rat (258) and human IDDM pregnancy (287).
When differentially stained blastocysts were examined under the fluorescence
microscope, cells with fragmented nuclei characteristic of apoptosis were observed in
blastocysts from both Diabetic DP- and Non-Diabetic DR-BB/E rats. It appeared that
apoptotic cells were observed more often in the ICM than in the TE although it was
not possible to accurately quantitate this phenomenon using differential staining.
Developmentally regulated cell death is widespread in embryogenesis (288) and
occurs by apoptosis in both vertebrate and invertebrate species. It is a widespread
feature in blastocysts of many mammals such as the cow (289); Rhesus monkey (290);
mouse (291); rat (292) and the human (268). The significance of these dead cells is
not fully understood and there is clearly a need to examine how apoptosis is regulated
in the blastocyst with respect to the balance of endogenous gene products and
exogenous signals.
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3.2 Experiment II: The Relative Influence of Maternal
Genetic Background and Metabolic Status on the
Development of the Pre-Implantation Embryo
Introduction
Earlier experiments (Section 3.1) have shown that pregnancy in the Diabetes Prone
BB/E rat with established IDDM is associated with severe disturbance in the
development of the pre-implantation embryo. The complexity of the intra-uterine
environment makes it difficult to identify the mechanism(s) leading to this
embryopathy. The aim of this study therefore, was to assess the relative contribution
of maternal genetic background and metabolic status on pre-implantation embryo
development. This was achieved by (1) studying pregnancy in the Diabetes Prone
BB/E rat during the pre-diabetic period, and (2) embryo transfer experiments.
3.2.1 Effect of Pre-Diabetes in the Mother
Introduction
As described earlier (Methods section 2.1.2.1), the BB/Edinburgh colony consists of
two selectively bred sublines: the Diabetes Prone and the Diabetes Resistant subline.
The incidence of diabetes is 50-60 % in the DP and zero in the DR subline. Since the
mean (± SD) age of onset of IDDM in the BB/E rat colony is 96 ± 18 days, and the
female rat is fertile at approximately 60 days of age, it is possible to achieve
pregnancy in the pre-diabetic period in these rats.
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Experimental Protocol
A small group (n = 12) of young female Diabetes Prone BB/E rats were studied
during the pre-diabetic period before pregnancy and during the first four days of
pregnancy.
Plasma samples were taken from all rats at three specific time points: (1) at the
beginning of the study (non-pregnant), (2) the morning after conception - day 0.5 of
pregnancy, and (3) the morning of day 4.5 of pregnancy. In this study males used for
mating were Non-Diabetic DR-BB/E rats. The concentration of plasma metabolites
was measured and compared with samples from pregnant non-diabetic DR-BB/E (n =
6) and established Diabetic DP-BB/E rat pregnancies (n = 10).
On day 4.5 of pregnancy, the blastocysts were flushed from all three groups of
pregnancies and taken through a differential staining technique to determine the
number of ICM and TE cells.
Results
Table 3.9 shows the concentration of plasma metabolites for the three groups of rats:
pre-diabetic DP-, Non-Diabetic DR- and established Diabetic DP-BB/E at the
beginning of the study prior to pregnancy. Pre-diabetic DP rats were not significantly
different from Non-Diabetic DR rats for any of the metabolic parameters measured,
showing that when the study began these rats did not have diabetes. Established
Diabetic DP rats were however, significantly different from both Non-Diabetic DR
and pre-diabetic DP rats for glucose (P < 0.0001 for both), pyruvate (P < 0.01 and
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P < 0.0001, respectively), glycerol (P < 0.05 and P < 0.01, respectively) and P-
hydroxybutyrate (BOHB) (P < 0.05 for both).
Table 3.9 : Concentration of plasma metabolites in non-pregnant pre-











Glucose 7.20 ±0.13 7.01 ±0.3 32.18 ± 1.98 0.0001
Pyruvate 0.18 ±0.007 0.18 ±0.02 0.07 ±0.01 0.0001
Lactate 2.84 ±0.18 3.93 ± 1.3 3.49 ±0.64 NS
Alanine 0.50 ±0.01 0.45 ±0.02 0.47 ±0.03 NS
Glycerol 0.22 ±0.02 0.20 ±0.05 0.40 ±0.46 0.001
P-hydroxybutyrate 0.11 ±0.01 0.09 ±0.008 0.81 ±0.24 0.007
Lactate/
Pyruvate ratio 15.18 ± 0.8 20.62 ±5.4 58.24 ±7.61 0.0001
n 12 6 10
Where NS denotes not significantly different by one-way analysis of variance
(ANOVA) and n is the number rats in each group
All three groups of rats were mated with Non-Diabetic DR male rats of proven
fertility. The concentration of plasma metabolites on day 0.5 of pregnancy (i.e. at
conception), is shown in Table 3.10 for Non-Diabetic DR, Diabetic DP and pre-
diabetic DP rats. Once again, pre-diabetic DP rats were not significantly different
from Non-Diabetic DR rats for any of the metabolites measured. Diabetic DP rats
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however, had significantly higher plasma glucose (P < 0.001), glycerol (P < 0.001)
and BOHB (P <0.01) measurements, but significantly lower levels of plasma pyruvate
(P < 0.001) than both Non-Diabetic DR- and pre-diabetic DP-BB/E rats.
Table 3.10: Concentration of plasma metabolites in pre-diabetic DP-, Non-











Glucose 6.77 ±0.13 6.47 ±0.4 19.63 ±2.44 0.0001
Pyruvate 0.19 ± 0.01 0.18 ± 0.01 0.07 ±0.01 0.0001
Lactate 2.84 ±0.19 3.63 ±0.72 3.40 ±0.43 NS
Alanine 0.45 ±0.03 0.43 ±0.03 0.50 ±0.02 NS
Glycerol 0.17 ±0.008 0.18 ±0.03 0.33 ±0.02 0.0001
P -hydroxybutyrate 0.08 ±0.01 0.04 ±0.009 0.32 ±0.06 0.0001
Lactate/
Pyruvate ratio 15.50 ±0.8 19.45 ±2.8 110.0 ± 57.1 NS
n 12 6 10
Where NS denotes not significantly different by one-way analysis of variance
(ANOVA) and n is the number rats in each group
Pregnancies were continued until day 4.5 when the final plasma sample was taken.
The concentration of plasma metabolites at day 4.5 of pregnancy for the three groups
of rats is shown in Table 3.11. The concentration of plasma glucose remained
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significantly higher in Diabetic DP rats than in either pre-diabetic DP or Non-Diabetic
DR rats (P < 0.0001 for both). The concentration of plasma pyruvate and alanine fell
significantly in Non-Diabetic DR rats at day 4.5 of gestation when compared to pre-
diabetic and diabetic DP rats (P < 0.0001 for both). There was no significant
difference between the three groups of rats for lactate, glycerol or P-hydroxybutyrate
at this stage of pregnancy.
Table 3.11: Concentration of plasma metabolites in pre-diabetic DP-, Non-











Glucose 6.55 ±0.09 6.53 ±0.13 21.38 ±2.79 0.0001
Pyruvate 0.19 ± 0.01 0.03 ±0.008 0.18 ±0.01 0.0001
Lactate 3.86 ±0.25 3.18 ± 0.22 4.45 ±0.59 NS
Alanine 0.54 ±0.02 0.41 ±0.02 0.62 ±0.02 0.0001
Glycerol 0.18 ±0.01 0.23 ±0.02 0.22 ±0.03 NS
P -hydroxybutyrate 0.05 ±0.005 0.08 ±0.01 0.08 ±0.01 NS
Lactate/
Pyruvate ratio 132.9 ±23.6 19.88 ±0.7 24.74 ± 1.93 0.0001
n 12 6 10
Where NS denotes not significantly different by one-way analysis of variance
(ANOVA) and n is the number rats in each group
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Table 3.12 shows the effect of early pregnancy on the maternal metabolic profile of
pre-diabetic DP-BB/E rats. These metabolic changes reflect the normal maternal
metabolic adaptations to pregnancy, such as a decrease in plasma glucose (P < 0.01),
an increase in plasma lactate (P < 0.01), accompanied by a significant fall in P-
hyroxybutyrate levels (P < 0.0001). The change in plasma lactate was reflected in the
increased lactate/pyruvate ratio (P < 0.0001).








Glucose 7.20 ±0.13 6.77 ±0.13 6.55 ±0.09 *
Pyruvate 0.18 ±0.007 0.19 ± 0.01 0.19 ± 0.01
Lactate 2.84 ± 0.18 2.84 ±0.19 3.86 ±0.25 *
Alanine 0.50 ±0.01 0.45 ±0.03 0.54 ±0.02
Glycerol 0.22 ±0.02 0.17 ±0.008 0.18 ±0.01
p-hyroxybutyrate
Lactate/
0.11 ±0.01 0.08 ±0.01 0.05 ±0.005 *
Pyruvate ratio 15.18 ± 0.8 15.50 ±0.8 19.88 ±0.73 *
n 12 12 12
Where * denotes significant difference between non-pregnant and 4.5 pregnant pre-
diabetic rats (Student's t test) : glucose and lactate : P < 0.01; p-hyroxybutyrate and
lactate/pyruvate ratio P < 0.0001
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Embryos were flushed from day 4.5 pregnant pre-diabetic DP rats and the number of
embryos at each morphological stage of development was recorded and compared
with those from Diabetic DP rats with established diabetes (Table 3.13). Diabetes
Prone BB/E rats in the pre-diabetic period had fewer unfertilised oocytes (P < 0.05)
and more expanded blastocysts (P < 0.01) per pregnancy than their DP counterparts
who had developed diabetes. These results suggested that the fertility of DP-BB/E
rats is normal prior to disease onset. Although the pre-diabetic DP-BB/E females
were considerably younger than the DP-BB/E rats with established IDDM (60.42 ±
3.4 vs 131.54 ±1.9 days of age for pre-diabetic vs Diabetic DP rats; P < 0.0001) it is
unlikely that age alone was sufficient to cause such a reduction in fertility since the
age of DP-BB/E rats with established diabetes at pregnancy was not significantly
different from that of the Non-Diabetic (DR-BB/E) rats (125.4±4.2vs 131.54+1.9
days of age for Non-Diabetic vs Diabetic DP rats, NS different).
Cell Lineage Analysis
Embryos were flushed from pre-diabetic DP-BB/E rats and those which had reached
the expanded blastocyst stage and taken through the differential staining procedure to
determine the number of ICM and TE cells. To examine whether blastocysts from
pre-diabetic rats were normally developed with respect to their ICM and TE cell
number, the mean cell number of each lineage was compared with blastocysts from
Diabetic DP and Non-Diabetic DR rats. The results are shown in Table 3.14.
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Table 3.14: Mean ICM and TE cell number in blastocysts from pre-diabetic
DP-, Non-Diabetic DR- and Diabetic DP-BB/E rats on day 4.5 of
pregnancy
Number of Cell lineage
Type of pregnancy Blastocysts Inner Cell Mass Trophectoderm
Pre-Diabetic DP 40 10.0 + 0.27 19.43 + 0.27
Non-Diabetic DR 43 10.40 + 0.25 20.23 + 0.41
Diabetic DP 33 8.25 +0.30 * 19.80 + 0.52
Data expressed as mean ± SEM.
* P < 0.0001 : significantly less than blastocysts from pre-diabetic DP and Non-
Diabetic DR-BB/E rats (Student's t test).
The data presented in Table 3.14 demonstrate that blastocysts from DP-BB/E rats
during the pre-diabetic stage were indeed normal as there was no evidence of an ICM
cellular deficit in these blastocysts. Blastocysts from Diabetic DP rats exhibited an
ICM cellular deficit which was significantly different from both pre-diabetic DP and
Non-Diabetic DR rat blastocysts (P < 0.0001).
The concentration of blood glucose was measured (using an ExacTech blood glucose
meter) in a small sample of tail blood taken from the three groups of rats 30 min
before the embryos were collected. Blood glucose at 4.5 days gestation in pre-
diabetic DP rats was within the normal range and not significantly different from
values obtained from Non-Diabetic DR rats (mean ± SEM blood glucose: pre-diabetic
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rats 4.13 ±0.1 mmol/L vs Non-Diabetic DR rats 4.26 ± 0.4 mmol/L), which
contrasted with the blood glucose measurements taken from Diabetic DP rats (mean ±
SEM, 21.93 ± 1.6 mmol/L). These results were later confirmed when the
concentration of plasma glucose was measured in these rats (see Table 3.11).
3.2.2 Embryo Transfer Experiments
Introduction
The effect of maternal metabolic status on early embryo development was examined
more closely using embryo transfer experiments. Embryos may be transferred either
at the blastocyst stage, directly into the uterus, which is a relatively quick and simple
procedure; or at the 2-cell stage requiring transfer into the oviduct of the recipient
animal. Since the ICM cellular deficit is already present in embryos at the blastocyst
stage, it was necessary to perform embryo transfers at the 2 cell stage.
Experimental Protocol
The aim of these experiments was to investigate whether (1) the diabetic uterine
environment could induce an ICM cellular deficit in embryos from normal non-
diabetic mothers, and (2) removing embryos from a potentially harmful diabetic
environment could 'rescue' the embryos and allow them to develop normally.
Embryos at the 2-cell stage were transferred into the oviduct of pseudopregnant
females and the pregnancy was continued until day 4.5. At this time the blastocysts
were flushed from the recipient females and differentially stained to determine the
number of ICM and TE cells.
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Results
In vitro and in vivo evidence exists to suggest that certain stimuli can induce
unfertilised oocytes to undergo parthogenic activation, these include ether (293) and
avertin anaesthesia (294), heat shock (295), electric stimulation of the oviduct (296)
and in vitro treatment with hyaluronidase (297). These findings stress the importance
of taking into account the possible consequences of anaesthesia, when operative
procedures are carried out in the post-ovulatory period. Although the rate of oocyte
activation with anaesthesia is low, it is possible that the anaesthetic used during the
embryo transfer procedure (a cocktail of hypnorm and hypnovel) could activate some
oocytes to develop parthenogenetically into structures that resemble blastocysts.
Therefore it was important to test this phenomenon before embryo transfer
experiments were carried out.
Six female BB/E rats (three Diabetic DP and three Non-Diabetic DR) were mated
with vasectomised males rats. On day 0.5 of pseudopregnancy the females were
anaesthetised with the cocktail of hypnorm and hypnovel (as described in section
2.2.8.2 of Materials and Methods). The rats were sacrificed at day 4.5 of
pseudopregnancy and the uterine horns flushed with culture medium. No
parthenogenetic blastocysts were found in any of the BB/E rats, suggesting that unlike
avertin (a commonly used anaesthetic) the mix of hypnorm and hypnovel did not
induce rat oocytes to develop parthenogenetically.
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The outcome of the embryo transfer experiments is shown in Table 3.15. Two cell
embryos from Non-Diabetic DR donor females were transferred into Non-Diabetic
DR recipient females to provide the control ICM and TE cell numbers. The
blastocysts flushed from these pregnancies were slightly larger than blastocysts from
previous pregnancies at 4.5 days gestation. This was to be expected because it is
standard practice to transfer 2 cell embryos from 1.5 day pregnant mothers into 0.5
day pseudopregnant recipients, this additional day allows the transferred embryos time
to adjust to the transfer procedure which can slow down cell proliferation. The
success rate for this procedure was approximately 54 % which is quite acceptable for
rat embryo transfers, which generally have lower rates of success than embryo transfer
in the mouse [50-75 % success rate, from Hogan et al (298)].
Transfer of embryos from Non-Diabetic DR donors into Diabetic DP recipients
however, had a much lower success rate (39 %). This was mainly due to problems
with the conventional insulin therapy the diabetic rats received. Nevertheless,
blastocysts from these transfers showed a significant decrease in the number of ICM
cells compared with those from Non-Diabetic DR recipients (P < 0.01). In addition,
these blastocysts also demonstrated a significant TE cellular accretion (P < 0.001).
Therefore it appeared that the oviductal/uterine environment of the Diabetic DP
recipient induced not only an ICM deficit but a TE cell accretion in blastocysts from
normal, Non-Diabetic DR parents. These results are consistent with those seen after
24 h blastocyst culture in growth media and uterine cell conditioned media (section
3.1.2.3), ruling out the possibility that the TE cell accretion is only seen in vitro and
could have been a cell culture artefact.
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The success rate for transfer of embryos from Diabetic DP donors into Non-Diabetic
DR-BB/E recipients was 62 %. Problems encountered with these transfers were
mainly due to poor embryo quality and lack of fertilised oocytes. Transfer of embryos
from Diabetic DP mothers into Non-Diabetic DR mothers did not prevent an ICM
deficit or a TE cell accretion occurring, as these blastocysts had significantly fewer
ICM cells (P < 0.001) and significantly more TE cells (P < 0.05) than the controls.
Discussion of embryo transfer data
Diabetic DP-BB/E rats treated with conventional insulin therapy i.e. a single daily
subcutaneous injection of long acting insulin (Bovine Ultratard U40, Novo Nordisk,
Denmark) each morning show marked diurnal fluctuations in their plasma glucose
concentrations with values ranging between 2.4 and 18 mmol/L (299). It was
necessary to perform the transfer procedures during the early afternoon so that the
embryos could be harvested at the correct stage but this was also the time when most
of the rats were becoming hypoglycaemic. When deciding the dose of insulin to be
given on the morning of the experiment, it was necessary to achieve a balance
between reducing the already present hyperglycaemia and the hypoglycaemia which
would develop later that afternoon. It was assumed initially, that the stress of the
procedure would cause the blood glucose to rise and so the mid-afternoon
hypoglycaemia would not be a problem, but this was not always the case since several
of the Diabetic DP rats responded differently to the effects of the anaesthetic (see
Table 3.16).
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For some, the stress of the operation did cause their blood glucose to rise, but in
others the blood glucose level fell post-anaesthetic. This made the decision regarding
insulin dosage very difficult.
One female in particular (rat number 2415), was significantly hyperglycaemic at the
time of transfer (despite having been given 2.0 units of long acting insulin, Bovine
Ultratard U40, that morning), after the operation she remained hyperglycaemic and
although fully conscious she became very lethargic and dehydrated. She was given
another dose of insulin and fed water with a syringe, and although she survived no
blastocysts were obtained from this pregnancy. The first two embryo transfers into
Diabetic DP recipients were highly successful with 73 % and 86 % embryo recovery
rates, however it became clear that in some rats the normal morning insulin dose had
to be almost halved to prevent severe post-anaesthetic hyopglycaemia. For the final
three transfers this protocol proved to be successful.
Conclusions from Experiment II
These experiments were designed to assess the relative influence of maternal genetic
background and metabolic status on pre-implantation embryo development. These
experiments clearly demonstrate that Diabetes Prone BB/E rats during the pre-
diabetic period have normal pregnancies and that embryo development up until the
blastocyst stage at least, proceeds normally. There was no evidence of an ICM
cellular deficit and all metabolic parameters measured throughout the first 4.5 days of
pregnancy were normal. From this it can be concluded that the full complement of
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IDDM susceptibility genes was not in itself, sufficient to disturb early embryo
development and/or give rise to an ICM cell deficit.
Experiments involving the transfer of two-cell embryos examined the influence of
maternal metabolic status more closely. The data show that the oviductal/uterine
environment of the Diabetic DP recipients could induce not only an ICM deficit (P <
0.01) but a TE cell accretion (P < 0.001) in normal embryos from Non-Diabetic DR
donor rats. These results were consistent with those seen after 24 h blastocyst culture
in growth media and uterine cell conditioned media (section 3.1.2.3) when blastocysts
from Diabetic DP mothers developed an ICM cell deficit in association with a TE cell
accretion. The data confirm therefore, that the TE cellular accretion was not simply
the result of in vitro culture conditions. Transfer of 2-cell embryos from Diabetic DP
mothers into Non-Diabetic DR mothers however, did not prevent an ICM deficit or a
TE cell accretion since these blastocysts had significantly fewer ICM cells (P < 0.001)
and more TE cells (P < 0.05) than the controls. These 2-cell embryos, flushed from
diabetic donor rats, had only been in the oviduct of the diabetic mother for 1.5 days
prior to transfer. Whether this short exposure to a disturbed metabolic environment
was sufficient to cause embryo damage is uncertain.
Comparison of maternal metabolic profiles in 0.5 day pregnant pre-diabetic DP-, Non-
Diabetic DR- and Diabetic DP-BB/E rats (Table 3.10) showed that DP rats with
established IDDM had significantly lower levels of plasma pyruvate than either pre-
diabetic DP and Non-Diabetic DR-BB/E rats (0.07 ± 0.01 vs 0.19 ± 0.01 and 0.18 ±
0.01; P < 0.001, for Diabetic DP vs pre-diabetic DP and Non-Diabetic DR rats
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respectively). Pyruvate and lactate are the two main energy sources for early pre-
implantation embryos, as embryos are unable to use glucose as their principal nutrient
until the blastocyst stage. Whether poor nutritional status accompanied by high levels
of inhibitory substrates such as glucose and P-hydroxybutyrate in the diabetic oviduct
could result in disturbed embryo development is not fully known.
In conclusion, these results suggest that early damage to the pre-implantation embryo
is due to a disturbed maternal metabolic state, and that the full complement of IDDM
susceptibility genes is not in itself, sufficient to cause an ICM cellular deficit. This
suggests that the embryonic damage seen in diabetic pregnancies is secondary to a
metabolic disturbance and is therefore potentially preventable by improved insulin
delivery systems.
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3.3 Experiment III: Is IDDM-Induced Embryopathy
Preventable?
Introduction
The data presented so far clearly demonstrate that it is difficult to achieve good
metabolic control in BB/E rats with IDDM in the earliest stages of pregnancy using
conventional insulin therapy i.e. one injection of long-acting insulin each morning.
This difficulty cannot be accounted for solely by pregnancy since it has previously
been shown that male BB/E rats with IDDM maintained on CIT exhibit marked
diurnal fluctuation in plasma glucose concentration (range 2.4-25 mmol/L), and are
only rarely normoglycaemic (299). The usual pattern is that between 6 and 10 a.m.
these rats are markedly hyperglycaemic, following the insulin injection at 10 a.m. the
plasma glucose falls rapidly to hypoglycaemic levels between 2 and 10 p.m.
Thereafter the concentration of circulating insulin declines slowly overnight resulting
in a concomitant steady rise in the plasma glucose concentration (299).
Sustained release insulin implants (SRIIs) represent an alternative insulin delivery
system (300). These are small rods (2 x 7mm) consisting of powdered bovine insulin
compressed with palmitic acid. Following implantation subcutaneously, erosion of the
implant begins at once and the effect of the released insulin on the blood glucose level
can be detected within 1 h of implantation. The SRII releases a steady basal dose of
insulin continuously throughout the day and night for up to 40-60 days, delivering
approximately 2 units of bovine insulin per 24 h per implant.
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SRIIs are easy to insert using local anaesthetic and a trocar and cannula, and animals
need no special aftercare. The initial starting dose can be augmented (either by
subcutaneous injections of insulin or insertion of additional pieces of SRII) if required.
Excellent metabolic control (without significant fluctuation in the blood glucose
profile) has been achieved previously in male BB/E rats with IDDM maintained on
SRIIs (299).
Such stable control can be achieved by a steady basal dose of insulin because rats with
IDDM eat more or less continuously, rather than mainly through the night as normal
rats do.
Experimental Protocol
A group of 21 young female Diabetic DP-BB/E rats were randomly selected for this
study. Plasma glucose concentrations at diabetes diagnosis ranged from 21.8 to 44.2
mmol/L.
The aim of treatment was to achieve a target blood glucose concentration of 3-10
mmol/L as quickly as possible, using various combinations of SRIIs and subcutaneous
injections of insulin.
Blood glucose measurements were taken at 10 a.m. every two days to assess
metabolic control. If the blood glucose concentration was found to be >15 mmol/L
an additional XA piece of the regular dose Linplant® or a whole LinBit™ SRII was
inserted.
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Table 3.17: Concentration of plasma metabolites on the day of diabetes








1747 44.2 0.005 3.34 0.45 0.19 0.63 668.0
1641 40.8 0.07 3.09 0.63 0.36 0.51 44.1
1675 40.3 0.17 3.08 0.54 0.38 1.22 18.2
1745 38.5 0.12 2.87 0.66 0.29 0.28 24.9
1633 34.4 0.06 4.14 0.57 0.35 0.45 75.2
1812 34.3 0.14 4.07 0.54 0.28 0.25 29.34
2306 33.5 0.02 4.68 0.56 0.20 0.38 23.3
2271 33.2 0.28 6.61 0.59 0.26 0.38 23.5
1542 32.8 0.16 3.37 0.95 0.22 0.22 21.1
1737 32.3 0.005 2.79 0.59 0.27 0.26 558.0
1748 31.5 0.17 3.29 0.60 0.33 0.47 19.91
1608 31.0 0.01 3.52 0.56 0.32 0.40 351.0
2313 30.2 0.15 2.88 0.40 0.48 1.45 19.2
2333 29.0 0.003 2.14 0.40 0.54 0.39 712.0
1669 28.3 0.04 4.18 0.71 0.23 0.10 119.3
2314 26.7 0.21 3.27 0.52 0.20 0.13 15.4
2309 25.9 0.22 3.05 0.57 0.19 0.14 14.1
2335 24.8 0.12 2.75 0.44 0.51 0.36 22.4
1625 24.5 0.10 6.85 0.65 0.23 0.004 72.1
2310 23.5 0.18 2.98 0.47 0.26 0.14 16.6
2270 21.8 0.20 3.85 0.57 0.18 0.05 19.2
mean 31.5 0.13 3.66 0.57 0.42 0.51 86.4
± SEM ± 1.3 ±0.02 ±0.26 ±0.03 ±0.13 ±0.14 ±39.0
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The rats were allowed to stabilise for 2-3 weeks before being mated with Non-
Diabetic DR-BB/E males of proven fertility. On the morning of conception a second
plasma sample was taken for metabolite analysis. The pregnancies were allowed to
continue until day 4.5 when the embryos were collected for analysis.
Results
3.3.1 Establishing pre-pregnancy metabolic control
Table 3.17 shows the concentration of plasma metabolites on the day of diabetes
detection in the 21 female Diabetic DP-BB/E rats. In Table 3.18 the group mean for
each metabolite in diabetic rats is compared with that of a group of non-pregnant
Non-Diabetic DR-BB/E rats.
The data in Table 3.18 show that the onset of diabetes in the DP-BB/E rat is
associated with significant hyperglycaemia (P < 0.0001), ketonaemia (P < 0.001) and
increased lipolysis (P < 0.01) when compared to Non-Diabetic DR rats. This acute
metabolic decompensation reflects the absolute lack of endogenous insulin seen in
these animals at diagnosis of diabetes (160). Plasma alanine was also significantly
raised in the diabetic animals due to increased muscle protein catabolism. The level of
plasma lactate was lower in the diabetic group although statistical significance was not
achieved. The ratio of lactate to pyruvate reflects the tissue free NADH : NAD+
ratio. If the plasma lactate concentration is increased but the pyruvate concentration
is unchanged or decreased it would suggest an increase in the cytosol NADH : NAD+
ratio, and under most circumstances this indicates cellular hypoxia. Although the
lactate : pyruvate ratio was greater in the diabetic rats it was not significantly different
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from the non-diabetic group. These metabolic disturbances demonstrate that at the
beginning of the study all 21 DP rats had permanent insulin-dependent diabetes
mellitus (IDDM).
Table 3.18: Comparison of plasma metabolites in Diabetic DP at diabetes
detection and non-pregnant Non-Diabetic DR-BB/E rats




Glucose 31.50 ±1.3 7.02 ±0.3 <0.0001
Pyruvate 0.13 ±0.02 0.19 ±0.08 <0.01
Lactate 3.66 ±0.26 3.93 ± 1.3 NS
Alanine 0.57 ±0.03 0.45 ±0.02 <0.001
Glycerol 0.42 ±0.13 0.18 ±0.02 <0.01
BOHB 0.51 ±0.14 0.09 ±0.008 <0.001
Lactate/Pyruvate ratio 86.4 ±39.0 20.62 ±5.4 NS
n 21 6
Data expressed as mean ± SEM and n is the number rats in each group
Where NS denotes not significantly different from Non-Diabetic DR-BB/E rats
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Table 3.19: Comparison of plasma metabolites in SRII-treated Diabetic DP-,
CIT-treated Diabetic DP-, and Non-Diabetic DR-BB/E rats at day
0.5 of pregnancy
Metabolite CIT-Diabetic a SRH-Diabetic Non-Diabetic a
P-value
(ANOVA)
Glucose 19.6 ±2.4 9.3 ± 1.4 6.47 ±0.4 <0.001
Pyruvate 0.07 ±0.001 0.12 ±0.02 0.18 ±0.04 <0.05
Lactate 3.40 ±0.4 3.34 ±0.15 3.63 ±0.72 NS
Alanine 0.50 ±0.02 0.52 ±0.02 0.43 ±0.03 <0.05
Glycerol 0.33 ±0.06 0.20 ±0.008 0.18 ±0.03 <0.001
BOHB 0.32 ±0.05 0.05 ±0.007 0.04 ±0.009 <0.001
Lactate/Pyruvate
ratio 110 ± 57.1 61.2 ±20.4 19.45 ±2.8 NS
n 10 15 6
Data expressed as mean ± SEM
Where n is the number of animals in each group and a indicates same data as shown in
Table 3.10.
Six rats were excluded from further study because target blood glucose levels were
not consistently achieved during the 2-3 week stabilisation period (rat number 1745,
1625, 2333 and 2271) or episodes of severe and prolonged hypoglycaemia (rat
number 2313 and 1542). Blood glucose measurements consistently within the target
range were achieved in the remaining 15 rats.
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3.3.2 Assessing maternal metabolic control at conception
These 15 rats were mated with Non-Diabetic DR-BB/E male rats of proven fertility.
Plasma samples were taken on the morning of day 0.5 of pregnancy (conception day)
and the profile of circulating metabolites was compared with those from Diabetic DP
rats treated conventionally with subcutaneous insulin injections and Non-Diabetic DR-
BB/E rats (Table 3.19). In order to assess the success of SRIIs as an alternative
delivery system two questions were asked:
(1) Did Diabetic DP rats treated with SRIIs achieve better metabolic control
than those treated with CIT?
Although conventional insulin therapy did improve the plasma glucose concentration
(plasma glucose at diabetes detection 31.5 mmol/L vs 19.6 mmol/L at conception; P <
0.01) the rats were still significantly hyperglycaemic compared to Non-Diabetic DR-
BB/E rats at this time. In addition, CIT did not have any effect on the
hyperketonaemia or increased lipolysis in these diabetic rats, as shown in Table 3.19
(P < 0.001 for glucose, glycerol and BOHB in CIT-treated Diabetic DP rats vs Non-
Diabetic DR BB/E rats).
However, Diabetic DP rats treated with SRIIs had significantly lower concentrations
of plasma glucose (P < 0.01), glycerol (P < 0.001) and BOHB (P < 0.001) than CIT-
treated Diabetic DP rats. There was no significant difference in plasma concentrations
of pyruvate, alanine or lactate between SRII- and CIT-treated Diabetic DP rats. All
differences were assessed by the student's t-test.
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(2) Did SRII-treatment achieve normal control?
SRII-treatment significantly improved maternal metabolic control, seen as a reduction
in plasma glucose, glycerol and BOHB closely approaching but not quite achieving
the normal range for Non-Diabetic DR rats (although there was no difference
statistically). Pyruvate remained significantly lower, and alanine significantly higher
(P < 0.05 for both differences) in SRII-treated rats than in Non-Diabetic DR-BB/E
rats. All differences were assessed by the student's t-test.
3.3.3 Assessing maternal metabolic control during pregnancy
Scrutiny of daily blood glucose readings for each individual animal showed that prior
to pregnancy the degree of metabolic control established in these SRII-treated females
was much more variable than that previously achieved in male SRII-treated rats (299).
Closer examination of blood glucose measurements revealed that at conception there
were two distinct blood glucose patterns: (i) in 5 rats the blood glucose concentration
remained within the target range during and following conception; and (ii) in the
remaining 10 rats there was a dramatic rise in the blood glucose level (range 20-25
mmol/L) at or following conception (mean blood glucose concentration pre¬
pregnancy vs day 2.5 of pregnancy 6.20 ± 0.4 vs 20.43 ± 1.17 mmol/L, respectively;
P< 0.0001).
The individual blood glucose profiles for the 15 SRII-treated rats are shown in
Figures 3.6 and 3.7. Figure 3.6 shows the profiles of the 10 rats which displayed a
dramatic rise in blood glucose concentration at or following conception. Figure 3.7
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shows the profiles of the 5 rats which did not show a rise in blood glucose
concentration at or following conception.
Figure 3.6: Blood glucose profiles of SRII-treated Diabetic rats showing good
metabolic control pre-conception followed by a post-conception rise in blood
glucose
Rat number 1669
0 5 10 15 20 25
Duration of SRII treatment (days)
Rat number 1812
0 5 10 15 20 25 30
Duration of SRII treatment (days)
Where day of conception is indicated by [■]
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Figure 3.6 (continued): Blood glucose profiles of SRII-treated Diabetic rats
showing good metabolic control pre-conception followed by a post-conception
rise in blood glucose
Rat number 1675
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Figure 3.6 (continued): Blood glucose profiles of SRII-treated Diabetic rats
showing good metabolic control pre-conception followed by a post-conception
rise in blood glucose
Rat number 1641
Rat number 1747
Where day of conception is indicated by [■]
153
Figure 3.6 (continued) : Blood glucose profiles of SRII-treated Diabetic rats
showing good metabolic control pre-conception followed by a post-conception





















0 1 1 1 1 1 1
0 5 10 15 20 25 30

























Duration of SRII treatment (days)
25
Where day of conception is indicated by [■] and * indicates additional SRII given
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Figure 3.6 (continued): Blood glucose profiles of SRII-treated Diabetic rats
showing good metabolic control pre-conception followed by a post-conception
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Figure 3.7 : Blood glucose profiles of SRII-treated Diabetic rats showing good
metabolic control pre-conception maintained through conception and during
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Figure 3.7 (continued) : Blood glucose profiles of SRII-treated Diabetic rats
showing good metabolic control pre-conception maintained through conception
and during early pregnancy with no blood glucose rise post conception
Rat number 2270




0 5 10 15 20 25
Duration of SRII treatment (days)
Where day of conception is indicated by 0
157
Figure 3.7 (continued): Blood glucose profdes of SRII-treated Diabetic rats
showing good metabolic control pre-conception maintained through conception
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Figure 3.8:
Mean blood glucose profiles of SRII-treated Diabetic DP-BB/E rats before
pregnancy, at conception and during the first four days ofpregnancy.
Panel A: shows the group profile of the 10 rats which displayed a significant rise in
blood glucose concentration at or following conception, indicated by * (P < 0.0001).
Panel B: shows the group profile of the five rats which did not show a rise in blood
glucose concentration at or following conception.
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A mean blood glucose profile for non-diabetic DR BB/E rats (n = 8) one week before
pregnancy, at conception and during the first four days of pregnancy is shown in
Figure 3.9. As expected, there was no post-conception blood glucose rise in these
rats.
Figure 3.9 : Mean blood glucose concentrations in Non-Diabetic DR-BB/E rats
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Maternal metabolic control during pregnancy was also assessed by HbAl
measurement. Whole blood was taken by tail tipping (without anaesthesia) on day 4.5
of pregnancy and used to measure the blood glucose concentration and the percentage
of glycosylated haemoglobin. The mean blood glucose and HbAl values for SRII-
treated Diabetic DP-, CIT-treated Diabetic DP- and Non-Diabetic DR-BB/E rats are
shown in Table 3.20.
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Table 3.20 : Mean blood glucose (BG) concentration and HbAl in SRII-
treated Diabetic DP-, CIT-treated Diabetic DP- and Non-Diabetic






(n= 15) 14.90 ±2.2 5.5 ±0.4
(i) Post-conception BG rise
(n =10) 20.24 ± 1.1 a 5.6 ±0.5
(ii) No Post-conception BG rise
(n=5) 4.12 ± 1.1 b 5.1 ±0.4
CIT-treated Diabetic DP-BB/E
(n = 10) 21.93 ± 1.6 c 5.3 ± 0.3 d
Non-Diabetic DR-BB/E
(n - 8) 4.26 ±0.4 3.1 ±0.2
Data are means ± SEM. Statistical differences by Student's t-test :
Blood glucose concentration:
a
SRII-Diabetic rats with post conception (p.c.) BG rise significantly different from
SRII-Diabetic with no p.c. BG rise (P < 0.0001), CIT-Diabetic (P < 0.05) and Non-
Diabetic (P < 0.0001) rats.
b
SRII-Diabetic rats with no p.c. BG rise significantly different from CIT-Diabetic rats
(P< 0.0001)
c
CIT-Diabetic significantly different from Non-Diabetic rats (P < 0.0001)
HbAl:
d
Non-Diabetic rats significantly different from SRII-Diabetic (P < 0.001) and CIT-
Diabetic (P < 0.0001) rats.
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Despite achieving good maternal metabolic control prior to pregnancy, the mean
HbAl value for the SRII-treated Diabetic DP rats was not significantly different from
CIT-treated Diabetic DP rats. When the HbAl values for the SRII-treated rats were
separated into those which had a post-conception blood glucose rise and those which
did not, statistical difference was still not achieved. Thus, both types of insulin
therapy, - SRII and CIT resulted in HbAl values significantly greater than those for
Non-Diabetic DR BB/E rats (P < 0.001 and P < 0.0001, respectively).
3.3.4 Morphology analysis
Pregnancy was continued until day 4.5 when the embryos were collected and the
number of embryos at each morphological stage of development recorded (Table
3.21).
There was no significant difference in the morphological distribution of embryos at
day 4.5 of pregnancy between SRII- and CIT-treated Diabetic DP rats. However,
when only those SRII-treated rats with good metabolic control at conception and
during pregnancy were compared with CIT-treated Diabetic DP rats there was a
significant improvement in fertility (reflected as a decrease in the number of
unfertilised oocytes). In addition, there was a significant increase in the number of
expanded blastocysts per pregnancy (P < 0.001). Comparing SRII-treated Diabetic
DP rats with and without the post-conception blood glucose rise there were
significantly more expanded blastocysts per pregnancy in SRII-Diabetic DP rats with
no post-conception blood glucose rise (45 expanded blastocysts from 10 pregnancies
with post-conception blood glucose rise vs 41 expanded blastocysts from 5
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pregnancies with no post-conception blood glucose rise, P < 0.05). Moreover,
pregnancies from SRII-treated Diabetic DP rats were not significantly different from
Non-Diabetic DR pregnancies with respect to the number of morulae, early
blastocysts, expanded blastocysts or unfertilised oocytes.
3.3.5 Cell lineage analysis
Expanded blastocysts were collected from each individual pregnancy on day 4.5 of
gestation and differentially labelled to determine the number of inner cell mass and
trophectoderm cells (Table 3.22)
Table 3.22: Mean ICM and TE cell number in blastocysts from SRII-treated
Diabetic DP-, CIT-treated Diabetic DP-, and Non-Diabetic DR-
BB/E rats
Type of No. of ICM cell TE cell
Pregnancy Embryos number number
SRII-treated Diabetic DP 74 8.00 ±0.45 * 19.43 ±0.48
(n = 15)
(i) Post-conception BG rise
(n =10) 38 8.00 ±0.41 * 19.66 ±0.44
(ii) No Post-conception BG rise
(n =5) 36 8.00 ±0.48 * 19.19 ± 0.51
CIT-treated Diabetic DP a 57 8.00 ±0.25 * 20.23 ±0.41
Non-Diabetic DRb 43 10.40 ±0.25 19.77 ±0.59
Where a indicates same data as Table 3.3 and b same data as shown in Table 3.2.
Data expressed as mean ± SEM. * P < 0.0001 : significantly less than blastocysts
from Non-Diabetic rats (Student's t test)
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Blastocysts from SRII-treated Diabetic DP rats were found to exhibit the same
disturbed development as that observed previously in poorly controlled CIT-treated
Diabetic DP rats, namely a 20 % cellular deficit in the ICM, despite achieving good
maternal metabolic control (blood glucose 3-10 mmol/L) for at least one week prior
to conception. Moreover, this 20 % ICM cellular deficit was also found in blastocysts
from pregnancies which did not exhibit a post-conception blood glucose rise.
3.3.5 Measurement of Progesterone
The hyperglycaemic peak which develops over the period of conception could be
associated with the physiological rise in progesterone which occurs at this time. A
third group of young female Diabetic DP-BB/E rats (n = 19) were treated with SRII
from the day of diabetes onset. Metabolic control was assessed by daily blood
glucose measurements (taken at 10 a.m. each morning), and as described earlier, good
metabolic control was defined as blood glucose readings consistently between 3-10
mmol/L. Rats which did not achieve good metabolic control a minimum of two
weeks prior to conception were rejected from the study. Ten of the SRII-treated
Diabetic DP rats were excluded because of failure to achieve good metabolic control.
The remaining nine females with good metabolic control were mated with fertile Non-
Diabetic DR rats. Serum samples were taken at day 0.5 and 2.5 of pregnancy and the
concentration of progesterone was measured by the laboratory of Professor S. Hillier,
Centre for Reproductive Biology, University of Edinburgh. There was a four-fold
increase in progesterone between day 0.5 and day 2.5 of pregnancy (26.0 vs 108.4
nmol/L, P< 0.001) (Table 3.23).
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day 0.5 day 2.5
P value
(t-test)
SRII-Diabetic (n = 9) 26.0 ±3.9 108.4 ± 15 <0.001
(i) Post-conception BG rise
(n = 6) 28.3 ±5.7 106.7 ± 14 <0.01
(ii) No Post-conception BG
rise (n = 3) 21.4 ±1.8 111.9 ±43 NS
Pseudopregnant (n = 5) 22.8 ±2.0 90.0 ± 16 <0.05
Data expressed as means ± SEM and where n is the number of animals in each group
and BG denotes blood glucose.
Of the nine SRII-treated Diabetic DP rats with good metabolic control, six had a
dramatic rise in the blood glucose level (range 20-25 mmol/L) at or following
conception previously observed in SRII treatment, whilst the remaining three rats had
blood glucose readings within the target range during and following conception. As
shown in Table 3.23 there was a four-fold increase in progesterone in response to
conception in all groups of SRII-treated Diabetic DP rats, although statistical
significance was not achieved in the smallest group because of large standard errors.
These data demonstrate that the reason for the hyperglycaemic peak in some of the
SRII-treated Diabetic DP rats was not simply due to these rats producing more
progesterone, - but presumably due to insufficient insulin.
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Serum progesterone was also measured in SRII-treated Diabetic DP rats mated with
vasectomised males. Although statistical significance was less (P < 0.05) there was
still a four-fold increase in progesterone between day 0.5 and 2.5 in these rats,
demonstrating that there was a hormonal response even in the absence of fertilisation.
Conclusions from Experiment III
(i) Assessing SRII as an alternative insulin-delivery system
Establishing good metabolic control from diabetes onset in female rats proved to be
very difficult. Despite the fact that all of the rats had approximately the same body
weight at diabetes detection (200 g) their insulin requirements were quite variable,
with some animals requiring additional SRII. Occasionally too much insulin was
given and the animals experienced long periods of hypoglycaemia (up to one week)
and had to be excluded from the study.
Some rats had very erratic blood glucose readings, changing from 2.5 to 18 mmol/L
over a period of 24 h for no apparent reason. The low dose LinBit implants were
easier to use in young female rats than the regular dose Linplant as it was possible to
'fine tune' the dose of insulin by adding variably sized pieces of insulin rod.
Despite the problems the degree of metabolic control achieved in 15 female rats
treated with SRII was significantly improved compared with CIT with respect to
reducing the concentration of plasma glucose, ketones and glycerol closely
approaching but not quite achieving the normal range for Non-Diabetic DR rats.
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(ii) Assessing SRII as an alternative insulin-delivery system to prevent
IDDM-induced embryopathy in pregnancy
As described earlier, pregnancy in the Diabetic DP-BB/E rat treated with conventional
insulin therapy is associated with a severe disturbance in embryo development, namely
(i) a five-fold increase in the number of unfertilised oocytes, (ii) a reduced number of
expanded blastocysts, and (iii) a -20 % ICM cellular deficit in embryos which reached
the expanded blastocyst stage. The aim of this study was to determine whether this
IDDM-induced embryopathy could be prevented using the sustained release insulin
implant.
Comparing the morphological distribution at day 4.5 of pregnancy in SRII- and CIT-
treated Diabetic DP rats there was no significant improvement. There was however, a
significant improvement in fertility and the number of expanded blastocysts per
pregnancy when only those SRII-treated rats with good metabolic control at
conception and during pregnancy were compared with CIT-treated Diabetic DP rats
(P < 0.001). Since all 15 rats had good metabolic control for at least one week before
conception, this suggests that normal metabolic control at the time of conception and
during the first few days of pregnancy was essential in determining successful
pregnancy outcome.
However, blastocysts from all SRII-treated rats exhibited a 20 % cellular deficit in the
inner cell mass, irrespective of maternal metabolic control at the time of conception.
This suggests that either there are different aetiologies for these two pathologies, or
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that the degree of metabolic control achieved in these rats was sufficient to restore
fertility to normal but not sufficient to prevent the ICM-specific embryopathy.
In conclusion, these data suggest that despite vastly improved maternal metabolic
control SRII-treatment was unable to prevent all of the IDDM-induced embryopathy
observed in Diabetic DP-BB/E rats in early pregnancy. Given the fact that the blood
glucose concentration during pregnancy in the Non-Diabetic DR-BB/E rat rarely falls
below 3.0 or rises above 5.5 mmol/L, failure of SRII-treatment in preventing
embryopathy may be due to the fact that the SRII-treated rats were not
normoglycaemic. Alternatively, an additional unknown factor may be responsible for
the ICM cellular deficit which although is associated with IDDM, is not directly
related to the degree of hyperglycaemia.
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3.4 Experiment IV : Investigating one possible mechanism
of the ICM Cellular Deficit
Introduction
As described in section 3.1, cells with features characteristic of apoptosis were
observed in differentially stained blastocysts from both Diabetic DP- and Non-
Diabetic DR-BB/E rats. It appeared that these cells with fragmented nuclei were
observed more often in the ICM than in the TE, and more often in Diabetic DP than
Non-Diabetic DR rats, although it was not possible to accurately quantitate this
phenomenon because of the limitations of using fluorescence microscopy (see
Discussion).
The following experiments were designed to investigate whether the reduction in ICM
cell number seen in blastocysts from Diabetic DP rats was due to disturbed regulation
of apoptosis. Conventional methods of mRNA analysis such as Northern and dot blot
hybridisation and nuclease mapping are not sensitive enough to detect mRNA in
samples limited by either low cell number or low copy number per cell. In situ
hybridisation allows detection of mRNA in single cells but is non-quantitative. The
reverse-transcriptase polymerase chain reaction (RT-PCR) however, is a very
powerful technique, and its unique sensitivity allows large amounts of complementary
DNA (cDNA) for the gene of interest to be rapidly produced from very small amounts
of starting material (302). The specificity and sensitivity of the PCR can be greatly
enhanced by using a nested PCR protocol where a fraction of the first round of
amplification is re-amplified with a new set of primers, complementary to the
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sequence contained within the initial product. Therefore, the non-specific priming
associated with the high number of PCR cycles required to amplify cDNA from single
embryos can be avoided.
The first gene shown to be specifically involved in the process of physiological cell
death was bcl-2 (303). bcl-2 is now known to belong to a growing family of
apoptosis-regulating genes, which may either be death antagonists {bcl-2, bcl-XL, bcl-
W, bfl-1, mcl-l and a I) or death agonists {bax, bak, bcl-Xs, bad, bid, bik and hrk).
The ratio of death antagonists to agonists is believed to determine whether a cell will
respond to an apoptotic signal. This death-life rheostat is mediated, at least in part, by
competitive dimerisation between selective pairs of antagonists and agonists (304,
305, 306, 307, 308).
The ratio of bcl-2 (a cell death antagonist gene) to bax (a cell death agonist gene)
expression was determined in blastocysts from Diabetic DP- and Non-Diabetic DR-
BB/E rats using quantitative RT-PCR. This technique has the potential to reveal
some of the earliest molecular events in the development of the rat embryo.
Quantitative RT-PCR is very difficult to achieve mainly because PCR amplification is
an exponential process, and minute differences in any of the parameters that control
the efficiency of the reaction can substantially affect the final yield of PCR product,
making it difficult to quantitate the amount of mRNA in the original material (309).
The use of RT-PCR to quantify the level of expression of a gene in terms of copy
number requires the availability of a standard with characteristics as close as possible
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to the target cDNA sequence - in particular, with regard to base composition and
amplified product length.
Quantitative RT-PCR Strategy
Internal standards for each gene of interest were created by inserting the external
primer PCR product into a commercial plasmid transcription vector - PCR2.1 (from
Invitrogen), and modifying the insert by increasing its length by 5-8 nucleotides. The
recombinant plasmid DNA was transcribed in vitro to produce synthetic mRNA.
Synthetic mRNA internal standards were created for the two genes of interest: bax
and bcl-2, and p-actin which served as a positive control for RNA quality. Figure
3.10 shows a schematic diagram outlining the creation of the synthetic (3-act in mRNA
internal standard.
Total RNA was prepared from single pre-implantation embryos using a scaled-down
protocol based on the method of Chomczynski and Sacchi (272). Known amounts of
bax, bcl-2 and 3-actin synthetic mRNA internal standard were added to the embryo
reverse transcription reaction and cDNA was then synthesised. One-tenth of this
cDNA was amplified using the external pair of oligonucleotide primers, followed by a
second round of amplification with the internal primer pair. The forward internal
primers used for the second round of amplification were labelled at the 5' end using
polynucleotide kinase and [y32P]-ATP. After amplification, the PCR products were
separated by polyacrylamide gel electrophoresis and visualised by autoradiography.
Radioactive signals were quantified by a phosphorimager (Molecular Dynamics) by
measuring intensity of each cDNA band.
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3.4.1 RT-PCR of single pre-implantation embryos
Before the embryo mRNA quantification experiments could begin the RT-PCR
protocol had to be optimised for the external and internal pairs of bax, bcl-2 and P-
actin primers. P-actin served as a positive control for RNA quality. Initially all
optimisation was carried out using ovary RNA from normal Sprague-Dawley rats,
reported to have high levels of bax and bcl-2 gene expression (310). Conditions
which required optimisation included concentrations of enzyme, dNTPs, magnesium
ions, and primers; amount of starting material (cDNA); temperatures of denaturation,
annealing, and extension; and cycle number. Once the PCR conditions had been set
total RNA was prepared from single pre-implantation embryos (morula, early
blastocyst and expanded blastocyst) from Non-Diabetic DR-BB/E rats. Half of the
total RNA was reverse transcribed and amplified using the nested PCR protocol
described in section 2.2.9 of Materials and Methods. After amplification one-fifth of
the reaction mixture was separated through a 2 % agarose gel and visualised by
ethidium bromide staining. A single band of the predicted size was observed for each
reaction (bax 372 bp; bcl-2 329 bp; P-actin 747 bp) (Figure 3.11). The negative
controls used were amplification of'extracted' embryo culture media, or amplification
without added template. No cDNA product was observed in these lanes indicating
that there was no contamination with extraneous cDNA or RNA.
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Figure 3.11:
Agarose gel showing the reverse transcription (RT)-PCR amplified products from
RNA derived from single pre-implantation embryos from Non-Diabetic DR-BB/E
rats using bax, bcl-2 and B-actin specific primers.
where: m = molecular weight marker (1000, 740, 341, 258, 219 and 105 bp)
a = 'No RNA' (negative control)
b = 'No RNA' + glycogen (negative control)
c = ovary (positive control)
d = single morula
e = single early blastocyst
f = single expanded blastocyst
The size of the expected RT-PCR products are shown in base pairs (bp)
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The RT-PCR experiments using bax, bcl-2 and P-actin primers were repeated a
minimum of three times with pre-implantation embryos at each stage. These data
demonstrate for the first time that bax and bcl-2 messages are present in pre-
implantation embryos.
The identity of the specific RT-PCR products was confirmed by DNA sequencing and
matched the published sequences in the GenBank database (276, 277, 275) for bcl-2,
bax and p-actin sequences respectively (see Appendix Figure 5.1, 5.2 and 5.3).
3.4.2 Preparation of internal standards
A 'TA' cloning kit (Invitrogen) was used to clone the bax, bcl-2 and P-actin RT-PCR
products directly from PCR reactions into the vector PCR2.1. Ligation took
advantage of the template-independent addition of a single deoxyadenosine (A) to the
3' ends of PCR products by thermostable polymerases such as Taq polymerase. The
linearised vector with single deoxythymidine (T) residues at each end allowed the
PCR products to ligate efficiently with the vector.
The recombinant colonies (i.e. those which contained the plasmid and insert) were
selected by insertional inactivation. The enzyme P-galatosidase which breaks down
lactose into glucose and galactose, is normally coded by the gene lac Z on the E.coli
chromosome. The E.coli strain TOP 10F' had a modified lac Z gene referred to as
lac Z' which codes for the a-peptide portion of the P-galactosidase. These mutants
can synthesise the enzyme only when they harbour a plasmid that carries the missing
lac Z' segment of the gene. The vector pCR2.1 contained the lacZa complementation
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in addition to ampicillin and kanamycin resistant genes for selection. Insertional
inactivation of the a-peptide allowed recombinant clones to be distinguished by their
inability to synthesise P-galactosidase. Thus, the addition of ampicillin, X-gal (a
lactose analogue which forms a blue product when broken down by P-galactosidase)
and IPTG to the agar allowed distinction of colonies which were able to synthesise P~
galactosidase (they were coloured blue) and recombinant colonies with a disrupted lac
Z' gene and unable to make P-galactosidase which were white.
Several white colonies were grown overnight in LB broth and plasmid DNA was
prepared. The presence of the insert synthesised by RT-PCR in the plasmid (PCR2.1)
was confirmed by restriction enzyme digestion at 37°C for 1 hour. Digestion of bax
recombinant plasmids (pBaxPCR2.1) with BamHl yielded fragments of either 3979
and 414 bp or 4275 and 118 bp (depending on the orientation of the insert). Vector
which did not contain the bax insert was distinguished from pBaxPCR2.1 as it yielded
only one DNA band of 3939 bp after digestion. Digestion of bcl-2 recombinant
plasmids (pBcl-2PCR2.1) with Bgll yielded fragments of either 2241, 365 and 1722
bp or 2241, 533 and 1544 bp (depending on the orientation of the insert), vector
which did not contain the bcl-2 insert yielded only two DNA bands of 2241 and 1659
bp after digestion. Similarly, digestion of P-actin recombinant plasmids
(pActPCR2.1) with Bgll yielded fragments of either 2241, 932 and 1474 bp or 2241,
285 and 2121 bp (depending on the orientation of the insert). Vector which did not
contain the P-actin insert yielded only two DNA bands of 2241 and 1659 bp after
digestion.
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The products of enzyme digestion were analysed by agarose gel electrophoresis and
the results shown in Figure 3.12 demonstrate the presence of the p-actin, bax or bcl-2
insert in representative examples of pActPCR2.1, pBaxPCR2.1 and pBcl-2PCR2.1
DNA digests.
As described in section 2.2.10.7 and shown in Figure 3.10 the size of the insert in the
recombinant plasmids was altered either by adding a new restriction enzyme site or by
filling in the 3' recessed ends after enzyme digestion. The mutated pBaxMutPCR2.1,
pActMutPCR2.1 and pBcl-2MutPCR2.1 DNA was digested with appropriate
restriction enzymes to distinguish between native and mutated recombinant plasmid
DNA. Plasmids which contained the mutated P-actin insert (pActMutPCR2.1) no
longer contained the BstEll restriction site and yielded only one DNA fragment after
digestion, whilst the native plasmid (pActPCR2.1) yielded two fragments of 4509 and
139 bp after enzyme digestion.
Plasmids which contained the mutated bcl-2 insert (pBcl-2MutPCR2.1) were
identified by the presence of a new restriction site in the insert. Thus, digestion of the
plasmids with Xba\ yielded two DNA fragments (4037 and 299 bp) from pBcl-
2MutPCR2.1 and only one from native pBcl-2PCR2.1 plasmids (4328 bp).
The presence of the mutated insert in pActMutPCR2.1 and pBcl-2MutPCR2.1 was
also verified by DNA sequencing. Partial nucleotide sequences of these plasmids are
shown in the Appendix (Figure 5.4 and 5.5).
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Figure 3.12:
Agarose gel showing the verification of recombinant plasmid DNA.
Panel A: Plasmid PCR2.1 containing the bax insert digested with BamHI, yielding
two fragments of 3979 bp and 414 bp (lane 1) or 4275 bp and 118 bp (lane 2).
Panel B: Plasmid PCR2.1 containing the bcl 2 insert digested with Bgll, yielding
three fragments of 2241 bp, 1722 bp and 365 bp (lane 1).
Panel C: Plasmid PCR2.1 containing the fi-actin insert digested with Bgl I, yielding
three fragments of 2241 bp, 221 bp and 285 bp (lane 1)
Lane M: Molecular weight marker (1000, 740, 341, 258, 219, 105 bp)
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To distinguish between plasmids which contained the mutated bax insert
(pBaxMutPCR2.1) and native plasmids (pBaxPCR2.1), plasmid DNA was amplified
with bax internal primers and the products were separated by polyacrylamide gel
electrophoresis. As shown in Figure 3.13A, PCR amplification of several clones
containing pBaxMutPCR2.1 resulted in PCR products of a slightly smaller or larger
size than the native pBaxPCR2.1. Plasmid DNA prepared from bacterial clone
number 6 was chosen to become the bax DNA internal standard as there was a good
separation between the mutant and native plasmid PCR products.
3.4.3 Quantitative RT-PCR
Quantitative RT-PCR is based on the assumption that cDNA synthesis efficiency is
identical for both the target mRNA (a fragment of specific mRNA from the gene to be
analysed, contained within the preparation of total RNA) and standard mRNA (a
fragment of recombinant synthesised RNA sharing identical primer binding sequences
with the target RNA, used as an internal control) (311). Thus, after reverse
transcription the ratio of target to standard cDNA molecules should be equal to the
initial ratio of target to standard cDNA molecules, and this ratio should remain
unchanged throughout the PCR amplification process. To achieve real quantification
by this method many of the variables of RT-PCR which can affect reaction efficiency
have to be controlled as much as possible (concentrations of dNTPs, cDNA,
magnesium ions, and primers and temperatures of denaturation, annealing, and
extension). Those variables particularly critical to quantitative RT-PCR relate to the
amount of starting material - mRNA, cDNA, and the ratio of standard to target RNA.
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Figure 3.13: Screening pBaxMutPCR2.1 mutant recombinant plasmids by PCR
A
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(A) In the autoradiograph shown here, lanes 1-11 correspond to PCR of






(B) Autoradiograph showing results of PCR amplification of pBaxPCR2.1 DNA and
three pBaxMutPCR2.1 plasmid clones. Lane 1 corresponds to pBaxPCR2.1 and
pBaxMutPCR2.1 clone #9; lane 2: pBaxPCR2.1 plasmid DNA and pBaxMutPCR2.1
clone #5; lane 3: pBaxPCR2.1 plasmid DNA and pBaxMutPCR2.1 clone #6.
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It was also necessary to determine the number of PCR cycles which would generate a
product proportional to the cDNA added to the reaction, and ensure that there was
good separation of the standard and target RT-PCR products by polyacrylamide gel
electrophoresis. Non-specific PCR products were prevented by increasing the primer
annealing temperature and the concentration of primers to 100 pmoles. Other
conditions requiring optimisation included gel running time, amount of product loaded
onto the gel and gel exposure time to X-ray film.
3.4.3.1 Validation of quantitative RT-PCR method
(i) Using DNA internal standards
In order to verily that the efficiency of amplification was equivalent for the standard
and the target, preliminary experiments were carried out demonstrate that (1) the
internal standard could be titrated over a range of concentrations, and (2) the
presence of target cDNA did not affect the amplification of the internal standard.
In Figure 3.14A a nested PCR using primers specific for bax is shown. Each reaction
contains a constant amount of ovary (target) cDNA amplified with increasing
concentrations of DNA internal standard (pBaxMutPCR2.1) in triplicate. The PCR
products were separated by denaturing polyacrylamide gel electrophoresis and
visualised by autoradiography. The upper bands are amplified from ovary cDNA and
the lower bands from the standard pBaxMutPCR2.1 DNA. The amount of 32P-
labelled primer in each reaction was quantified by means of a Molecular Dynamics
Phosphorimager system (as described in section 2.2.11.4 of Materials and Methods)
and the intensity (measured in arbitrary units) of the target cDNA and standard DNA
Figure 3.14A:
Autoradiograph showing results of PCR amplification ofboth target (ovary) cDNA
templates and pBaxMutPCR2.1 standard DNA templates with increasing amounts of
pBaxMutPCR2.1 standard DNA using bax specific primers. Amounts of
pBaxMutPCR2.1DNA were 1.92 pg (lanes 1-3); 3.84 pg (lanes 4-6); 7.68 pg (lanes
16-18).
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bands were calculated (shown in Table 3.24) and plotted against the amount of
standard DNA (pBaxMutPCR2.1) added to the reaction (Figure 3.14B). Regression
analysis of the curves showed that for the pBaxMutPCR2.1 DNA standard curve R2 =
0.9871 and for the ovary cDNA R2 = 0.0024.
The ratios of standard DNA/ovary cDNA band intensity were plotted against amount
of standard pBaxMutPCR2.1 DNA and an exponential curve was produced (Figure
3.14C). These data confirm that the efficiencies of amplification of the target and
standard were equal under these conditions and there was a linear relationship with
increasing amounts of standard pBaxMutPCR2.1 between 7 pg and 20 pg.
Table 3.24: Mean intensity of pBaxMutPCR2.1 DNA standard and ovary











1.92 38.06 + 2.45 160.3 + 8.5 0.24
3.84 60.66 + 2.5 182.8 + 2.5 0.33
7.68 122.3 ±11.5 221.7 + 2.5 0.55
11.52 249.8 + 5.1 203.3 + 6.3 1.23
15.36 306.8 + 9.7 186.5 + 9.4 1.65






Analysis of bax PCR with constant ovary cDNA and variable concentrations of
pBaxMutPCR2.1 DNA standard. Each reaction contains a constant amount of ovary
(target) cDNA amplified with increasing concentrations of pBaxMutPCR2.1 DNA
standard. Regression analysis of the curves showed that for the DNA standard curve
R2 = 0.9871 and for the ovary cDNA R2 = 0.0024.
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Figure 3.14C:
Ratios of standard pBaxMutPCR2.1 DNA/ovary cDNAband intensity plotted against
pBaxMutPCR2.1 DNA concentration.
Figure 3.15A shows a similar nested PCR, using P-actin specific primers. A constant
amount of target (ovary cDNA) was amplified with increasing amounts of
pActMutPCR2.1 DNA standard. The upper bands are amplified from the standard
plasmid DNA and the lower bands from ovary cDNA. The intensity of each band was
calculated (Table 3.25) and plotted against the concentration of standard
pActMutPCR2.1 DNA (Figure 3.15B).
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Figure 3.15 A:
Autoradiograph showing results of PCR amplification of both target (ovary) cDNA
templates and pActMutPCR2.1 standard DNA templates with increasing amounts of
pActMutPCR2.1 standard DNA using B-actin specific primers. Amounts of
pActMutPCR2.1 DNA were 19.20 pg (lanes 1-3); 9.50 pg (lanes 4-6); 3.84 pg (lanes
7-9); 1.92 pg (lanes 10-12); 0.38 pg (lanes 13-15).
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Table 3.25: Mean intensity of pActMutPCR2.1 DNA and ovary cDNA after
nested PCR using P-actin specific primers
pActMutPCR2.1 pActMutPCR2.1
DNA DNA Ovary cDNA Ratio DNA
concentration (pg) band intensity band intensity standard/ovary
0.38 26.08 ±2.9 43.9 ±6.8 0.59
1.92 120.13 ±9.3 46.1 ±8.1 2.60
3.84 249.47 ± 37 47.45 ±3.9 5.26
9.50 390.63 ±24.3 40.83 ± 1.1 9.57


















Concentration of pActMutPCR2.1 DNA
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Figure 3.15B: Analysis of P-actin PCR with constant ovary cDNA and
variable concentrations of pActMutPCR2.1 DNA standard. Each reaction contains a
constant amount of ovary (target) cDNA amplified with increasing concentrations of
pActMutPCR2.1 DNA standard. Regression analysis of the curves showed that for
the DNA standard curve R2 = 0.954 and for the ovary cDNA R2 = 0.109.
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Figure 3.15C:
Ratios of standard DNA/ovary cDNA band intensity plotted against pActMutPCR2.1
DNA concentration. A linear curve was produced where R2= 0.9946.
The results of a nested PCR, using bcl-2 specific primers is shown in Table 3.26
(autoradiograph not shown because signal was very weak). As described above, a
constant amount of target (ovary) was amplified with increasing amounts of standard
pBcl-2MutPCR2.1 DNA. The intensity of each band was plotted against the
concentration of standard pBcl-2MutPCR2.1 DNA (Figure 3.16A).
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Table 3.26: Mean intensity of pBcI-2MutPCR2.1 DNA and ovary cDNA











1.92 2.68 ± 1.1 9.48 ±2.8 0.28
3.84 8.05 ±3.5 16.50 ±4.3 0.49
7.68 30.1 ±5.2 16.44 ±1.8 1.83
11.52 57.86 ±4.3 15.42 ±3.5 3.75
15.36 63.19 ±1.2 11.10 ±2.0 6.00
19.20 88.84 ±3.2 11.35 ± 0.8 7.83
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Figure 3.16A:
Analysis of bcl-2 PCR with constant ovary cDNA and variable concentrations of
pBcl-2MutPCR2.1 standard DNA Each reaction contains a constant amount of
ovary (target) cDNA amplified with increasing concentrations of pBcl-2MutPCR2.1
standard DNA. Regression analysis of the curves showed that for the DNA standard
curve R2 = 0.981 and for the ovary cDNA R2 =0.048.
The ratios of standard/ovary band intensity were plotted against amount of pBcl-




Ratios of band intensity (standard pBcl-2MutPCR2.1 DNA/ ovary cDNA) plotted
against pBcl-2MutPCR2.1 DNA concentration. An exponential curve was produced
where R2= 0.981.
These figures (3.14, 3.15 and 3.16) are representative examples of at least two
independent repeat experiments. These results confirm that for each of the genes the
internal standard could be titrated over a range of concentrations, and the presence of
target cDNA did not affect the amplification of the internal DNA standard.
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(ii) Using mRNA internal standards
The plasmids pActMutPCR2.1, pBaxMutPCR2.1 and pBcl-2MutPCR2.1 were
transcribed in vitro to produce synthetic mRNA. To be certain that no contaminating
template DNA remained after transcription and isolation of the synthetic message, an
aliquot of the transcription reaction (after the DNase treatment) was subjected to
electrophoresis through agarose. No template DNA was detected after ethidium
bromide staining.
To determine the optimal amount of mRNA internal standard to add to embryo RNA,
RT-PCR was carried out using a constant amount of blastocyst (target) total RNA
and variable amounts of internal standard mRNA. When the synthetic internal
standard/endogenous RNA signal is plotted against the concentration of the standard
a hyperbolic curve is seen. The most accurate measurement is taken in the linear
portion of the curve, where the signal ratios are most similar (309). A representative
example of this is shown in Figure 3.17A. Five different concentrations of P-actin
synthetic mRNA standard (854 fg, 1.7 pg, 3.4 pg, 6.8 pg, and 13.6 pg) were reverse
transcribed and amplified with embryo total RNA (prepared from 5 pooled blastocysts
so that each RT reaction contained embryo RNA equivalent to half a single
blastocyst). Each reaction was performed in duplicate. Since one single blastocyst
provides sufficient RNA for only two RT reactions it was necessary to use pooled
blastocysts for this part of the procedure, mainly to ensure that each RT reaction
contained RNA of equal quality and quantity. Table 3.27 shows the phosphorimage
analysis data and Figure 3.17B shows the standard/embryo RNA ratios plotted against
the concentration of standard mRNA.
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Figure 3.17A:
Results of RT-PCR showing co-amplification of 13-actin mRNA internal standard and
blastocyst Actin mRNA. Amounts ofActin mRNA internal standard added were 854
fg (lanes 1 and 2); 1.7 pg (lanes 3 and 4); 3.4 pg (lanes 5 and 6); 6.8 pg (lanes 7 and
8); 13.6 pg (lanes 9 and 10).
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Table 3.27: Results of phosphorimager analysis of P-actin RT-PCR using


















0.854 14.49 126.8 0.114 0.1085
0.854 15.62 151.4 0.103
1.70 13.41 76.71 0.175 0.1795
1.70 22.64 123.1 0.184
3.4 89.14 161.9 0.551 0.5515
3.4 94.42 171.0 0.552
6.8 131.2 179.4 0.731 0.764
6.8 176.8 221.7 0.797
13.6 226.5 238.9 1.116 1.1055
13.6 251.8 230.0 1.095
From the phosphorimager data calculated in Table 3.28, the concentration of synthetic
P-actin mRNA standard appropriate for quantitative RT-PCR of single blastocysts
was calculated to be between 6.8 and 13.6 pg.
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Figure 3.17B:
Synthetic P-actin mRNA standard/embryo mRNA band intensity ratios plotted against
the concentration of synthetic P-actin standard mRNA. Five different concentrations
of synthetic P-actin mRNA standard (854 fg, 1.7 pg, 3.4 pg, 6.8 pg, and 13.6 pg)
were reverse transcribed and amplified with embryo total RNA and the
autoradiograph band intensity ratios were plotted against synthetic P-actin standard
mRNA concentration.
Since expression levels differ between genes, unique amounts of standard RNA were
required for each gene under investigation. P-actin mRNA is a relatively abundant
mRNA species and so it was likely that the amount of bax and bcl-2 internal standard
mRNA required to give an endogenous/standard RNA ratio of approximately 1.0
would be considerably less. Four concentrations of synthetic bax mRNA standard
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(68 fg, 6.8 fg, 3.4 fg and 1.7 fg i.e. lOOx, lOOOx, 2000x and 4000x less than (3-actin
mRNA standard respectively) were reverse transcribed and amplified with embryo
total RNA (prepared from 5 pooled blastocysts - each RT reaction contained embryo
RNA equivalent to half a single blastocyst). Each reaction was performed in
duplicate. From the phosphorimager data calculated in Table 3.28, Figure 3.18A was
plotted and the concentration of synthetic bax mRNA standard appropriate for
quantitative RT-PCR of single blastocysts was calculated to be approximately 3.4 fg.
A representative autoradiograph is shown in Figure 3.18B.
Table 3.28: Results of phosphorimager analysis of bax RT-PCR using

















1.7 2.8 12.0 0.23 0.3
1.7 6.9 18.7 0.37
3.4 14.3 15.7 0.91 0.85
3.4 12.9 16.3 0.79
6.8 19.2 12.3 1.56 1.73
6.8 28.3 14.9 1.90
68 55.1 17.5 3.15 3.64
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Figure 3.18A :
Synthetic bax mRNA standard/embryo mRNA band intensity ratios plotted against the
concentration of synthetic bax standard mRNA. Four concentrations of synthetic bax
mRNA standard (68 fg, 6.8 fg, 3.4 fg and 1.7 fg) were reverse transcribed and
amplified with embryo total RNA and the autoradiograph band intensity ratios were
plotted against synthetic bax standard mRNA concentration.
The same procedure was repeated using four concentrations of synthetic bcl-2 mRNA
standard (0.4 fg, 0.8 fg, 2.0 fg and 5.0 fg). Each internal standard was reverse
transcribed and amplified with the bcl-2 primer pairs. From the phosphorimager data
shown in Table 3.29 Figure 3.19A was plotted and the concentration of synthetic bcl-
2 mRNA standard appropriate for quantitative RT-PCR of single blastocysts was
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Results of RT-PCR showing co-amplification of bax mRNA internal standard and
blastocyst bax mRNA. Amounts of bax mRNA internal standard added were:
Panel (A): 68 fg (lanes 1 and 2); 6.8 fg (lanes 3 and 4); 3.4 fg (lanes 5 and 6); 1.7 fg
(lanes 7 and 8).
Panel (B): 3.4 fg (lanes 1 and 2)






Results of RT-PCR showing amplification ofbcl.2 mRNA internal standard. Lane 1
corresponds to 0.4 fg standard mRNA; lane 2: 0.8 fg standard mRNA; lane 3: 2.0 fg
standard mRNA; lane 4: 5.0 fg standard mRNA: lanes 5 and 6: 5.0 fg standard
mRNA co-amplified with blastocyst bcl.2 mRNA.
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Table 3.29: Results of phosphorimager analysis of bcl-2 RT-PCR using
synthetic bcl-2 mRNA internal standard co-amplified with
blastocyst bcl-2 mRNA
fg of bcl-2 bcl-2 mRNA Embryo Ratio of
mRNA standard band standard/embryo
standard band intensity intensity
added
0.4 1.2 ± 0.5 - -
0.8 7.8 ± 1.1 - -
2.0 50.5 ± 1.9 - -
5.0 162.8 + 4.5 - -
5.0 176.1 ± 1.9 145.9 ±5.9 1.22
Figure 3.19A:
Analysis of bcl-2 RT-PCR with variable concentrations of synthetic bcl-2 mRNA
internal standard. Four concentrations of synthetic bcl-2 mRNA standard (0.4 fg, 0.8
fg, 2.0 fg and 5.0 fg) were reverse transcribed and amplified with the bcl-2 primer
pairs. From the phosphorimager data shown in Table 3.29 Figure 3.19A was plotted
and the concentration of synthetic bcl-2 mRNA standard appropriate for quantitative
RT-PCR of single blastocysts was calculated to be approximately 5.0 fg.
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3.4.3.2 Quantification of bax and bcl-2 gene expression in the single blastocyst
The preliminary experiments described above have demonstrated that under the
described RT-PCR conditions the levels of bax, bcl-2 and P-actin mRNA can be
detected in blastocysts and ovaries from non-diabetic rats. Moreover, experiments
which involved the titration of standard mRNA for the three genes has identified the
optimum amount of standard to add to each RT reaction giving a ratio of standard :
endogenous embryo RNA ratio of approximately 1.0, and additional analysis has
shown that the amplification of target mRNA was not compromised by the presence
of standard mRNA within a range of concentrations. Having established this,
experiments could then be carried out comparing the expression of bax, bcl-2 and p-
actin genes in single blastocysts from Diabetic DP- and Non-Diabetic DR-BB/E rats.
Experimental Protocol
To reduce the inter-assay variation, each stage of the analysis of the embryos from
Diabetic DP- and Non-Diabetic DR-BB/E rats was carried out on the same day.
Total RNA was prepared from eight single blastocysts (four from Diabetic DP- and
four from Non-Diabetic DR-BB/E rats). Ten individual RT reactions were set up:
eight contained half of the RNA from a single embryo plus the three synthetic mRNA
internal standards (6.8 pg P-actin, 3.4 fg bax and 5.0 fg bcl-2 synthetic mRNA).
Parallel reactions, containing (1) embryo RNA alone (no internal standard mRNA),
and (2) no RNA and no standard mRNA, as negative controls were amplified
simultaneously. The RNA was reverse transcribed and amplified firstly using the P-
actin nested PCR protocol. The RT-PCR products were separated by polyacrylamide
gel electrophoresis. Once the RNA quality had been checked with p-actin, the same
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cDNAs were amplified using the bax primers, and the products separated by
polyacrylamide gel electrophoresis and analysed by means of a phosphorimager. The
same procedure was followed using the bcl-2 specific primers.
Results
The RT-PCR products were visualised by autoradiography and are shown in Figure
3.20 (panels A, B and C: P-actin, bax and bcl-2 RT-PCR experiments respectively).
The intensity of the bands on the gels was analysed by means of a phosphorimager
and since the amount of internal standard added to the starting reaction (i.e. the RT
reaction) is known, the amount of endogenous P-actin, bax and bcl-2 mRNA was
calculated. Tables 3.30, 3.31 and 3.32 show the amount of endogenous P-actin, bax
and bcl-2 mRNA in single blastocysts for the four Diabetic DP- and four Non-
Diabetic DR-BB/E rats. An example of how the data were calculated is shown at the
bottom of each table.
202
Figure 3.20: Quantification of B-actin, bax and bcl-2 mRNA in single pre-
implantation embryos from Non-Diabetic DR and Diabetic DP-
BB/E rats
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Autoradiographs showing the detection of B-actin mRNA (Panel A), bax mRNA
(Panel B) and bcl-2 mRNA in single blastocysts from Diabetic DP-BB/E rats
(lanes 1-8) and Non-Diabetic DR-BB/E rats (lanes 9-16) on day 4.5 of gestation.
Lane 17: blastocyst mRNA amplified without internal standard; lane 18: no RNA
negative control.
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The data presented in Table 3.30 show that the level of P-actin mRNA expression in
the single blastocysts ranged from 10.52 to 19.0 pg. These data can also be expressed
as the number of copies of mRNA per nanogram of total RNA (1 mol = 6.02 x 1023
Avagadro's constant). Copy numbers ranging from 2.4 x 107 to 4.4 x 107 were
calculated.
Table 3.30: Analysis of P-actin gene expression in single blastocysts from
Non-Diabetic DR- and Diabetic DP- BB/E rats
Blastocysts Embryo (E) Standard Ratio Mean P-actin
from: Peak height (S) (E/S) E/S mRNA (pg)
Peak height ratio
Non-Diabetic DR N/D a 82.12 N/D N/D N/D
#1 N/D 93.49 N/D
Non-Diabetic DR 110.8 144.5 0.767 0.781 10.60
#2 106.7 134.4 0.794
Non-Diabetic DR 113.7 130.1 0.874 0.886 12.04
#3 107.9 120.1 0.898
Non-Diabetic DR 137.0 170.1 0.805 0.774 10.52
#4 137.9 185.7 0.743
Diabetic DP 147.8 137.6 1.074 1.099 14.96
#1 153.3 138.3 1.123
Diabetic DP 169.2 170.3 0.994 0.951 12.92
#2 179.6 197.9 0.908
DiabeticDP 219.0 159.5 1.373 1.396 19.0
#3 203.6 143.5 1.419
Diabetic DP 127.9 110.0 1.163 1.185 16.12
#4 163.1 135.2 1.206
Embryo alone 213.2 11.0 - - -
a
where N/D denotes not detected
Calculation of P-actin mRNA in single blastocysts:
6.8 pg of synthetic mRNA standard was added to V2 blastocyst RNA
For blastocyst #1 (from a Non-Diabetic DR rat) Embryo/Standard ratio = 0.781
.'.0.781 x 6.8 = 5.31 pg per half blastocyst or 10,6 pg per whole blastocyst
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The data presented in Table 3.31 show that the level of bax mRNA expression in the
single blastocysts ranged from 4.1 to 6.02 fg. These data can also be expressed as the
number of copies of mRNA per nanogram of total RNA, copy numbers ranging from
1.5 x 104 to 2.1 x 104 were calculated.
Table 3.31: Analysis of bax gene expression in single blastocysts from
Non-Diabetic DR- and Diabetic DP- BB/E rats
Blastocysts Embryo (E) Standard Ratio Mean E/S bax mRNA
from: Peak height (S) (E/S) ratio (fg)
Peak height
Non-Diabetic DR N/D 28.13 N/D N/D N/D
# 1 N/D 17.93 N/D
Non-Diabetic DR 62.68 79.03 0.793 0.841 5.72
#2 86.94 97.81 0.889
Non-Diabetic DR 54.45 90.71 0.600 0.636 4.32
#3 65.33 97.40 0.671
Non-Diabetic DR 59.66 71.49 0.835 0.882 6.0
#4 101.70 109.6 0.928
Diabetic DP 87.58 134.9 0.650 0.614 4.18
#1 76.11 131.9 0.577
Diabetic DP 77.56 113.7 0.682 0.680 4.62
#2 84.01 123.9 0.678
Diabetic DP 91.24 96.99 0.941 0.886 6.02
#3 77.44 93.36 0.830
Diabetic DP 86.30 96.45 0.895 0.886 6.02
#4 81.62 93.09 0.877
Embryo alone 94.02 -
a
where N/D denotes not detected
Calculation of bax mRNA in single blastocysts:
3 .4 fg of synthetic mRNA standard was added to VS> blastocyst RNA
For blastocyst #1 (from a Non-Diabetic DR rat) Embryo/Standard ratio = 0.841
.'.0.841 x 3.4 = 2.86 fg per half blastocyst or 5.72 fg per whole blastocyst
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The data presented in Table 3.32 show that the level of bcl-2 mRNA expression in the
single blastocysts ranged from 3.05 to 7.76 fg. These data can also be expressed as
the number of copies of mRNA per nanogram of total RNA, copy numbers ranging
from 1.1 x 104 to 3.2 x 104 were calculated.
Table 3.32: Analysis of bcl-2 gene expression in single blastocysts from
Non-Diabetic DR- and Diabetic DP- BB/E rats
Blastocysts from: Embryo Standard Ratio Mean bcl-2 mRNA
(E) (S) (E/S) E/S (fg)
Peak height Peak height ratio
Non-Diabetic DR N/D 12.5 N/D N/D N/D
#1 N/D 30.6 N/D
Non-Diabetic DR 40.2 45.5 0.884 0.761 7.76
#2 8.8 13.8 0.638
Non-Diabetic DR 15.8 18.4 0.859 0.903 9.21
#3 38.2 40.4 0.946
Non-Diabetic DR 10.5 22.9 0.459 0.404 4.12
#4 8.9 25.6 0.348
Diabetic DP 13.7 46.8 0.293 0.299 3.05
#1 14.9 48.9 0.305
Diabetic DP 15.5 36.9 0.420 0.422 4.30
#2 16.3 38.4 0.424
Diabetic DP 20.4 32.9 0.620 0.751 7.66
#3 40.3 45.7 0.882
Diabetic DP 35.1 48.1 0.730 0.709 7.23
#4 32.9 47.8 0.688
Embryo alone 40.9 -
a
where N/D denotes not detected
Calculation of bcl-2 mRNA in single blastocysts:
5.1 fg of synthetic mRNA standard was added to Vi blastocyst RNA
For blastocyst #1 (from a Non-Diabetic DR rat) Embryo/Standard ratio = 0.761
.".0.761 x 5.1 = 3.88 fg per half blastocyst or 7,46 fg per whole blastocyst
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From the level of bax and bcl-2 mRNA expression the ratio of bcl-2 to bax in the
seven blastocysts was determined, and is presented in Table 3.33.
Table 3.33: Ratio of bcl-2 to bax mRNA in single blastocysts from
Non-Diabetic DR- and Diabetic DP-BB/E rats at 4.5 days
gestation.









Non-Diabetic DR #1 - - -
Non-Diabetic DR #2 7.76 5.72 1.36
Non-Diabetic DR #3 9.21 4.32 2.13
Non-Diabetic DR #4 4.12 6.0 0.69
Diabetic DP #1 3.05 4.18 0.73
Diabetic DP #2 4.30 4.62 0.93
Diabetic DP #3 7.66 6.02 1.27
Diabetic DP #4 7.23 6.02 1.20
Although the mean bcl-2 to bax ratio was slightly higher in the blastocysts from non-
diabetic BB/E rats (1.393 ± 0.42 vs 1.033 ± 0.12 for Non-Diabetic DR- vs Diabetic
DP-BB/E rats respectively) statistical significance was not achieved.
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Conclusions from Experiment IV
RT-PCR analysis of pre-implantation embryos revealed the expression of bax and bcl-
2 genes at all stages examined (morula through to expanded blastocyst stage). This is
the first time the expression of bax and bcl-2 genes has been measured in pre-
implantation embryos, or indeed at any stage of embryo development. However,
there was no statistical difference between the mean bcl-2 : bax ratio in blastocysts
from Diabetic DP- and Non-Diabetic DR-BB/E rats (1.033 ± 0.12 vs 1.393 ±0.42,
respectively). Data published by Oltvai et al (304) have shown that overexpressed
Bax protein accelerates apoptotic death induced by cytokine deprivation in an In¬
dependent cell line (RL7). Cells with a high Bcl-2 : Bax protein ratio of 2.04
possessed viable cells over 2 weeks following IL-3 deprivation, whereas cell lines with
the lowest ratios (0.55) lost all viability by day 7. Although these results are
calculated from levels of expressed protein in cultured cell lines and no direct
comparison can be made, it is interesting that the ratio of bcl-2 to bax mRNA in single
blastocysts was within the same range. Since only a few individual blastocysts were
assayed for bax and bcl-2 gene expression statistical difference may be achieved with
larger numbers of blastocysts from the Diabetic DP- and Non-Diabetic DR-BB/E
groups.
There was however, a considerable difference in the P-actin copy number calculated
from this study (2xl07) and that previously reported by Gaudette and Crain (312)
(1.4xl05). The reasons for this discrepancy may lie in differences between the
methods of quantification, the amount of P-actin in rat and mouse blastocysts, or
errors in calculating the concentration of synthetic mRNA internal standard. The
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standards prepared in the present work were prepared in large volumes, quantitated
by spectroscopy, aliquoted and frozen in RNase free microcentrifuge tubes at -70°C.
Nevertheless, these data demonstrate for the first time that bax and bcl-2 messages are
present in pre-implantation embryos and the method for quantifying the level of their
expression has been established and can easily be applied to other systems where there




The mechanisms underlying the phenomena of (i) fetal early growth delay, (ii)
congenital malformation, (iii) prematurity due to spontaneous pre-term labour, and
(iv) babies small for gestational age in human autoimmune-induced IDDM pregnancy
have yet to be precisely defined but circumstantial evidence suggests that they may
result primarily from embryonic damage in the earliest stages of pregnancy.
Experimental approaches in the study of human IDDM pregnancy are limited by
practical and ethical considerations and this hypothesis has therefore been examined
directly using the BioBreeding/Edinburgh (BB/E) rat,- which spontaneously develops
autoimmune-induced IDDM,- as a model for the human disorder.
Pregnancy in the Diabetic DP-BB/E rat was associated with a five-fold increase in the
number of unfertilised oocytes. This phenomenon could not be correlated with any
particular male rat, indeed all the males used in this study had previously been shown
to be consistently highly fertile when mated with female Non-Diabetic DR-BB/E rats.
However, this finding in the Diabetic DP-BB/E rat supports the data published by
Diamond et al (312) who reported that STZ-diabetic mice had a lower percentage of
2-cell zygotes (48 h after superovulation) than non-diabetic control mice. It has been
suggested that appropriate metabolic control during the period of folliculogenesis may
be necessary to avoid the development of embryopathy in the offspring of the diabetic
mother (313). Diamond et al (312) also reported that oocytes from STZ-diabetic
mice show significantly less germinal vesicle breakdown (GVB) (which signals the
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resumption of meiosis I and oocyte maturation) when compared with non-diabetic
mice (P < 0.001). When near normoglycaemia was achieved in these mice, the delay
in oocyte maturation was reversed. No attempt was made to assess the degree of
GVB in oocytes from Diabetic DP-BB/E rats but it is possible that poor or delayed
oocyte maturation could be responsible for the high number of unfertilised oocytes in
rats with established IDDM. Infertility is often a problem in poorly controlled diabetic
women but fertility can be restored when metabolic control is improved (314). The
importance of this and the work published by Diamond et al (312) is that the
deleterious effects of poor metabolic control on oocyte maturation are potentially
reversible, suggesting that the outcome of pregnancy in the Diabetic DP-BB/E rat
could also be improved by better diabetic management prior to conception.
Studies have shown that non-diabetic human pregnancies, where the father has
IDDM, have normal rates of perinatal mortality (approximately 2 %) (315). Similar
findings were seen in experiments designed to investigate the effect of paternal
diabetes on blastocyst development in BB/E rats. Non-Diabetic DR-BB/E rat
pregnancies with Diabetic DP fathers demonstrated a normal morphological
distribution of embryos at day 4.5, and normal numbers of ICM and TE cells in
blastocysts from these pregnancies. In addition, there was no evidence to suggest that
pregnancies generated from two Diabetic DP-BB/E parents had any more
developmental disturbance than those where only the mother had diabetes.
Within the group of Diabetic DP-BB/E rats studied at 4.5 days gestation there
appeared to be two distinct populations of pregnancies - one with a high incidence of
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unfertilised oocytes and a reduced number of expanded blastocysts, and the other with
no unfertilised oocytes and a normal complement (more than 6) of expanded
blastocysts. The reasons for this phenomenon are as yet unknown. Comparing
mothers from these two populations there was no difference in age at pregnancy,
duration of diabetes and blood glucose concentration measured at 10 a.m. on the day
when embryos were retrieved, the majority being >20 mmol/L. Closer examination
showed that expanded blastocysts from these apparently normal pregnancies were in
fact not normal since they exhibited an ICM cellular deficit similar to that described
previously in rats with STZ-induced diabetes (316). The ICM cellular deficit was
similar in pregnancies with and without unfertilised oocytes, suggesting a different
aetiology for these two pathologies.
At 4.5 days gestation, the expanded blastocyst has two distinct cell lineages : the inner
cell mass which forms all three germ layers of the fetus as well as complementary
contributions to the extraembryonic membranes, and the trophectoderm which forms
the placenta and the extraembryonic membranes (286). There is substantial in vitro
evidence that the cells of the ICM are more sensitive than TE cells to damage inflicted
by a range of chemicals, drugs and antimetabolites, such as [3H]-thymidine (317); X-
rays (318); cyclophosphamide (319) and mitomycin-C (320) and that this is usually
manifest as loss of ICM cells and suppression of differentiation of the ICM into
primitive egg cylinders in vitro. Only the highest doses of metabolic inhibitors affect
TE cell integrity and differentiation (320). The underlying cause of the differential
sensitivity of the ICM to damage is not fully understood but it has been proposed that
the high proliferative activity (321, 322) and the active metabolic status (323, 324)
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needed to support its own growth and to control TE development may make the ICM
cells more vulnerable. Normal blastocyst formation depends on adequate cellular
interaction between ICM and TE cells (325). Thus, a diabetes-associated disturbance
in any component of the intra-uterine milieu during the pre-implantation period is
likely to affect the ICM more than TE cells, and to disturb the ICM-TE cell
interaction.
The nature of the ICM cellular deficit was investigated further by culturing blastocysts
in growth medium or conditioned medium, for 24 h in vitro. Blastocysts from
Diabetic DP-BB/E mothers failed to show any sign of 'catch up' growth in the ICM,
but under these conditions a TE cellular accretion also occurred. This is the first time
that trophectoderm cellular accretion has been described in blastocysts from any
species. However these results differ from in vitro culture studies reported by
Pampfer et al (282) who used blastocysts from rats with STZ-induced diabetes to
demonstrate a similar lack of'catch up' growth in the ICM but also describe a -8.5 %
decrease in TE cell number. There are however, several obvious differences between
the two animal models which are listed below: (i) the rats used by Pampfer and
colleagues were outbred Wistar rats with a much greater biological variation than the
inbred BB/E rat colony, (ii) the outbred Wistar rats rendered diabetic by STZ
injection were diabetic for approximately 14 days before pregnancy, whereas the
Diabetic DP-BB/E rats had a mean duration of diabetes of 39 ± 2.7 days prior to
pregnancy, (iii) the blood glucose concentration used to diagnose diabetes was lower
for the STZ-induced diabetic rats at 11 mmol/L than for the DP-BB/E rats at 18
mmol/L (a blood glucose concentration of >18 mmol/L in the BB/E rat is invariably
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associated with loss of weight, ketonuria, undetectable circulating endogenous insulin
and the permanent need for daily treatment with insulin to ensure survival, the STZ-
induced diabetic rats were not treated with insulin at any point prior to or during
pregnancy), (iv) the preferred method of killing BB/E rats, particularly pregnant rats,
is cervical dislocation,- Pampfer and colleagues however chose to ether anaesthetise
their pregnant rats. Thus the difference in results obtained from the two models is
likely to be related to be animal/model related as all of the experimental procedures
used were identical. Since it is the inner cell mass which forms all three of the fetal
germ layers, whilst the trophectoderm forms the placenta and the extra-embryonic
membranes (286), it is possible that this combination of a reduction in ICM cell
number and an increase in TE cell number in pre-implantation blastocysts could be a
presage of the low birth weight pups and large placentae which has been previously
described in Diabetic DP-BB/E rat pregnancies (258). These features also occur
commonly in human IDDM pregnancy (287).
Although the method of preparing uterine or decidual cell conditioned media has been
described several times (326, 327, 328) these authors have largely focused on later
stages of pregnancy in the mouse (day 9.5 - 14.5 of pregnancy) and have assayed the
concentration and activity of only one growth factor, transforming growth factor (3-2
(TGFP-2) in these conditioned media. Since this growth factor is involved in
immunosuppression in later stages of post-implantation embryo development and is
first detected in the mouse at day 9.5 of pregnancy, it is unlikely that significant
amounts of TGFP-2 were present in the uterine conditioned media from diabetic and
non-diabetic BB/E rats in the present study. No attempt was made to assay the
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uterine cell conditioned media for any growth factors or cytokines for several reasons:
(i) the volume of conditioned media prepared from each uterus was very small and
most assays required a minimum volume of 100 pi, (ii) a paper published by Bienvenu
and colleagues (329) outlined substantial differences in sensitivity and behaviour of
commercial ELISA-kits for cytokine analysis, and (iii) most of the commercially
available kits for cytokine measurement are designed for mouse proteins and in the
few kits that were tried there was poor cross-reactivity between the mouse
monoclonal antibody and the rat protein (J.E McCracken and R.G Lea, unpublished
observations).
The conditioned media prepared from BB/E rat uterine cells were unable to stimulate
'catch-up' growth of the ICM in blastocysts from diabetic rats, or to induce a deficit
in the ICM of blastocysts from non-diabetic rats. This suggests that either the embryo
damage which results in an ICM cell deficit occurs much earlier on in pregnancy and it
is too late at 4.5 days gestation for the conditioned media to affect ICM development,
or that the conditioned media did not contain growth factors and cytokines able to
cause a developmental disturbance. Since the total cell counts of morulae and early
blastocysts from diabetic rats were not different from embryos from Non-Diabetic DR
rats, culturing morulae or early blastocysts in the uterine cell conditioned media may
have tested the activity of the media to induce or prevent an ICM cell deficit/TE cell
accretion more efficiently than culturing blastocysts.
The present study provided the opportunity to observe early pregnancy in the
Diabetes Resistant BB/E subline, and compare it with that of outbred Wistar Han rats.
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Despite the immunological abnormalities of the DR-BB/E subline, early experiments
(Experiment I) showed that pregnancies in these rats were similar to those of standard
outbred Wistar Han rats with respect to the morphological distribution of embryos at
4.5 days gestation, indicating that the DR-BB/E subline was a excellent control for
studying the effects of IDDM on rat pregnancy.
Further evidence to support this came from data obtained from pregnant Diabetes
Prone (DP) BB/E rats during the pre-diabetic period (Experiment II). Since the mean
(± SD) age of onset of IDDM in the BB/E rat colony is 96 ±18 days, and the female
rat is fertile at approximately 60 days of age, pregnancy was achieved in the pre-
diabetic period. These experiments are simply not possible in either the chemically-
induced rodent models or the human. The data show that these rats had normal
numbers of unfertilised oocytes and expanded blastocysts and the expanded
blastocysts from these pregnancies were completely normal with respect to the
number of ICM and TE cells. Maternal metabolic profiles were identical to those of
Non-Diabetic DR-BB/E rats at all stages of pregnancy. These results suggest that
early damage to the pre-implantation embryo is due to a disturbed maternal metabolic
state, and that the full complement of IDDM susceptibility genes is not in itself,
sufficient to cause an ICM cellular deficit. It is likely that the embryonic damage is
secondary to a metabolic disturbance and is therefore potentially preventable by
improved insulin delivery systems.
It was clear from Experiment III that the degree of metabolic control established in
female Diabetic DP-BB/E rats treated with sustained release insulin implants was
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much more variable in female rats than that previously achieved in male Diabetic DP-
BB/E rats (299). There are several explanations for this apparent sex-related
difference in response to SRII-treatment. Firstly, assessment of metabolic control and
SRII-treatment began in the female diabetic BB/E rats from day of diabetes detection,
whereas all of the previous SRII studies have used male rats previously treated with
subcutaneous insulin injections for some time before SRII-treatment. It is unrealistic
to expect an insulin-deficient individual be they a newly diagnosed patient with IDDM
or a BB/E rat, to have well controlled diabetes from day of diagnosis. Indeed, the
degree of hyperglycaemia at diabetes diagnosis varied considerably in the female
BB/E rats in this study (plasma glucose concentrations ranging from 21.8 to 44.2
mmol/L) and as in the human, their insulin regime was tailored for each individual rat
to achieve metabolic control as near normal as possible.
Secondly, the female rats used in Experiment III were considerably younger and
smaller than the males which had been studied previously (299). In the treatment of
children with IDDM the insulin requirement will alter considerably as they grow.
Although the diabetic female BB/E rats were only maintained on SRII-treatment for a
maximum period of 4-5 weeks the effect of growth (as seen as an increase in body
weight over the period of treatment) cannot be ignored.
Thirdly, and perhaps the most striking difference between the male and female
Diabetic DP-BB/E rats treated with SRIIs was the effect of circulating female sex
hormones during the oestrus cycle. This appeared to have a major influence on blood
glucose concentration both during the pre-conception period and particularly during
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the first two days of pregnancy. Although SRII treatment resulted in improved
conception rates (as indicated by a reduction in the number of unfertilised oocytes to
normal levels) and reduced the concentration of maternal plasma metabolites to
almost normal levels, this degree of metabolic control was insufficient to prevent the
ICM-specific embryopathy.
With one recent exception (330), there are no published data using SRIIs to control
diabetes in female mice or rats. These authors used SRII-treatment to achieve normal
metabolic control (target blood glucose concentration 4-6 mmol/L) in ICR mice with
STZ-induced diabetes, and make no mention of any difficulty in achieving good
metabolic control. This may be related to the fact that animals with STZ-induced
diabetes commonly have some endogenous insulin and are not therefore completely
dependent on insulinfor survival. Interestingly, the STZ-diabetic mice treated with
SRIIs became hyperglycaemic at the time of embryo implantation (although no
information is given regarding maternal blood glucose profiles between conception
and implantation). This early pregnancy blood glucose rise is similar to that found in
ten out of the fifteen diabetic BB/E rats treated with SRIIs.
It is difficult to explain why some of the SRII-treated rats had a post-conception rise
in blood glucose concentration and some did not. There was no difference in
maternal age, weight, duration of diabetes, dose of insulin or results of daily urine
tests for glucose and ketone bodies between these two groups of SRII-treated
Diabetic DP-BB/E rats. Indeed, given (i) the inbred status of the BB/E colony, (ii)
the fact that it is held in a barrier unit under strictly controlled conditions and screens
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negative for all the common rat viruses, and (iii) that all the Diabetic rats involved in
the study had established IDDM as defined by strict criteria, these Diabetic rat
mothers were a remarkably homogeneous group. Nevertheless, subtle differences
may exist in these two populations of pregnancies. In the normal animal with an
intact glucose responsive insulin delivery system, the hyperglycaemia caused by the
anti-insulin action of progesterone is prevented by an increase in the production of
endogenous insulin. Although there was a four-fold increase in progesterone in
response to conception in all groups of SRII-treated Diabetic DP rats, those rats with
a post-conception blood glucose rise did not have an abnormally high progesterone
response to conception. These data suggest that the hyperglycaemic peak in some of
the SRII-treated Diabetic DP rats was not simply due to these rats producing more
progesterone. Progesterone is essential for endometrial preparation for blastocyst
implantation in most mammals and inadequate endometrial maturation and
progesterone insufficiency are well known causes of infertility. Progesterone also
inhibits superoxide radical formation (331) and tumour necrosis factor-a production
in the endometrium (332). Both these factors induce degenerative changes in the
uterine tissue. Superoxide dismutase is a scavenging system for superoxide radicals,
has been detected in human uterine fluid during the pre- and peri-implantation stages
(333) and may play a role in protecting blastocysts from superoxide radical damage.
Under the influence of progesterone various endometrial cellular compartments
differentiate and undergo cell-cell interaction, which allows the endometrium to
secrete into the luminal milieu a variety of active biomolecules which support embryo
growth (334). The viable embryo in turn secretes different types of biomolecules
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which influence embryo growth (autocrine effect) and endometrial receptivity
(paracrine effect).
One possible explanation as to why some of the SRII-treated rats had a post-
conception rise in blood glucose concentration may simply be due to the fact that rats
without the post-conception blood glucose rise were given sufficient insulin (prior to
pregnancy in the form of a SRII insulin rod) to prevent a progesterone-associated
blood glucose rise during early pregnancy.
With almost 75 years' experience using exogenous insulin in the treatment of IDDM,
it has become increasingly clear that insulin treatment via the subcutaneous tissue,
either by intermitent injection (CIT) or slow continual release from an implant (SRII),
is far from ideal. It is unphysiological and plagued by slow and erratically varying
absorption. Furthermore, this method of delivering insulin is not subject to the natural
pancreatic feedback control by the prevailing blood glucose concentration. A normal
metabolic state will only be achieved using an insulin delivery system which is
glucose-responsive.
The first pancreas transplants in patients with IDDM were reported by Kelly et al in
1966 (335). Two patients with long-standing diabetes and end-stage renal disease
underwent simultaneous kidney and renal transplantation. The procedure was
associated with limited success. Less than 10 % of early transplant recipients
achieved and maintained normoglycaemia, and only a fraction were insulin-
independent beyond one year post-transplant (336). By the late 1970's significant
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improvements in surgical technique, treatment of acute rejection, and the management
of immunosuppression prompted renewed interest in pancreas transplantation.
Today, patients undergoing simultaneous pancreas-kidney transplantation have a 75
% chance of pancreas graft survival and a 92 % chance of renal graft survival one year
following the procedure (337). However, the risks of immunosuppressive therapy
remain significant, and as a consequence routine use of pancreas transplantation is not
recommended by the American Diabetes Association (338). Thus, pancreatic
transplantation is only considered as an acceptable therapeutic alternative to insulin
treatment in patients with end-stage renal disease who have had or plan to have a
kidney transplant.
The future of IDDM treatment lies in the development of a bioartificial pancreas able
to secrete insulin in response to the concentration of blood glucose. The principle of
the bioartificial pancreas is to permit non-syngeneic islet transplantation by separating
the islets from the recipient's immune system using an artificial membrane (permeable
to glucose and insulin but not immunoglobulins and cells). One area of active
investigation is the search for alternative sources of islet tissue. For islet
transplantation, sources of tissue could include human allogeneic tissue, xenografts
from other mammalian species (such as porcine or bovine islets), fetal tissue or
manufactured insulin-releasing cells. It is necessary to surround the transplanted
islets with a semi-permeable membrane since it is clear that in both rat and man, the
immune system retains the ability to recognise and destroy transplanted islet (3 cells
long after IDDM has developed and the infiltrate has disappeared. Previous work
carried out in our laboratory by C. Lynch et al (unpublished observations)
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demonstrated that microencapsulation and transplantation of rat islets into Diabetic
DP-BB/E rats successfully resulted in normoglycaemia. It would be of particular
interest and relevance to this project to follow on these experiments, transplanting rat
islets into Diabetic DP females prior to pregnancy and monitoring their blood glucose
concentration at conception and through early pregnancy, and observing the effect on
pregnancy outcome, with particular reference to the ICM cellular deficit.
Transport or secretion of growth factors into the blastocoele may be essential for the
formation of a micro-environment critical for the development of the ICM since the
ICM is sequestered from the maternal environment by the tight epithelium formed by
the TE. Lack of ICM cells in blastocysts from diabetic rats may be due to poor
development of the ICM as a result of either abnormally low levels of maternally
derived growth factors in the uterine environment, or poor function of the TE to
transport or secrete the necessary growth factors.
The development of pre-implantation embryos to the blastocyst stage is, at least
partially, a function of autoregulation. In vitro and in vivo studies indicate that a
number of peptide growth factors contribute in an autocrine fashion to pre-
implantation development. Other growth factors are maternally derived and act in a
paracrine manner on the embryo. Some of these factors such as insulin-related factors
stimulate growth preferentially, whilst others such as EGF play more important roles
in differentiation. Cytokines are generally involved in the later stages of pre- or peri-
implantation embryo development, as the embryo meets the challenge of the mother's
immune system.
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The insulin-like growth factor family consists of insulin, insulin-like growth factors I
and II (IGF-I and IGF-II), the insulin receptor, IGF-I receptor (IGF-IR) and IGF-II
receptor (IGF-IIR) and at least six insulin-like growth factor binding proteins
(IGFBP1-6) that are all involved in metabolism, growth and development. IGF-II
mRNA has been demonstrated in pre-implantation embryos from the 2-cell to the
blastocyst stage (339) but only the maternal IGF-II receptor gene is active in pre-
implantation embryos as the paternal copy is inactivated by genomic imprinting (340).
IGF-I however, is not produced by the embryo during the pre- or post-implantation
stage and is only produced by the maternal tissues. IGF-I has been described as a
survival factor, able to prevent apoptosis (341). In vitro culture of mouse blastocysts
in IGF-I and II has been shown to stimulate ICM cell proliferation without any visible
effect on TE cell development (342, 343). The role of IGF-I in anomalies of embryo
development remains to be clarified. However, the observation that diabetes
decreases concentrations of circulating IGF-I in the human (reviewed in 344) provides
an interesting link with respect to IDDM-induced embryopathy of the pre-
implantation embryo.
EGF and TGF-a (which bind to the same receptor, the EGF-R) have been reported to
increase the frequency of oocyte germinal vesicle breakdown (343), increase the
number of blastocysts and the blastocyst hatching rate (345) and to stimulate
blastocoele expansion (346). In the mouse, the location of the EGF-receptor in the
morula stage is predominantly apical. At blastocyst formation, the receptor is found
mainly on the basal surfaces of the TE with less on the apical surfaces and on the ICM
(347). It has been suggested that the function of the EGF-receptor in the early
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embryo is to receive signals from maternal EGF in the oviduct, and when the
receptors begin to receive signals from blastocyst-derived endogenous TGF-a they
shift to an internal location. In a clinical study, Oehninger et al (348) demonstrated
that women with IDDM had a follicular milieu resembling that of non-diabetic
women, except for a lack of epidermal growth factor.
The expression of LIF fluctuates with the oestrus cycle and is highest after ovulation
and on the day of implantation in the mouse (349) and human (350). Furthermore,
female mice lacking both copies of the LIF gene fail to implant their blastocysts. If
these blastocysts are transferred into normal pseudopregnant recipient female mice
they implant normally (351). LIF may also preserve the high rate of cell proliferation
in the ICM. The major source of LIF is the uterus as the blastocyst has only low
expression (352).
The expression of TNF-a in the mouse, has been detected in oviductal and uterine
tissues throughout the pre-implantation period (353, 354). In the rat, during the peri-
implantation period TNF-a is synthesised by epithelial cells lining the uterine lumen
and the decidualized cells adjacent to the implanted embryo (355). Mouse and rat
pre-implantation blastocysts have been shown to express TNF-a receptors and in
vitro culture of these blastocysts in culture medium containing TNF-a significantly
downregulates the proliferation of the ICM cells of the blastocyst (356, 357). The
selective inhibitory action of TNF-a on the ICM cell lineage supports the hypothesis
that TNF-a could contribute to the aetiology of many unexplained reproductive
failures in women with high concentrations of TNF-a in the reproductive tract (358,
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359). Thus it appears that high concentrations of TNF-a in the local uterine milieu is
not beneficial for pre-implantation growth or development.
Culture of pre-implantation embryos in vitro has several limitations, particularly
between the late morula and expanded blastocyst stage when the culture requirements
become more complex and the growth factors and cytokines described above come
into play. Rather than continue with in vitro culture experiments it was possible to
examine the same hypothesis using embryo transfer experiments. The aim of these
experiments was to answer two questions: (i) can the diabetic uterine environment
induce an ICM cell deficit in embryos from a Non-Diabetic DR-BB/E mother? and (ii)
can removal of embryos from a potentially harmful diabetic environment 'rescue' the
embryos and allow them to develop normally? The data shown in Experiment II
demonstrate that the maternal diabetic uterine environment is able to induce both an
ICM cell deficit (- 9 %) and a TE cell accretion (+ 19 %) in blastocysts from Non-
Diabetic DR-BB/E rats transferred at the 2-cell stage. However, the transfer of 2-cell
embryos from Diabetic DP mothers to Non-Diabetic DR recipients did not prevent the
development of an ICM cell deficit (17 %) or a TE cell accretion (9 %) implying
earlier damage to germ cells. These findings indicate that maternal IDDM in the
BB/E rat has deleterious effects on pre-implantation embryo development which
persists despite the removal of embryos from the diabetic mother and transfer to a
non-diabetic milieu. To date, there is only one other publication of data relating to
the transfer of embryos from diabetic animals into non-diabetic recipients (360).
Vesela et al (360) transferred 2-cell embryos from BALB/c donor mice (given a sub-
diabetogenic dose of streptozotocin) into non-diabetic pseudopregnant ICR recipient
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mice, and 2-cell embryos from control (non-diabetic) BALB/c mice into non-diabetic
recipient ICR mice. The embryos were recovered from the recipient mice 24-28 h
later and morphological evaluation revealed that almost half of the embryos from the
streptozotocin-treated donor females were incapable of development to the eight-cell
stage even when transferred to a non-diabetic maternal environment. Although the
authors made no attempt to transfer embryos from non-diabetic mice into STZ-
diabetic recipient mice, their data support the findings observed in BB/E rat embryo
transfers.
The embryo transfer experiments showed that maternal diabetes had a major effect on
embryonic development. The embryo transfers were carried out at the 2-cell stage,
the embryos had been exposed to a diabetic maternal environment (the oviduct) for
1.5 days before transfer. Although a direct effect of the oviductal environment on
early pre-implantation embryo development (i.e. day 0.5 to day 1.5 of pregnancy)
cannot be excluded however unlikely, the most likely explanation is that maternal
diabetes has affected oocyte development and/or fertilisation. Reasons for this are
based on the fact that (i) early pre-implantation embryos are undifferentiated, non-
vascularised entities which divide rapidly but show no net growth (361); (ii) genetic
control of development is, to begin with, dependent on maternal mRNA before the
embryonic genome is expressed (362), and (iii) embryos at this stage are largely
insensitive to hormones and growth factors. It is late pre-implantation embryos which
exhibit net growth (363), differentiate into ICM and TE cells, and increase their
sensitivity to growth factors and hormones at the blastocyst stage. The oviduct
provides mainly physical and chemical factors to facilitate embryo development.
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Physical factors include the action of the cilia lining the oviduct and the contraction of
the myosalpinx, used to transport the embryos down the oviduct towards the uterus.
Chemical factors include oxygen tension, electrolytes and nutrients (pyruvate, lactate,
glucose and amino acids). Pyruvate and lactate are the main regulatory substrates for
early pre-implantation embryo growth. Glucose however, has been shown to be
inhibitory to the in vitro development of early pre-implantation embryos in the
hamster (364), mouse (365), rat (366), cow (367, 368), sheep (369) and human
(370). Studies by Nichol et al (371) measuring the concentration of glucose in
samples of oviductal fluid from anaesthetised, unmated pigs, pre- and post-ovulatory,
and from mated pigs, post-ovulatory, have shown that the concentration of glucose in
the unmated ampulla fell sharply from pre-ovulatory values of 0.97 mM to 0.47 mM
post-ovulation. After mating, the glucose concentration was even lower at 0.25 mM.
The reasons for these data are unclear but it is tempting to speculate that these
findings in the pig represent a strategy adopted by the female reproductive tract to
protect embryos from exposure to glucose at too high a concentration. The degree to
which oviductal fluid glucose levels are elevated in pregnant diabetic women has not
been established, but it has been reported in normal subjects that oviductal fluid
glucose levels are approximately half that of serum levels (372). Therefore, the only
way to determine definitively the exact effect of the maternal metabolic environment
on the development of the pre-implantation embryo would be to carry out in vitro
fertilisation followed by embryo transfer. This would remove all possible effects of a
damaging oviductal environment on donor embryo development.
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The growth and maturation of oocytes depend on their surrounding somatic cells.
Many in vitro studies have shown that up to the formation of the antral cavity the
growth of the oocyte is paralleled by the proliferation of the granulosa and thecal
cells. During the first phase of follicular growth, that is the pre-antral phase, the
granulosa cells are largely independent of the antral cavity, oocyte growth ceases and
the follicles become dependent on the presence of Follicle Stimulating Hormone
(FSH) for further growth and differentiation. Apart from FSH, the major specific
hormonal stimulus for granulosa cells, many other locally produced factors determine
the fate of the follicle unit. Circulating growth factors, theca- and interstitial cell-
derived factors, and stimuli originating in the oocyte itself are able to condition the
granulosa cells toward proliferation and/or differentiation. These factors include
IGF's and their binding proteins, EGF, TGFs, oestrogens, inhibins and activins (373).
Activin PA has been localised in rat oocytes, suggesting a role for activin in meiotic
maturation (374). There is a potential role for growth factors in the intrafollicular
control of meiosis. IGF-I is a potent mitogen for granulosa cells (375) and enhances
nuclear maturation in oocytes surrounded by cumulus cells in the cow (376) and
human (377). IGF-I is also known to stimulate oocyte maturation in Xenopus (378),
rabbit (379) and buffalo (380). The addition of IGF-I during in vitro maturation of
buffalo oocytes not only helped in achieving nuclear maturation but also influenced
cytoplasmic maturation and improved early embryonic development (380). Thus it is
possible that the stimulatory effect of IGF-I on cumulus and granulosa cell
proliferation might enhance the syncytial network and nutrient uptake by oocytes
during cytoplasmic maturation and result in beneficial effects on embryo development.
Since the only source of IGF-I throughout the pre-implantation period is a maternal
228
one, and IGF-I is known to be a survival factor, able to prevent apoptosis (341), it is
also possible that low maternal IGF-I levels in the Diabetic DP-BB/E rat may be
responsible for poor oocyte development and the ICM cellular deficit (possibly due to
increased apoptosis). No data are currently available in relation to the levels of IGF-I
and II in animals with chemically-induced or spontaneous diabetes during the pre-
implantation stage.
Many studies of the pathogenesis of diabetic embryopathy have involved animals with
chemically-induced diabetes and have largely focused on the period of organogenesis.
However, the relevance of these animal models to human IDDM (an autoimmune-
induced disorder) is clearly very limited, particularly in relation to disease aetiology.
The dosage of alloxan and streptozotocin required to induce insulin-dependence may
have additional widespread extra pancreatic toxic effects, on the parental germ cells
for example. Many of the STZ-diabetic rodents used for pregnancy studies are not
insulin-dependent. Although they have severe hyperglycaemia they are rarely treated
with insulin and are able to survive without developing lethal ketoacidosis. Indeed,
some workers regard a single random blood glucose measurement of >11 mmol/L
sufficient to diagnose IDDM (292, 381, 281). Even studies using the NOD mouse
(281) use ill-defined criteria for diabetes diagnosis and these mice do not require
insulin treatment for survival, casting further doubt on the relevance of these models
to human insulin-dependent diabetes mellitus. It has been suggested that conventional
treatment with a daily subcutaneous injection of insulin completely prevents diabetic
embryopathy in rats and mice with STZ-induced diabetes and in NOD mice (283, 381,
382). This contrasts with the data presented here since all the DP-BB/E rats with
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IDDM are completely and irreversibly insulin deficient and require daily injections of
insulin to survive and still develop severe embryopathy. In this respect they differ
from NOD mice and rats with STZ-induced diabetes, which are not totally insulin
deficient and are capable of spontanoeus regeneration of islet P cells (260).
The clinical relevance of many of the in vitro studies reported in the literature is
questionable. For example, many studies have shown that various components of
serum, glucose and ketone bodies are toxic to pre- and post-implantation embryo
development. However, the concentration of these compounds is so high that they
would only be observed in women with life-threatening ketoacidosis. Three particular
examples include (i) Eriksson and Borg (383) who cultured 11.5 day old rat embryos
in media containing 50 mmol/L glucose (ii) Diamond et al (384) who used media
containing 53 mmol/L glucose to inhibit mouse pre-implantation embryo
development, and (iii) Shum and Sadler (385) who used media containing 32 mmol/L
P-hydroxybutyrate for their in vitro culture studies when the concentration of P-
hydroxybutyrate in normal rat serum is approximately 0.25 mmol/L.
When differentially stained blastocysts were examined under the fluorescence
microscope, apoptotic cells were observed in blastocysts from both Diabetic DP- and
Non-Diabetic DR-BB/E rats. It appeared that cells with fragmented nuclei were
observed more often in the ICM than in the TE although it was not possible to
accurately quantitate this phenomenon because of the limitations of using fluorescence
microscopy, unless a confocal microscope was used. Particular problems included the
speed of apoptosis and the rapidity of clearance of apoptotic cells; identifying
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apoptotic cells in a three-dimensional structure such as a blastocyst; and the fragility
of cells undergoing apoptosis, which are effectively lost when the blastocyst is
flattened to facilitate accurate counting of cells. However, it is possible that the
reduction in ICM cell number seen in blastocysts from Diabetic DP-BB/E rats may be
due to disturbed regulation of apoptosis. It has been suggested that apoptosis occurs
in the ICM of the blastocyst during the transition from early blastocyst (when the ICM
has the potential to form trophectoderm cells) to expanded blastocyst (when the ICM
no longer has the potential to form trophectoderm cells) and that this cell death is
designed to eliminate redundant ICM cells with trophectodermal potential (291). In
addition, it has been proposed that the mechanism of action of apoptosis in the
blastocyst is mediated by epigentic factors in the fluid of the blastocoele (386). The
data from total cell counts of morulae and early blastocysts from Diabetic DP-BB/E
rats, shows that at this stage of development there is no difference in embryos from
Diabetic DP and Non-Diabetic DR rats, and is consistent with the hypothesis that
maximum cell death in the blastocyst occurs between the early and expanded
blastocyst stage.
Cell death can occur by one of two distinct processes, necrosis or programmed cell
death through apoptosis. Necrosis is usually associated with injury, and results in
cellular swelling and rupture of the plasma and internal membranes. True
programmed cell death (PCD) is genetically programmed, and requires the activation
of specific genes involved in the execution of cell death. Developmentally regulated
cell death is widespread in embryogenesis (288) and occurs by apoptosis in both
vertebrate and invertebrate species. It is a widespread feature in blastocysts of many
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mammals such as the cow (289); Rhesus monkey (290); mouse (2291) and the human
(268). The significance of these dead cells is not fully understood, but it has been
suggested that the primary function is to allow for the removal of redundant or
defective cells from the blastocyst (288), or the elimination of ICM cells retaining the
potential to form TE (291). Other suggestions include lack of survival factors in vitro
or in vivo, and chromosomal abnormalities (387). In mouse blastocysts it has been
recently reported that embryonic cells have a death-by-default mechanism that
requires constant suppression (388). Apoptosis is a physiological cell death process
triggered by external or internal stimuli, the process can be divided into four phases
(389). The first phases may occur in response to an external trigger delivered through
surface receptors (e.g. fas ligand and CD40 ligand), or may originate inside the cell
from the action of a drug, toxin, or radiation (284). The next phase involves
detection of this signal and transduction of the signal. The activation or signalling
phase encompasses a great variety of signal transduction pathways including tyrosine
kinases, steroid receptors, ceramide, inositol phosphates and cytokine receptors. The
death effector phase is the third part of the cell death mechanism and includes the
cysteine proteases that are activated during apoptosis. The fourth phase is the post¬
mortem phase, in which the cell's chromatin condenses and its DNA is degraded into
oligonucleosome chains (seen as DNA 'laddering' on gel electophoresis) (284).
Depending on their ratio, Bcl-2 and similar proteins can inhibit the action of the
proteases, either by blocking their activation or by preventing them from reaching
their targets. Other proteins implicated in the regulation of apoptosis include tumour
suppressor protein p53 which triggers apoptosis in cells with damaged DNA, and c-
Myc which can inhibit apoptosis in the presence of factors such as IGF-I, insulin and
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EGF (390). This suggests that the increase in ICM cell numbers in blastocysts grown
in IGF-I and insulin in vitro could be due to these factors reducing the level of cell
death rather than having a direct mitogenic effect (reviewed in 391).
Prior to the introduction of sensitive molecular biology techniques such as RT-PCR,
the quantification of dead cells was limited to the histological localisation and analysis
of serial sections of blastocysts which was both laborious and time-consuming. For
these reasons only a small number of blastocysts could be analysed this way (392,
393). In addition, the initial stages of apoptosis appear to be extremely rapid with
cytoplasmic fragmentation occurring within minutes (394) therefore histological or
differential labelling techniques provide only a 'snapshot' of the embryo at a specific
point in time during the final phase of the cell death process. Using a quantitative RT-
PCR protocol with its unique sensitivity, the level of expression of apoptosis
regulating genes can be quantified before the cells undergo the final morphological
changes.
Several methods of quantitative PCR have been described (308, 311, 395, 396, 397)
all of which use different strategies to quantify PCR product yield. Some methods
base quantitation upon co-amplification of a reporter gene which differs from the
target gene (396, 398). This method however, is not a particularly reliable strategy
since differences in primer efficiencies can lead to differences in the amount of
amplified product. Others such as Wang et al (397) have compared the co-
amplification of target cDNA to cloned genomic sequences (containing introns). The
disadvantage of this method is that the effects of reverse transcription and the possible
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differences in the amplification efficiencies of large genomic DNA and cDNAs are not
taken into consideration. Methods based on large size differences between the target
and standard sequences must be applied and interpreted with caution.
Standards prepared for quantitative RT-PCR can be internal or external, and be added
to the reaction as mRNA (added prior to the reverse transcriptase step) or cDNA
(added prior to amplification step). Internal standards must allow the distinction of
amplified products in order to be useful. This can be based on differences in size
between the target and standard, the main disadvantage of which as described above,
is that even small differences in size may affect amplification efficiency. Alternatively,
an internal standard can de designed so that its PCR product contains a unique
restriction site not found on the target amplified product (399). The standard PCR
products are differentiated from that of the target by gel electrophoresis of the
restriction enzyme digest of the amplified products. One caveat of this method is that
under conditions in which primer is rate limiting, annealing may occur between
heterologous strands of mutant and target templates, forming heteroduplexes which
cannot be cleaved by the restriction enzymes.
External standards can be prepared by cloning the PCR product into a transcription
vector. mRNA is synthesised, purified and quantified in the same way as internal
standards. The biggest concern when using this method is tube-to-tube variability.
The parameters that are particularly important are magnesium ion concentration and
the proportion of primer to template cDNA.
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Given the stringent requirements in quantitative PCR to relate the precise yield of
PCR product to the abundance of the target template to be quantified, the reliability of
any quantitative PCR procedure is susceptible to minor variations in PCR reagents
and/or amplification conditions which can substantially affect the yield of product.
Internal standard procedures have the intrinsic advantage that the method avoids
variability of reagents and conditions because the internal standard and target are in
the same tube and any variables affecting the PCR conditions in those tubes will
equally affect the amplification of standard and target.
Many of the disadvantages of other available quantitative PCR and RT-PCR methods
were taken into consideration when designing an appropriate and sensitive method of
quantitative RT-PCR in single rat blastocysts. This technique was used to investigate
whether the reduction in ICM cell number seen in blastocysts from diabetic rats was
due to disturbed regulation of apoptosis. Synthetic mRNA transcribed in vitro from
mutated cloned PCR sequences was used as the internal mRNA standard. mRNA
rather than cDNA standards were chosen so that differences in reverse transcription
could be taken into consideration. The increase in insert length was limited to a
maximum of eight nucleotides so that both target and standard cDNAs would have
approximately the same reverse transcription and PCR amplification efficiencies.
Such small differences in size between the target and standard PCR products required
separation by polyacrylamide rather than agarose gel electrophoresis. Since
separation of the 32P-labelled PCR products by polyacrylamide gel electrophoresis is
much more sensitive than agarose gel electrophoresis with ethidium bromide staining,
the PCR can be optimised more stringently and the presence of non-specific PCR
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products (which would not be detected with agarose gel separation) can be seen and
conditions changed accordingly to prevent them, thus increasing the accuracy of
quantification.
The quantitative RT-PCR method used in the present study however, did not detect a
significant difference in the ratio of bcl-2 : bax mRNA in 8 single expanded
blastocysts from diabetic and non-diabetic BB/E rats. There may be several reasons
for this: firstly, the Bcl-2 family has many members and it may be necessary to look at
the expression levels of several other genes in addition to bax and bcl-2. This was not
possible in this study because of time limitations but now that the methods of RNA
extraction, reverse transcription and PCR amplification have been established for the
single blastocyst it would be possible to observe the ratio of death antagonist and
agonist genes in much more detail. Secondly it appears that members of the Bcl-2
family interact with each other to form a dynamic equilibrium between homo- and
heterodimers at the protein level and so it would be interesting to complement the
RT-PCR data with immunohistochemistry to localise the proteins with particularly
high gene expression to the ICM or TE. It was important to establish a method which
was sensitive enough to detect small changes in mRNA levels in the single pre-
implantation embryo. Pooling large numbers of blastocysts together is not only
expensive in terms of animal numbers but may also mask subtle changes in gene
expression in individual blastocysts, as it is clear from the data presented in
Experiment I that in any one pregnancy each embryo is a completely separate entity.
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Since derivatives of the ICM give rise to all germ layers of the fetus, it is likely that
the ICM cellular deficit could be an underlying cause of the high rate of fetal
resorptions and malformations reported by Eriksson et al (258) in Diabetic DP-BB/E
rats maintained on conventional insulin therapy. To date, no post-implantation studies
have been carried out using embryos from BB rats so speculation about the future
consequences of the ICM cellular deficit is difficult. However, it has been shown that
normal mouse blastocysts with a reduced ICM implant normally (400) but
organogenesis is disturbed (320). While these blastocysts might eventually achieve
normal future growth and development, this impairment is consistent with the
retardation of growth observed in human pregnancies with poorly controlled IDDM,
which may lead to congenital malformation or IUGR.
There is a 3-4 fold increase in major congenital malformation in infants of mothers
with IDDM. Congenital malformations are now the most common cause of neonatal
death in these infants. Cardiac anomalies affect up to 4 % of IDDM pregnancies
presenting as ventricular-septal defects, complex lesions of the great vessels and
coarctation of the aorta. IDDM pregnancy also carries an especially high risk for
neural tube defects (NTDs): 19.5 per 1000 pregnancies compared to 2 per 1000 for
normal pregnancies (104). High rates of perinatal mortality and congenital
malformation, in particular neural tube and skeletal defects, have also been reported in
the BB rat (256, 257, 258, 259). The association between early growth delay (EGD)
and congenital malformation has been reported by Pedersen and Molsted-Pedersen
(92). This is a controversial area since one centre has suggested that EGD disappears
when the correct time of conception is determined (99). However, the time of
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conception in the BB/E rat studies was precisely known as a sperm positive vaginal
plug was found the morning after mating and designated day 0.5 of pregnancy. Thus
the data show that at day 4.5 of pregnancy blastocysts from rats with IDDM are
already exhibiting signs of early growth delay. Whether it is these blastocysts which
develop into fetuses with the types of congenital malformations previously described
in diabetic BB/E rats is at present unknown. It would be interesting for future studies
to investigate the fate of the ICM deficit with particular reference to malformations
such as cardiac and neural tube defects. In addition, clinical studies have shown that
EGD is associated with poorer psychomotor development postnatally (95) and it
would be of particular relevance to the clinical situation to study psychomotor
development in the offspring of diabetic BB/E rats, a phenomenon which has not yet
been described in either the BB rat or rodents with STZ -induced diabetes.
Most non-genetic and non-toxic IUGR is believed to be due to a reduction in nutrient
or oxygen delivery to the fetus either because of maternal illness or due to placental
dysfunction (401). IGF-I, IGF-II and their respective receptors are synthesised by a
number of fetal tissues and are believed to be involved in an autocrine/paracrine
stimulation of cellular proliferation and differentiation in development (402).
Alterations in these growth factors may result in developmental abnormalities such as
macrosomia or intra-uterine growth retardation. Much of what is known of the
effects of the IGF's and their receptors has been obtained from mice knockout
experiments. Mice null mutants for IGF-I, IGF-II, insulin receptor and IGF-IR all
exhibit reduced birthweight (40-60 %) and are associated with neonatal lethality (403,
404, 405).
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Using in situ hybridisation Chernicky et al (406) found that some embryos from STZ-
induced diabetic mice at day 6 of gestation were growth retarded and had significantly
low levels of IGF-II gene expression. Those embryos from diabetic mice which were
not growth retarded had normal IGF-II expression. These studies complement that of
Shen et al (407) who previously demonstrated that an increase in placental IGF-II
levels in term placentae from diabetic mothers, is often associated with macrosomia.
IGF-I levels are highest in first- and second-trimester placentae compared with term
placentae, indicating that it may be more important in early gestation as a placental
growth factor, when organogenesis and rapid cell proliferation occur (408).
A recent paper by Abu-Amero et al (409) has described a quantitative PCR method
used to compare transcription levels of the IGF family in human term placentae from
normal and IUGR births. They found no significant difference in the levels of
transcripts for IGF-I, insulin receptor, or IGF-IIR between normal and IUGR
placentae. However, the IUGR placentae had significantly higher levels of IGF-II and
IGF-IR expression compared with the normal term placentae. The increase in the
transcription of IGF-II and IGF-IR in IUGR term placentae may represent a counter
regulatory mechanism in response to the growth retardation.
Clinical observations in the human suggest that IUGR is associated with
developmental alterations in the 'programming' of a number of key homeostatic
mechanisms leading to the development of disease in adulthood such as NIDDM,
cardiovascular disease and hypertension (410, 411, 412). Direct experimental
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evidence to support this model has shown that the progeny of undernourished
pregnant rats became hypertensive postnatally (413, 414). In these rats catch-up
growth is delayed postnatally and appears to be associated with a delayed
development of responsivity to growth hormone or IGF-I therapy. Patients with
poorly controlled / uncontrolled IDDM are very similar metabolically to individuals
suffering from prolonged starvation. During periods of starvation there is an
increased secretion of glucagon, gluconeogenesis is increased in the liver and
glycolysis is switched off. As a result, muscle shifts from using glucose as fuel to
using fatty acids, and there is a large increase in the amount of acetoacetate and (3-
hydroxybutyrate (ketone bodies) in the blood - produced by the liver and used by the
brain for fuel. Clearly these metabolic changes are very similar to those described in
section 1.1.1 of the Introduction (and Figure 1.1) the metabolic consequences of
insulin-deficiency. Thus, the diabetic BB rat can be also seen as a model for
pregnancy under conditions of relative starvation and used to investigate the
phenomenon of small for gestational age babies and the effect of IUGR later on in
adult life.
In conclusion, the data presented here clearly demonstrate that autoimmune-induced
IDDM which develops spontaneously in the DP-BB/E rat was associated with a
severe disturbance in pre-implantation embryo development. Perhaps the most
significant data of all came from the embryo transfer experiments. The maternal
uterine environment of the Diabetic DP recipient was able to induce a small ICM
cellular deficit (9 %) accompanied by a substantial TE cellular accretion (19 %) in
blastocysts transferred from Non-Diabetic DR donor rats at the 2-cell stage. It has
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been suggested that normal blastocyst formation depends on adequate cellular
interaction between ICM and TE cells. The increase TE cell number may represent a
counter regulatory mechanism in response to the ICM cellular deficit. However,
transfer of two-cell embryos from Diabetic DP- into Non-Diabetic DR-BB/E mothers
did not prevent the development of an ICM cellular deficit or a TE cell suggesting
that maternal IDDM in the BB/E rat may negatively influence oocyte maturation
and/or the oviductal milieu where fertilisation occurs.
IGF-I and IGF-II are synthesised by a number of maternal, embryonic and fetal tissues
and are believed to be involved in an autocrine/paracrine stimulation of cellular
proliferation and differentiation in development (404). Although no definitive
evidence is presently available for the exact role of IGF's in diabetes-induced
embryopathy, STZ-induced diabetic rats with IUGR have been shown to express low
levels of IGF-II. It is possible therefore that maternal IDDM may affect the balance
of these growth factors resulting in the formation of some of the developmental
abnormalities of the pre-implantation blastocyst seen in Diabetic DP-BB/E rats.
The aims of these studies were (i) to elucidate the mechanism of the teratogenic effect
of IDDM by studying the interaction of maternal genetic background and metabolic
profile on pre-implantation embryo development using the BB/E rat as a model for
human IDDM, and (ii) to examine the effect of the degree of diabetic metabolic
control achieved before and at various points after conception on embryonic
development. Although the exact mechanisms underlying the teratogenic effect of
maternal IDDM have not been precisely defined, these studies using the BB/E rat
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support the hypothesis that a detrimental effect induced by maternal IDDM occurs on
oocytes during folliculogenesis and on early pre-implantation embryos during
progression from the two-cell stage to the blastocyst stage of development. These
findings and those obtained from Diabetic DP rats treated with SRIIs indicate that in
order to achieve normal pregnancy outcome exceptionally good metabolic control
(i.e. normoglycaemia) may need to be established from diabetes onset.
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Figure 5.1: Partial nucleotide sequence of rat bax cDNA aligned with the
published rat bax cDNA sequence from nucleotide number 115 to 518
(GenBank accension number U49729). The bax cDNA fragment was isolated
using RT-PCR with total RNA prepared from Non-Diabetic DR-BB/E rat
blastocysts (internal primer sequences are shown in boxes).
Genbank sequence: iTTGTTACAGGGTTTCATCCAGGATtCGAGCAGGGAGGATGG 115

















Differences between the published Rattus rattus cDNA sequence and the BB/E rat
bax cDNA sequence are shown in red.
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Figure 5.2: Partial nucleotide sequence of BB/E rat bcl-2 cDNA aligned with
the published rat bcl-2 cDNA sequence from nucleotide number 372 to 662
(GenBank accension number L14680). The bcl-2 cDNA fragment was isolated
using RT-PCR with total RNA prepared from Non-Diabetic DR-BB/E rat
blastocysts (internal primer sequences are shown in boxes).
Genbank sequence : ItGGCATCTTCTCCTTCCaBcCTGAGAGCAACCGaACGCCC 372













Differences between the published Rattus norvegicus cDNA sequence and the BB/E
rat bcl-2 cDNA sequence are shown in red.
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Figure 5.3: Partial nucleotide sequence of rat p-actin cDNA aligned with the
published rat P-actin cDNA sequence from nucleotide number 2235 to 2907
(Genbank accension number V01217 J00691). The P-actin cDNA fragment was
isolated using RT-PCR with total RNA prepared from Non-Diabetic DR-BB/E
rat blastocysts (internal primer sequences are shown in boxes).
Genbank sequence : iGCCATCCAGGCTGTGTTGTCCdTGTATGCCTCTGGTCGTA 2235

























Differences between the published Rattus ncDNAsequence and the BB/E
rat P-actin cDNA sequence are shown in red.
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Figure 5.4: Partial nucleotide sequence of pBcl-2Mut.PCR2.1. The size of the
insert in the recombinant plasmid was increased by eight nucleotides by
inserting an Xbal linker (shown in red) into the Nhel site.







Figure 5.5: Partial nucleotide sequence of pActMut.PCR2.1. The size of the
insert in the recombinant plasmid was increased by five nucleotides by filling in
the 3' recessed ends after BstElI digestion, as shown in red.









Disturbed Development of the Preimplantation
Embryo in the Insulin-Dependent Diabetic
BB/E Rat
Richard G. Lea, Jane E. McCracken, Susan S. Mclntyre, William Smith, and Joyce D. Baird
Although improved regulation of maternal IDDM dur¬
ing pregnancy has resulted in a major fall in the still¬
birth rate, the rates for other problems, such as spon¬
taneous preterm labor, fetuses small for gestational
age, congenital malformation, and the incidence of
large placentas, remain raised. This has suggested the
possibility that the damaging effect of conventionally
treated but poorly regulated IDDM may operate pri¬
marily at the earliest stages of gestation, even before
the diagnosis of pregnancy has been made. This study
shows that spontaneous autoimmune IDDM in the Bio
Breeding/Edinburgh (BB/E) rat is associated with
severe disturbance in the development of the preim¬
plantation embryo in a majority of pregnancies, as
indicated by a fivefold increase in the incidence of
degenerate fragmented embryos and a 33% reduction
in the number of expanded blastocysts and in those
blastocysts that reach the expanded stage a 20% cel¬
lular deficit in the inner-cell mass without any change
in trophectoderm cell number. In addition, we find
that blastocysts removed from diabetic rats and cul¬
tured in vitro for 24 h show no sign of "catch-up"
growth of the inner-cell mass, although under these
conditions, the trophectoderm exhibits a 25% cellular
accretion. It is tempting to speculate that these phe¬
nomena are a presage of the characteristic combina¬
tion of fetal growth retardation and large placentas,
which are a feature of both BB/E rat and human IDDM
pregnancy. Diabetes 45:1463-1470, 1996
The main causes of the high perinatal mortalityrate (PNMR) in women with IDDM are suddenintrauterine death, particularly in the 3rdtrimester of pregnancy; prematurity, resulting
from either spontaneous preterm labor or elective early
delivery performed to avoid late intrauterine death;
infants small for gestational age; and malformation.
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BB/E, Bio Breeding/Edinburgh; BSA, bovine serum albumin; DNP, dini-
trophenyl; DP, diabetes-prone; DR, diabetes-resistant; EGD, early growth
delay; ICM, inner-cell mass; LBW, low birth weight; PNMR, perinatal mor¬
tality rate; STZ, st.reptozotocin; TE, trophectoderm.
Intrauterine death (the "classical accident" in diabetic
pregnancy) has been shown to be due to fetal hypoxia,
attributable to a 23% increase in the oxidative metabo¬
lism of glucose and lactate consequent on fetal hyper-
glycemia/insulinemia induced by maternal hyper¬
glycemia. The mechanisms underlying the teratogenic
effect of IDDM, initiation of preterm labor, and the devel¬
opment of infants small for gestational age remain
obscure. It is, however, recognized that these complica¬
tions tend to be associated with each other (in both dia¬
betic and nondiabetic pregnancy) and occur particularly
in mothers with IDDM, who also have clinically evident
microangiopathy, preeclampsia, and/or early growth
delay (EGD). The latter can be demonstrated by ultra¬
sound scanning at 7-14 weeks' gestation in 30-40% of
IDDM pregnancies and has been shown to be a marker
for low birth weight (LBW) and malformation (1).
There is a general agreement that 1) the main factor
responsible for the improved outcome of pregnancy in
women with IDDM in the past 2 decades is better regula¬
tion of maternal diabetes during pregnancy, 2) the main
impact of good metabolic control is the reduction of the
number of late intrauterine deaths, and 3) the effect of
improved diabetic control during pregnancy on the rates
of malformation, LBW, and spontaneous preterm labor is
much less impressive (2). This has suggested that the
damaging effect of IDDM may operate at the very earliest
stages of pregnancy. However, prospective studies
designed to test this hypothesis have yielded conflicting
results (3,4), and today, even in "centers of excellence,"
the PNMR for diabetic pregnancy remains approximately
four times that for nondiabetic women (4-8% vs. 1-2%)
(5), and 15-20% of the infants born to mothers with IDDM
experience neonatal morbidity severe enough to require
a stay of >10 days' duration in intensive care (6). A sub¬
stantial proportion of the excess neonatal morbidity in
IDDM pregnancy and 30-60% of all perinatal deaths are
now due to malformation. In addition, there is increasing
concern about long-term morbidity in the children born
to mothers with IDDM. Careful studies from Copenhagen
are particularly important in that they confirm and
extend earlier less-substantial reports by showing that 1)
30% of the children born to IDDM mothers have a range
of problems (7,8), indicating cerebral dysfunction, which
is comparable to those seen in LBW children born to non-
diabetic mothers; and 2) children who have had EGD,
premature birth, and/or LBW are at greatest risk of devel¬
oping long-term problems.
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Our hypothesis is that the noxious effect of IDDM,
which results in malformation, EGD, LBW, and preterm
labor, operates primarily at the very earliest stages of
pregnancy.
Obviously, direct study of the embryo in the earliest
stages of human pregnancy is impossible, and prospec¬
tive epidemiological studies have major problems and
limitations (4). Appropriate animal models provide a
direct approach for studying disturbances early in preg¬
nancy and the effect of various interventions can be
investigated. With few exceptions (9-14), in vivo studies
of the pathogenesis of diabetic embryopathy in IDDM
pregnancy have involved animals with chemically
induced diabetes and have largely focused attention on
the period of organogenesis (15). Studies of the preim-
plantation period are less common (16-18). In this study,
we have used the spontaneously diabetic Bio Breed¬
ing/Edinburgh (BB/E) rat as a model for human IDDM
pregnancy to study the effects of maternal diabetes on
the development of the preimplantation embryo.
RESEARCH DESIGN AND METHODS
Animals
BB rats. A breeding colony of BB Wistar rats was established in Edinburgh
in 1982 from a small nucleus of animals (three male and four female)
donated by Dr. P. Thibert from the original outbred BB rat colony in Ottawa.
The BB/E colony consists of two sublines created by selectively breeding for
and against diabetes. These two lines have now been through 24 generations
of strict brother-sister mating on site, thus meeting the international crite¬
rion for designation as an inbred line, and we have also confirmed their
inbred status by skin allograft experiments. All animals are weighed twice
weekly from 40 days of age. If they fail to gain weight or lose weight, they
are tested for glycosuria (Multistix SG reagent strips, Bayer Diagnostics). If
glycosuria is detected, the blood glucose concentration is measured
(ExacTech blood glucose meter, Medisense) from a blood sample obtained
by tail tipping without anesthesia. In the Edinburgh BB colony, a blood glu¬
cose concentration of >18 mmol/1 is invariably associated with loss of
weight, ketonuria, undetectable circulating endogenous insulin, and the
need to treat with a daily injection of insulin (Bovine Ultratard U40, Novo
Nordisk, Denmark) to ensure survival, and these parameters constitute our
criterion for classifying an animal as having IDDM. In the high incidence dia¬
betes-prone mainline (DP BB/E), the incidence of IDDM is 50-60% and the
mean ± SD age at onset is 96 ± 18 days. In the diabetes-resistant subline (DR
BB/E), the incidence of diabetes is zero. The lymphoid status of the two lines
has been characterized in detail using fluorescence-activated cell sorter
analysis, and it has been shown that the BB/E colony is unique in that both
lines are identical in all the immunological parameters examined (19). This
makes the DR BB/E subline an exceptionally good control strain for studies
of the effect of diabetes on any parameter selected.
Non-BB Wistar Han rats. Adult Wistar Han rats (outbred on site for 5
years) were obtained from our breeding facility.
All animals were maintained at 20°C on a 12-h light/12-h dark cycle and
allowed free access to food and water. BB/E rats were fed rat and mouse
Number 1 Expanded Feed, and Wistar Han rats were fed CRM rat and mouse
Breeder and Grower Diet, both from Special Diet Services (Witham, U.K.).
Experimental protocol
Diabetic pregnancies. Female DP BB/E rats (n = 52; age 129 ± 2.4 [mean
± SE] days) with established IDDM (duration of diabetes, 39 ± 2.7 days)
were mated overnight with established insulin-dependent diabetic BB/E
male rats of proven fertility.
Nondiabetic pregnancies. Nondiabetic female DR BB/E rats (re = 51; age
124 ± 5.4 days; not significantly different from diabetic group) were mated
overnight with nondiabetic DR BB/E males.
Wistar Han pregnancies. Female Wistar Han rats (re = 40; 150 days of age)
were mated overnight with Wistar Han males. Pregnancy was confirmed the
following morning by the presence of a sperm-positive vaginal smear and
was designated day 0.5 of gestation.
Pregnant rats were killed by cervical dislocation on day 4.5 of gestation
and the uterine horns immediately removed. Embryos were gently flushed
from the excised uteri with prewarmed Nutrient Mixture (Ham's) F10 (Gibco
BRL) supplemented with 0.1% bovine serum albumin (BSA) Fraction V
(Sigma), 100 U/ml penicillin, and 100 pg/ml streptomycin (Sigma).
Embryos from each individual pregnancy were transferred to an inverted
microscope (Nikon) and classified as having reached a recognized and well-
defined stage of development (20), namely morula, early blastocyst with a
nascent blastocoele, and expanded blastocyst with a clearly demarcated tro-
phectoderm (TE) and inner-cell mass (ICM). The remaining structures were
classified as abnormal embryos and defined as those exhibiting cytoplasmic
fragmentation, a collapsed blastocoele, and/or blastomeres of unequal size
(21). The number and percentage of 1) embryos at each developmental stage
and 2) abnormal embryos were determined and recorded for each preg¬
nancy. All embryos classified as expanded blastocysts appeared to be nor¬
mal and were collected for further study.
Differential staining of TE and ICM. The number of TE cells (the cell lin¬
eage giving rise to the placenta) and ICM cells (the cell lineage giving rise to
the fetus) was determined in expanded blastocysts from diabetic and nondi¬
abetic BB/E rats using a dual fluorochrome differential staining technique
originally described by Handyside and Hunter (22) and modified by Pampfer
et al. (23). Blastocysts were subjected to a 15-min incubation in 0.4%pronase
(Boehringer Mannheim, U.K.) in M2 medium containing 10 mg/ml BSA
(Sigma) at 37°C, 5% C02. The denuded blastocysts were washed four times
in BSA-free M2 and incubated in 4 mmol/1 picrylsulfonic acid (trinitroben-
zenesulfonic acid, Sigma) in BSA-free M16 with 1% polyvinylpyrrolidone
(Calbiochem, La Jolla, CA) for 30 min on ice. After further washing in BSA-
free M2, the blastocysts were incubated with 10 pg/ml rabbit anti-dinitro-
phenyl (DNP)-BSA complex polyclonal antibody (ICN Biomedicals) in BSA-
free M2 for 30 min at 37°C, 5% C02. After a final washing step, the blasto¬
cysts were incubated in 10% whole guinea pig serum (Sigma) as a source of
complement in BSA-free M2 containing 10 pg/ml propidium iodide (Sigma)
and 20 pg/ml bisbenzimide (Sigma) for 30 min at 37°C, 5% C02. This sequen¬
tial treatment results in the anti-DNP-BSA antibody binding to the trinitro-
phenol groups on the surface of the TE cells. In the presence of complement,
the TE cells are partially lysed allowing access of propidium iodide (which
is excluded from viable cells) and bisbenzimide to the TE cell nuclei. The
ICM remains intact because of the tight junctional seal of the trophectoderm
and is labeled with bisbenzimide alone. Under our conditions of ultraviolet
light excitation, the different fluorescent spectrum of each dye results in the
ICM staining blue and the TE staining red/pink. The differentially stained
blastocysts were individually mounted on microscope slides in a small
amount of medium in the center of a silicone ring with a coverslip on top and
incubated at room temperature in a dark box for 20 min. The numbers of
ICM and TE cells were counted directly under a Leitz Orthoplan fluores¬
cence microscope fitted with a Leitz A filter after gently pressing the edges
of the coverslip to convert the blastocyst into a two-dimensional form to
facilitate accurate cell counting.
The cell counts were done over a period of 4 months with three people
being involved (J.E.M., S.S.M., and R.G.L.). Initial counting was done by
R.G.L. and S.S.M., and, later, J.E.M. and S.S.M. were mainly involved. Ran¬
dom analysis of cell counts obtained during these two periods of time shows
identical results.
Embryo culture. Expanded blastocysts flushed from the uterine horns of
diabetic and nondiabetic BB/E rats on day 4.5 of pregnancy were cultured in
vitro in Nutrient Mixture (Ham's) F10 medium supplemented with 0.1% BSA,
100 U/ml penicillin, and 100 pg/ml streptomycin for 24 h at 37°C, 5% C02.
After culture, blastocysts were reexamined on an inverted microscope,
washed with BSA-free M2 medium, and differentially stained.
Statistical analysis. Mean ± SE is used throughout. Differences were
assessed by unpaired Student's t test.
RESULTS
Embryo morphology. Table 1 shows the number of
morulae, early blastocysts, expanded blastocysts, and
abnormal embryos recovered from BB diabetic, BB non¬
diabetic, and outbred non-BB Wistar Han rats at 4.5 days'
gestation. The mean number of embryos (viable + nonvi¬
able) per pregnancy for BB diabetic and BB nondiabetic
rats was not significantly different (6.94 ± 0.35 vs. 7.19 ±
0.29 for diabetic and nondiabetic BB/E rats, respec¬
tively); however, both BB diabetic and BB nondiabetic
rats had significantly fewer embryos per pregnancy than
Wistar Han rats (P < 0.0001). This low fertility is charac¬
teristic of a highly inbred line. Figure 1 depicts the same
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TABLE 1
Number of embryos recovered from BB diabetic, BB nondiabetic, and non-BB nondiabetic Wistar Han rats on day 4.5 of gestation
Total Abnormal Early Expanded Embryos per
Pregnancies embryos embryos Morulae blastocysts blastocysts pregnancy
Diabetic 52 361 81 36 57 187 6.94 ± 0.35*
Nondiabetic 51 372 15 30 58 269 7.19 ± 0.29*
Wistar Han 40 400 28 31 33 308 10.00 ± 0.39
Data are n or means ± SD. *P < 0.0001: significantly less than Wistar Han (Student's t test).
data expressed as the mean percentage of embryos in
each developmental category for the diabetic and the two
nondiabetic groups. The percentage of morulae per preg¬
nancy did not differ significantly between the three
groups of animals. The percentage of early blastocysts
was significantly greater in BB rat pregnancies (both dia¬
betic and nondiabetic) than Wistar Han pregnancies at
4.5 days' gestation (P < 0.05 for BB diabetic vs. Wistar
Han; P < 0.01 for BB nondiabetic vs. Wistar Han). Dia¬
betic and nondiabetic BB pregnancies did not differ signi¬
ficantly in this regard. The percentage of embryos reach¬
ing expanded blastocyst stage did not differ significantly
in Wistar Han and BB nondiabetic pregnancies. However,
significantly fewer embryos reached the expanded blas¬
tocyst stage in BB diabetic pregnancies than in BB non¬
diabetic and Wistar Han pregnancies (P < 0.0001 for both
differences), and the percentage of abnormal embryos
was significantly higher in diabetic pregnancies than in
both groups of nondiabetic pregnancies (P < 0.0001 for
both differences).
Figure 2A shows that in the 51 BB nondiabetic preg¬
nancies, the number of expanded blastocysts per preg¬
nancy is normally distributed at day 4.5 of gestation. In
contrast, the distribution of expanded blastocysts recov¬
ered from BB diabetic rats (n = 52) is markedly disturbed
(Fig. 2B), with 62% of diabetic pregnancies showing fewer
than five expanded blastocysts per pregnancy compared
with only 31% of nondiabetic pregnancies. Because the
number of embryos per pregnancy is variable in both non¬
diabetic and diabetic pregnancies, the same data have
also been expressed as the percentage of expanded blas¬
tocysts in each pregnancy (nondiabetic Fig. 2C and dia¬
betic Fig. 2D). The effect of this is to emphasize the out¬
standing difference between diabetic and nondiabetic
pregnancies, namely the high proportion of diabetic preg¬
nancies with <10% expanded blastocysts. Further analysis
(Fig. 3) shows that these same diabetic pregnancies with
few expanded blastocysts were also characterized by a
high number of abnormal embryos (Fig. 3B). Figure 4
depicts the close inverse correlation between these two
parameters (r = 0.866). Figure 3/1 shows that although
abnormal embryos also occurred in BB nondiabetic preg¬
nancies, they were few in number and randomly distrib¬
uted. Comparing diabetic mothers with and without
abnormal embryos, we found no difference in age at preg¬
nancy (132 ± 4.7 vs. 130 ± 3.0 days, respectively; NS),
duration of diabetes (38 ± 4.9 vs. 39 ± 3.6 days, respec¬
tively; NS), and blood glucose concentration measured at
1000 on the day when embryos were retrieved, using an
ExacTech meter, the majority being >20 mmol/1.
Expanded blastocyst cell lineage analysis
Cell numbers. Figure 5A is a photograph of a healthy
expanded blastocyst stained as described above to show
the clearly polarized ICM (blue) and surrounding TE
(red). Figure 5B shows the same blastocyst after slight
pressure has been applied to facilitate cell counting.
Table 2 shows ICM and TE cell numbers in expanded
blastocysts with apparently normal morphology isolated
from diabetic and nondiabetic BB/E rats on day 4.5 of
gestation. The number of cells in the ICM was signifi¬
cantly less in blastocysts from diabetic compared with
nondiabetic BB/E rats (P < 0.0001); this represents a
-20% ICM cellular deficit. The ICM cellular deficit seen in
diabetic pregnancies occurred to the same extent in
expanded blastocysts from pregnancies with and without
abnormal embryos. In contrast, there was no difference
in the number of TE cells in blastocysts from diabetic
and nondiabetic rats.
Effect of 2U-h culture on cell numbers. To determine
if growth-retarded embryos were capable of catch-up
growth when removed from the maternal diabetic envi¬
ronment, blastocysts were flushed from diabetic and
nondiabetic rats and cultured in vitro for 24 h in Ham's
F10 growth medium supplemented with 0.1% BSA. Table










Morulae Early Expanded Abnormal
Blastocysts Blastocysts Embryos
FIG. 1. Mean ± SE percentage of embryos at each morphological
stage of development recovered from 40 non-BB Wistar Han (□),
51 BB/E nondiabetic (^), and 52 BB/E diabetic (■) rats on day 4.5
of gestation. Significant differences in the percentage of embryos
at each developmental stage in the three groups are indicated by
* (Student's t test). Early blastocysts: P < 0.05 for BB diabetic vs.
Wistar Han rats and P < 0.01 for BB nondiabetic vs. Wistar Han
rats. Expanded blastocysts: P < 0.0001 for both BB diabetic vs. BB
nondiabetic and Wistar Han rats. Abnormal embryos: P < 0.0001 for
both BB diabetic vs. BB nondiabetic and Wistar Han rats.
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FIG. 2. Distribution of the number of expanded blastocysts in each pregnancy (A and 5). BB nondiabetic pregnancies (/i = 51) are
indicated by hatched bars; BB diabetic pregnancies (« = 52) are indicated by solid bars. Same data are expressed as a percentage
of expanded blastocysts in each pregnancy (C and D).
exhibit any sign of ICM catch-up growth in vitro, with the
ICM cellular deficit virtually the same as that found in
vivo at -18% (P < 0.001). In contrast, in culture TE cellu¬
lar accretion was 25% greater in blastocysts from diabetic
mothers than from nondiabetic mothers (P < 0.0001).
Cell death in the blastocyst. Closer examination of
stained blastocysts revealed that cells with fragmented
nuclei were seen in blastocysts from both diabetic and
nondiabetic rats. Although this technique does not
allow accurate quantitation, it appeared that cells with
fragmented nuclei were observed more often in the ICM
than in the TE (Fig. 6A). At high magnification (X500),
these cells show the features characteristic of apopto-
sis, including cell surface blebbing, nuclear condensa¬
tion and fragmentation, and, finally, splitting of the cell
itself into multiple membrane bound "apoptotic bodies,"
some of which contain nuclear fragments (24). Dead
cells were often seen at the edge of the ICM (Fig. 6B)
and, in some cases, appeared to be in the process of
extrusion (Fig. 6C).
FIG. 3. The relationship between the num¬
ber of expanded blastocysts and abnormal
embryos in individual nondiabetic and dia¬
betic pregnancies. Each dot (•) represents
a single pregnancy with one or more abnor¬
mal embryos. The right-hand axis indicates
the number of abnormal embryos in each
individual pregnancy. The bars represent
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Number of Expanded Blastocysts per Pregnancy
FIG. 4. Relationship between the number of expanded blastocysts
and abnormal embryos in BB diabetic pregnancies.
DISCUSSION
We have used the BE/E ral to demonstrate thai preg¬
nancy in established diabetic rats maintained on daily
injections of insulin is associated with a severe distur¬
bance in the development of the preimplantation embryo
in vivo as indicated by i) a high incidence of abnormal
(that is, degenerate and fragmented) embryos, 2) a
reduced percentage of expanded blastocysts, and 3) a
-20% ICM cellular deficit in blastocysts that reach the
expanded blastocyst stage (with no alteration in TE cell
number) compared with pregnancy in both nondiabctic
BB and Wistar Han rats. Moreover, blastocysts removed
from the maternal diabetic environment and cultured in
vitro for 24 h showed no sign of catch-up growth in the
ICM, although under these conditions, a TE cellular
accretion of +25% occurred.
Women with IDDM have been shown to have an
increased rate of early fetal loss (25,26). Perhaps the
most striking feature of the disturbance associated with
IDDM pregnancy in our study is the high incidence of
degenerate and fragmented embryos at 4.5 days' gesta¬
tion. This phenomenon has been reported previously in
hormonally superovulated mice with both chemically
induced (27) and spontaneous (12) diabetes and also in
rats, which were not superovulated, with streptozotocin
(STZ)-induced diabetes (28). The latter paper is impor¬
tant because superovulation per se has been shown to
increase the incidence of abnormal embryos (29); how¬
ever, streptozotocin-induced damage to oocytes cannot
TABLE 2
ICM and TE cell number in expanded blastocysts from diabetic






Inner cell mass Trophectoderm
Diabetic 57 8.35 ± 0.34* 20.09 ± 0.42
Nondiabetic 43 10.40 ± 0.25 20.23 ± 0.41
% increase/decrease -19.7 -0.7
Data expressed as mean ± SE. *P < 0.0001: significantly less
than blastocysts from nondiabetic rats (Student's t test).
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FIG. 5 .A: micrograph of three-dimensional BB/E rat blastocyst
differentially stained by immunofluorescence to show ICM cells
(blue) and TE cells (pink). B: same blastocyst after slight pressure
has been applied to create a two-dimensional form.
be ruled out in this study. Although abnormal preimplan¬
tation embryos are not specific to diabetic pregnancy, it
appears that diabetes is associated with a five- to eight¬
fold increase in their incidence. In our studies, the inci¬
dence of abnormal embryos in the two nondiabetic
groups, namely DR BB/E and non-BB Wistar Han, was
not significantly different (Fig. 1), ruling out a BB
strain-related effect in the diabetic BB/E group.
TABLE 3
ICE and TE cell number in expanded blastocysts from diabetic






Inner cell mass Trophectoderm
Diabetic 33 10.61 ± 0.54* 37.88 ± 1.47t
Nondiabetic 40 12.93 ± 0.50 30.18 ± 0.94
% increase/decrease -17.9 +25.5
Data are means ± SE. *P < 0.001: significantly less than blasto¬
cysts from nondiabetic rats (Student's t test); fP < 0.0001: signi¬




FIG. 6. A: differentially stained BB/E rat expanded blastocysts
showing dead cells and fragmented nuclei, the appearances being
characteristic of apoptosis (see text) in the ICM. B: dead cells
located at the edge of the ICM. C: dead ICM cells on the outer
edge of the embryo TE.
Analysis of the distribution of pregnancies with
abnormal embryos (Fig. 3) not only emphasizes the low
number of pregnancies with abnormal embryos in the
nondiabetic group (8 out of 51 = 16%) but also shows
that in this group, the number of abnormal embryos per
pregnancy is never more than two and the distribution
of pregnancies with abnormal embryos is random. In
contrast, in the diabetic group, 58% (30 out of 52) of all
1468
pregnancies have one or more abnormal embryo, the
number of abnormal embryos per pregnancy can be as
high as seven, and abnormal embryos do not occur ran¬
domly but rather are concentrated in pregnancies with
no or few expanded blastocysts. Indeed, the data sug¬
gest that the lack of expanded blastocysts is a direct
result of the high incidence of abnormal embryos and
that this also accounts for our inability to demonstrate
the retardation of embryonic development (as meas¬
ured by distribution of developmental stages) that has
been reported by others (12,28).
While our data suggest two distinct populations of
pregnancies within the BB diabetic group—one with a
high incidence of abnormal embryos and a reduced num¬
ber of expanded blastocysts and the other with no abnor¬
mal embryos and a normal complement (more than six)
of expanded blastocysts—we show that the morphologi¬
cally normal expanded blastocysts from both popula¬
tions of diabetic pregnancies are not in fact normal, since
they exhibit an ICM cellular deficit similar to that
described previously in rats with STZ-induced diabetes
(28). This suggests either that the mechanisms underly¬
ing the development of abnormal embryos and the ICM
cellular deficit are different or, more probably, that these
two pathological features result from either variation in
the degree of genetic susceptibility and/or damaging
environmental factors to which the gametes and/or
embryos are exposed.
Although there is evidence that paternal genes exert an
influence on the development of the preimplantation
embryo and formation of the blastocyst (30), we cannot
correlate the occurrence of abnormal embryos with any
particular male rat(s), and, indeed, all the male diabetic
rats used in this study had previously been shown to be
consistently highly fertile when mated with female non-
diabetic DR BB/E rats over a considerable period of time
before this study began. Moreover, the ICM cellular
deficit appears to be solely a function of maternal dia¬
betes with no input from the father (ICM cell number:
diabetic DP BB/E mother X diabetic DP BB/E father, 8.35
± 0.34*; diabetic DP BB/E mother X nondiabetic DR
BB/E lather, 8.00 ± 0.30*; nondiabelic DR BB/E mother X
diabetic DP BB/E father, 10.48 ± 0.43; nondiabetic DR
BB/E mother X nondiabctic DR BB/E father, 10.40 ± 0.25
[*P < 0.0001 for all differences]).
So far, we have been unable to identify any difference
between diabetic pregnancies with and without abnor¬
mal embryos in relation to maternal features, such as
age, duration of diabetes, daily dose of insulin, results of
daily urine tests for glucose and ketone bodies, and
blood glucose measured at 1000 on day 4.5 of gestation.
Indeed, given 7) the inbred status of the BB/E colony, 2)
the fact that it is held in a barrier unit under strictly con¬
trolled conditions and screens negative for all the com¬
mon rat viruses, and 3) that all the diabetic rats involved
in the study had established IDDM as defined by strict
criteria detailed above, these diabetic rat mothers were
a remarkably homogeneous group. Nevertheless, subtle
differences may exist in the diurnal metabolic profile of
these two populations of pregnancies—perhaps includ¬
ing secondary alterations in growth factors and/or
cytokines, which have been shown to play important
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regulatory roles in the development of the preimplanta-
tion embryo and in implantation (31-33)—and further
work is planned.
Our results showing a diabetes-related cellular deficit
specific to the ICM are in agreement with previous stud¬
ies in rats with STZ-induced diabetes (28). Pampfer et al.
(34) also cultured blastocysts in vitro for 24 h and, like
us, found no sign of catch-up growth in the ICM during
this period. This concordance contrasts with the results
obtained for TE cells in culture, since we find a highly
significant TE cellular accretion (+25%; P < 0.0001), while
Pampfer et al. describe a -8.5% decrease in cell number
(P < 0.05). We are unable to explain this difference in the
results obtained from these two models, but we have pre¬
viously shown that pregnancy in diabetic BB/E rats is
characterized by low birth weight pups and large placen¬
tas (11) and these features also occur commonly in
human IDDM pregnancy.
We have also previously observed that diabetic BB/E
rats maintained on continuous conventional insulin ther¬
apy have a higher rate of fetal resorption than nondia-
betic DR BB/E rats (11). This could be related to the ICM
cellular deficit seen in preimplantation embryos from
diabetic BB/E rats, since it has been shown that although
mouse blastocysts with a reduced or even absent ICM
implant normally (35), organogenesis is disturbed (36). In
addition, normal blastocyst formation depends on ade¬
quate cellular interaction between ICM and TE cells and
in vitro studies have shown that ICM cells are more sus¬
ceptible than TE cells to damage by a range of chemicals,
drugs, and antimetabolites (36). Thus, a diabetes-associ¬
ated disturbance in any component of the intrauterine
milieu during the preimplantation period is likely to
affect ICM more than TE cells and to disturb ICM-TE cell
interaction. Indeed, it is possible that the abnormal fetal
growth and development characteristic of human IDDM
pregnancy has its origin in the damage incurred by the
preimplantation embryo.
Other groups have suggested that conventional treat¬
ment with subcutaneous injection of insulin completely
prevents diabetic embryopathy in rats and mice with
STZ-induced diabetes and in NOD mice. This contrasts
with our results in the BB/E rat, since all our rats with
IDDM (as described above) are completely and irre¬
versibly insulin deficient and require daily injections of
insulin to survive (J. Freeman, R.M. Lindsay, J.D. Baird, J.
Foster, C.R. Elcombe, D.J. Harrison, H. Wolf, C.R. Wolf,
unpublished observations). In this respect, they differ
from NOD mice and rats with STZ-induced diabetes,
which are not always totally insulin deficient and are
capable of spontaneous regeneration of islet (3-cells (37).
We have previously documented the metabolic status of
BB/E rats with IDDM maintained on conventional insulin
therapy in detail, both during pregnancy (11) and when
not pregnant (38,39).
Coordinated apoptosis is a crucial factor in normal
morphogenesis. The reduction in ICM cell number seen
in blastocysts from diabetic BB/E rats may be due to dis¬
turbed regulation of apoptosis. Apoptosis may occur
either as a programmed "cell-autonomous" event, the
activating switch for which is unknown, or in response to
an external trigger. Drugs, toxins, radiation, cellular
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ligands (e.g., fas ligand and CD40 ligand), cytokines (e.g.,
tumor growth factor (3 and tumor necrosis factor a), and
matrix attachment factors are among those identified
(24). At this stage, we are unable to say whether or not
apoptosis is upregulated in blastocysts from diabetic
mothers because there are major difficulties in quantitat-
ing the phenomenon using microscopy. Problems include
the speed of apoptosis and the rapidity of clearance of
apoptotic cells; identifying apoptotic cells in a three-
dimensional structure, such as a blastocyst; and the
fragility of cells undergoing apoptosis, which are effec¬
tively lost when the blastocyst is flattened to facilitate
accurate counting of cells.
In conclusion, we have demonstrated major distur¬
bances in embryo development at the earliest stages of
pregnancy in an animal model with spontaneous autoim¬
mune IDDM. It is not known whether improved diabetic
control at conception can prevent or reverse the pathol¬
ogy documented in this study. Further studies are in
progress in which development of the preimplantation
embryo is examined in relation to the maternal metabolic
profile at various levels of maternal blood glucose con¬
trol established before and after conception.
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SUMMARY
The morphogenetic function of the transient phase of eel!
death that occurs during blastocyst maturation is not
known but it is thought that its regulation results from a
delicate balance between survival and lethal signals in the
uterine milieu. In this paper, we show that blastocysts from
diabetic rats have a higher incidence of dead cells than
control embryos. Differential lineage staining indicated
that increased nuclear fragmentation occurred mainly in
the inner cell mass. In addition, terminal transferase-
mediated dUTP nick end labeling (TUNEL) demonstrated
an increase in the incidence of non-fragmented DNA-
damaged nuclei in these blastocysts. Analysis of the
expression of clusterin, a gene associated w ith apoptosis, by
quantitative reverse transcription-polymerase chain
reaction detected an increase in the steady-state level of its
transcripts in blastocysts from diabetic rats. In situ hybrid¬
ization revealed that about half the cells identified as
expressing clusterin mRNA exhibited signs of nuclear frag¬
mentation. In vitro experiments demonstrated that high D-
glucose increased nuclear fragmentation, TUNEL labeling
and clusterin transcription. Tumor necrosis factor-a (TNF-
a), a cytokine whose synthesis is up-regulated in the
diabetic uterus, did not induce nuclear fragmentation nor
clusterin expression but increased the incidence of TUNEL-
positive nuclei. The data suggest that excessive cell death in
the blastocyst, most probably resulting from the overstim¬
ulation of a basal suicidal program by such inducers as
glucose and TNF-a, may be a contributing factor of the
early embryopathy associated with maternal diabetes.
Key words: blastocyst, cell death, clusterin, diabetes, glucose, rat,
TNF-a
INTRODUCTION
It has long been recognized that many critical developmental
events occur through the death of selected cells in predictable
places and at predictable times (Glucksmann, 1951; Sanders
and Wride, 1995). The fact that these cells appear to die
naturally led to the proposal that their elimination results from
the operation of a physiological procedure which was desig¬
nated 'programmed cell death' (Wyllie et ah, 1980). Active cell
elimination appears to be engaged very early in development
since the process of proamniotic cavity formation already relies
on the destruction of selected cells (Coucouvanis and Martin,
1995). Several reports also suggest that this eliminative process
may be activated even earlier, at the blastocyst stage. Following
the initial description of dead cells in preimplantation embryos
(Potts and Wilson, 1967), additional evidence has been based
on electron microscopy (El-Shershaby and Hinchliffe, 1974),
reconstruction of serial sections (Copp, 1978) and differential
labeling with DNA fluorochromes (Handyside and Hunter,
1986). In mouse blastocysts, cell death occurs as they reach
maximal expansion, with most disintegrating cells located in
the inner cell mass (ICM) lineage. It has been hypothesized
that the primary function of this process is to allow for the
removal of redundant or defective cells from the blastocyst,
hence eliminating the risk of maintaining a subgroup of cells
with unwanted developmental potential within the embryonic
germ layers (Pierce et al., 1989).
It is not clear whether the elimination process observed in
blastocysts is cell autonomous or controlled by extraembryonic
signals. Mouse blastocysts rendered unresponsive to both intra¬
cellular and extracellular survival signals simultaneously have
been shown to engage in massive cell death, suggesting that
embryonic cells are equipped with a death-by-default
mechanism that requires constant suppression (Weil et al.,
1996). One uterine survival agent may be transforming growth
factor-a. This effector is expressed in the pregnant mouse
uterus at the time of implantation (Paria et al., 1994) and its
addition to the composition of culture medium reduces the
incidence of dead cells in mouse blastocysts in vitro (Brison
and Schultz, 1997). Thus, if the normal programming of devel¬
opmental genes, including those involved in cell death,
depends on the correct integration of multiple signals, it seems
reasonable to speculate that, under certain pathological con¬
ditions, an imbalance in these signals would lead to inappro¬
priate cell determination (Kimmel et al., 1993). In addition,
because the correct allocation of cells to the ICM is of funda-
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mental importance for the subsequent formation of the
embryonic germ layers (Tarn, 1988), it can be postulated that
excessive cell death in this lineage at the blastocyst stage would
predispose to later developmental deficiencies.
Experiments on animal models have shown that the devel¬
opmental status of embryos recovered at the blastocyst stage
from diabetic females is markedly altered (Pampfer and De
Hertogh, 1996). Rat blastocysts from streptozotocin-induced
diabetic rats contain fewer cells than control embryos
(Vercheval et al., 1990) and this cellular loss is predominantly
located in the ICM (Pampfer et al., 1990a). Recent investiga¬
tions on blastocysts from genetically prone diabetic BB/E rats
have confirmed both the cellular deficit and the higher suscep¬
tibility of the ICM (Lea et al., 1996). In addition, when blas¬
tocysts from streptozotocin-induced diabetic rats are incubated
in vitro, their viability continues to decline in contrast to
control blastocysts (Pampfer et al., 1994a), suggesting that the
impact of the maternal disorder is long-lasting. Because
diabetes is associated with a myriad of hormonal, metabolic
and other alterations, identifying which imbalanced factor(s)
are responsible for the developmental anomalies detected
before implantation may prove difficult. Although high glucose
concentrations are likely to be accumulated in the uterine
lumen of the diabetic female (Nilsson et al., 1980) and high
glucose is detrimental to rat blastocysts (De Hertogh et al..
1991), recent data suggest that more indirect effects may be
involved. Previous observations that tumor necrosis factor-a
(TNF-a) is up-regulated in the diabetic uterus (Pampfer et al.,
1995a, 1997) combined with findings that TNF-a inhibits rat
blastocyst growth (Pampfer et al., 1994b) support the hypoth¬
esis that inappropriate release of this cytokine may be integral
in inducing the early embryopathy associated with maternal
diabetes.
In the present work, we used different cellular and molecular
techniques to detect an increase in the incidence of cell death
in blastocysts recovered from diabetic rats and in normal blas¬
tocysts incubated with high glucose and/or TNF-a.
MATERIALS AND METHODS
Animals and embryos
In experiments involving diabetic rats, adult females were adminis¬
tered a single injection of streptozotocin and tested 24 hours later
for their glycosuria (Vercheval et al., 1990). 2-4 weeks after drug
treatment, diabetic females were mated to normal males and
pregnancy was determined on the next morning by the presence of
a vaginal plug (gestational day 1). Normal pregnant females were
used in parallel as controls. On day 5 or day 6, the uterine horns
from diabetic and control rats were flushed to recover the embryos.
Only those embryos displaying the morphology of mid-expanded
blastocyst on day 5 or hatched blastocyst on day 6 were selected for
further study. Whole blood glycemia was measured using a glucose
test strip meter. Serum levels of P-hydroxybutyrate were measured
using a colorimetric assay (ref. 310-A, Sigma, St Louis, USA) and
serum concentrations of TNF-a were measured by means of an
enzyme-linked immunosorbent assay (ref. 80-3905-01, Genzyme,
Boston, USA). For in vitro experiments, blastocysts were recovered
from normal rats on day 5 and incubated at 37°C in a humidified
atmosphere with 5% CO2 for 24 hours. The basal culture medium
was Ham's F-10 (ref. 04-1040-20, Gibco. Buckinghamshire, UK)
supplemented with 1 mM glutamine, 0.1% bovine serum albumin,
100 U/ml penicillin and 100 |ig/ml streptomycin. Depending on the
experiments, various combinations of glucose (control 6 mM D-
glucose, 17 mM D-glucose, 6 mM D-glucose + 11 mM L-glucose)
and/or 3000 U/ml of rat recombinant TNF-a (ref. CY-044, Inno-
genetics, Zwijnaarde, Belgium) were added to the culture medium.
The specificity of TNF-a action was confirmed using a neutralizing
rabbit anti-rat TNF-a antibody (ref. CY-051, Innogenetics) in 100-
fold molar excess.
Differential nuclear staining
The number of cells per embryo and their distribution between the
inner cell mass (ICM) and the trophectoderm (TE) were counted using
a differential staining technique based on the partial immunolysis of
the outer TE layer and the exposure of the embryo to two DNA dyes
with different permeability and fluorescent properties (Pampfer et al.,
1990b). Partial complement-mediated lysis of the peripheral TE layer
resulted in the permeabilization of that lineage to propidium iodide
(PI, which is normally excluded from membrane-intact cells) whereas
bisbenzimide (Hoechst 33258, HO) entered into all the cells of the
embryo, including the ICM. Nuclei in the ICM were found clustered
at the center of the embryo and stained blue under u.v. light whereas
nuclei of TE cells looked more spread, larger in size and stained pink.
In both cell lineages, some nuclei appeared fragmented or scattered
into highly fluorescent chromatin particles which were still comprised
within intact cell boundaries as determined under visible light. For
each blastocyst, the incidence of disintegrating nuclei in the two cell
lineages was expressed as percentage of the corresponding numbers
of ICM and TE cells (nuclear fragmentation index). In a limited set
of experiments, rat blastocysts were exposed to the two DNA dyes
without prior treatment with pronase and complement. The observa¬
tion of cells containing either HO-stained or Pi-stained fragmented
nuclei was restricted to the TE layer in these embryos.
Terminal transferase-mediated dUTP nick end labeling
(TUNEL)
Nuclei containing abundant 3'-hydroxyl termini were detected using
the TUNEL technique (Gavrieli et al., 1992). Blastocysts were
exposed to 0.4% pronase, fixed in 4% paraformaldehyde in PBS.
exposed to 0.3% hydrogen peroxide in methanol and permeabilized
in 0.1% Triton X-100 in 0.1% sodium citrate. Following a rinse in
PBS supplemented with 0.5% Tween-20 (PBS-T). the embryos were
prestained with 25 pg/ml of HO in PBS-T. Incubation with 50 units/ml
of terminal transferase and 15 pM of fluorescein-dUTP was
performed for 35 minutes at 37°C in 50 pi drops. The embryos were
exposed to sheep anti-fluorescein antibody conjugated to peroxidase
and nuclear TUNEL staining was developed in a solution of
diaminobenzamide and nickel chloride. Exposure of the embryos to
u.v. light allowed to visualize and count the total number of HO-nuclei
and the proportion of fragmented nuclei. Observation under visible
light allowed for the counting of TUNEL-positive nuclei. For each
blastocyst, the incidence of fragmented nuclei (F-index), TUNEL-
positive nuclei (T-index) and nuclei with both labeling features (F+T-
index) was calculated as percentage of the total cell number. For
negative control experiments, the terminal deoxynucleotidyl trans¬
ferase was omitted from the labeling reaction. For positive control
reactions, blastocysts were pretreated with 15 units/ml of deoxyri-
bonuclease I before labeling.
Quantitative reverse transcription-polymerase chain
reaction (RT-PCR)
The steady-state level of clusterin transcripts was assessed by means
of a quantitative RT-PCR method based on the co-amplification of
the unknown amount of clusterin cDNA in each sample with a
known amount of internal standard. To construct the standard, a 564
bp-long amplicon was generated from rat placental cDNA with two
primers (SP1 and SP2) specific for clusterin (Fig. 1). The genomic
structure of rat clusterin and its cDNA sequence (GenBank M64723)
have been reported (Wong et al.. 1993). The amplicon was inserted
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Fig. 1. Primers and probes
used to analyse clusterin/
TRPM-2 mRNA expression.
The position of specific
primers (arrows) for
descriptive and quantitative
analysis of clusterin mRNA is
mapped on a cDNA sequence
numbered according to
published data (GenBank
M64723). The position of the
probes used for ISH
(rectangles) and of the genomic
introns are indicated (inverted
triangles).
into a pCRII plasmid (clone pl6rCLUn) and modified to increase its
length by 4 nucleotides. One of the mutated constructs (p9rCLUm)
was used as internal standard for PCR. To study clusterin mRNA
expression in blastocysts, total RNA was extracted from pools of 30
embryos and retrotranscribed with 200 gM random hexamers and
MMLV reverse transcriptase (100 U per reaction) (Pampfer et al.,
1994b). A fixed amount of internal standard (5xl05 molecules) was
added to each cDNA sample which was then serially diluted in PCR
reaction mixture. Each dilution series (1:1, 1:3 and 1:9) was
amplified with 1 gM of primers SP28 and SP29 (Fig. 1) and Taq
DNA polymerase (5 U per reaction). PCR reactions were terminated
after 32 cycles when the amplification process was still within the
exponential phase so that the ratio of unknown target to known
internal standard at the initiation of the reaction was conserved.
Aliquots of PCR reactions were electrophoresed on 5% polyacryl-
amide gel containing 8 M urea. Silver-stained amplicons produced
from the target cDNA (459 bp) and the internal standard (463 bp)
were quantitated by direct scanning densitometry. For each cDNA
sample, the ratio between the integrated intensities of the target and
the internal standard was calculated at the three dilutions tested and
the average ratio value was expressed in arbitrary units. Two control
cDNAs, one from a group of clusterin negative rat preblastocyst
embryos (morula stage) and one from clusterin positive rat ovaries,
were serially diluted after addition of internal standard and run in
parallel in each assay, together with a mock sample prepared without
RNA input. The blastocyst cDNAs were also tested for variations in
the retro-transcription step by amplifying the samples with primers
complementary to nucleotide positions 273-292 (SP30) and 552-571
(SP23) of the rat (3-actin cDNA sequence (Nudel et al.. 1993). Cor¬
rections made to the clusterin expression values never exceeded 10%
of the original result.
In situ hybridization (ISH)
Localization of clusterin mRNA expression in rat blastocysts was
studied by ISH using specific 5'-end biotinylated probes. A combina¬
tion of two oligonucleotides (antisense 1SHB and ISHD) comple¬
mentary to distinct regions of the clusterin cDNA sequence was used
against a combination of corresponding reverse oligonucleotides
(sense ISHA and 1SHC) as controls (Fig. 1). Blastocysts were fixed
in 3% paraformaldehyde/0.5% glutaraldehyde in PBS, rinsed in PBS
containing 0.1% Triton X-100 (PBS-TR), exposed to 10 pg/ml pro¬
teinase K in PBS-TR and washed in 2 mg/ml glycine in PBS-TR
before refixation in 4% paraformaldehyde/0.2% glutaraldehyde in
PBS. The blastocysts were then incubated in 0.1% sodium borohy-
dride and prehybridized in a solution described elsewhere (MacPhee
et al., 1994). The embryos were hybridized in the same solution con¬
taining the probes ISHB+ISHD or ISHA+ISHC at 0.5 pM of each
oligonucleotide for 34 hours at 50°C with agitation. Post-hybridiz¬
ation consisted of successive, washes in 300 mM NaCl, 1 mM EDTA,
10 mM Pipes and 1% SDS; in 50 mM NaCl, 1 mM EDTA, 10 mM
Pipes and 0.1% SDS; in 500 mM NaCl, 10 mM Pipes and 0.1% Triton
X-100 before transfer into the latter buffer with 100 pg/ml ribonu-
clease A and 100 U/ml ribonuclease Tl. Post-hybridization was
continued in 300 mM NaCl, 1 mM EDTA, 10 mM Pipes, 50%
formamide and 1% SDS; in 150 mM NaCl, 1 mM EDTA, 10 mM
Pipes, 50% formamide and 0.1% Triton X-100 and in 500 mM NaCl
with 0.1% Triton X-100. Following a rinse in PBS supplemented with
0.5% Tween-20 (PBS-T), the embryos were treated in 0.3% hydrogen
peroxide in PBS-T, incubated in 0.1% sodium citrate and 0.1% Triton
X-100 and then exposed to a streptavidin-biotin-peroxidase complex.
The embryos were prestained with 25 pg/ml of HO in PBS-T and
transferred into a solution of diaminobenzamide and nickel chloride.
Exposure of the embryos to u.v. light allowed to visualize intact and
fragmented nuclei whereas visible light allowed for the detection of
clusterin mRNA-positive cells.
Statistical analysis
Except for the data in Table 1, which were compared by either
Student's r-test or Mann-Whitney U-test. differences between control
values and experimental values were compared by one-way analysis
of variance coupled with Scheffe's F-test. Except in Fig. 9, the data
are given as mean±s.e.m. For each set of experiments, blastocysts
from 4 to 8 females (normal or diabetic) were pooled before either
direct observation or assignment to different incubation groups. Inter-
litter variations, if any, have been previously found to be neutralized
by this randomization process. In addition, the results in Figs 3, 4, 6
and 7 as well as in Table 2 were based on reproducible data collected
from at least three independent and 'blind' repeats.
RESULTS
Embryo collection
On both day 5 and day 6, hyperglycemia and ketosis were
confirmed in the diabetic group (P<0.05) (Table 1). Although
the average serum TNF-a value in diabetic rats on day 6 was
twice the control value, on neither day was the difference sta¬
tistically significant. On day 5, both the total number of
embryos recovered per rat (9.4±0.2 versus 7.7+0.3) and the
number of blastocysts per rat (Table 1) were decreased in the
diabetic group. No difference was found on day 6, however,
probably because the most advanced blastocysts in the control
group had already implanted at the time of uterine flushing.
Nuclear fragmentation in blastocysts in vivo
The occurrence of cell death was analyzed by means of a dual
staining technique that discriminates between ICM and TE
400
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Table 1. Recovery of rat blastocysts on gestational day 5 and day 6
Day 5 Day 6
Parameter Control Diabetic P-value Control Diabetic P-value
Blood glycemia (mM) 5.8±0.2 23.3±0.5 ** 6.6±0.3 24.3±0.5 **
n 83 74 66 61
Serum p-hydroxybutyrate (pM) 1.7±0.2 3.3±0.4 ** 1.2±0.2 1.9±0.2 *
n 19 20 11 11
Serum TNF-a (U/ml) 323.4 266.7 0.74 262.1 605.3 0.19
Confidence interval 35.1-611.7 132.9-400.4 89.5-434.6 276.6-1487.2
n 20 20 20 20
Number of blastocysts per rat 8.2±0.3 4.9±0.3 ** 2.4±0.2 2.7±0.4 0.23
n 79 62 56 46
Data are means ± s.e.m. with n representing the number of values. (*) and (**) indicate P<0.05 or 0.01 respectively.
nuclei (Fig. 2). When blastocysts from diabetic rats were
collected on day 5 and compared to control embryos, a 18.3%
deficit in the total cell number was found in the diabetic group
(P<0.01) (Fig. 3), with about 4/5 of this loss located to the
ICM. Closer examination revealed that the percentage of OH-
stained fragmented nuclei increased to 8.4±1.7% in the ICM
of blastocysts in the diabetic group from 1.1 ±0.3% in the ICM
of control embryos (P<0.01). In contrast, the percentage of PI-
stained fragmented nuclei, which was below 1.0% in the TE
lineage of control blastocysts, was not statistically different in
embryos from diabetic rats. Altogether, 48.9% of the blasto¬
cysts in the day 5 diabetic group contained at least one disin¬
tegrating nucleus versus 18.2% in the control group. These
observations were repeated on blastocysts recovered on day 6.
Compared with control embryos, blastocysts in the diabetic
group contained fewer cells (16.8% loss) on the average
OP<0.01) (Fig. 3) with the deficiency again predominantly
D
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Fig. 2. Nuclear fragmentation in blastocysts. Differential staining
with HO and PI was used to distinguish ICM (blue) and TE (pink)
nuclei (A). Closer examination revealed the presence of fragmented
HO-stained ICM nuclei (B; arrow) and fragmented Pi-stained nuclei
(C; arrowhead) in some blastocysts. In some blastocysts, expelled
cells with HO-stained nuclear fragments were observed in the
perivitelline space (D; arrow). Blastocysts were from a control rat
(A), from diabetic rats (B, C) or following incubation in high D-
glucose (D). The scale bar represents 50 gm in A,D and 10 pm in
B,C.
located to the ICM. The nuclear fragmentation index was
increased in the ICM of blastocysts from diabetic rats,
7.1 ±1.1% against the control value of 2.2±0.9% (P<0.05),
whereas it remained low in TE cells. Exactly 50% of the blas¬
tocysts from day 6 diabetic rats had at least one fragmented
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Fig. 3. Nuclear fragmentation in blastocysts exposed to maternal
diabetes. Embryos were recovered from control (CTR) and diabetic
(DIAB) rats on day 5 (upper panels) or day 6 (lower panels) and
counted for the total number of cells per embryo (A,C) and for the
frequency of nuclear fragmentation (B,D) in the inner cell mass
(ICM) and trophectoderm (TE) lineages. More than 45 embryos were
examined in each group on day 5 and more than 30 embryos on day
6. (**) indicates a statistically significant difference from
corresponding control value (P<0.01).
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Fig. 4. Nuclear fragmentation in blastocysts exposed to
high glucose and TNF-a. Embryos were recovered from
normal rats and incubated in control medium (CTR, n-55
embryos) or in high D-glucose (HIGH GLUCOSE, n=36),
TNF-a (TNF, n-32) or a combination of high D-glucose
and TNF-a (TNF + HIGH GLUCOSE, n=32) before
examination for the total number of cells per embryo (A)
and for the frequency of nuclear fragmentation (B) in the
inner cell mass (ICM) and trophectoderm (TE) lineages.
(**) indicates a statistically significant difference from
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Nuclear fragmentation in blastocysts in vitro
Blastocysts from normal rats were incubated under different
conditions. At the initiation of the culture, the mean cell
number per blastocyst was 37.6±1.3 with 13.5±0.5 of ICM
cells and 24.1 ±0.9 TE cells. After 24 hours, there was a 2.3-
fold increase in the mean cell number per embryo in control
culture medium. Compared with control blastocysts, fewer
cells were counted in embryos incubated in the presence of 17
mM D-glucose (13.3% loss), 3000 U/ml rat recombinant TNF-
a (13.8% loss) or in a combination of high D-glucose and
TNF-a (17.7% loss) (P<0.01) (Fig. 4). In all these groups, the
cell deficiency was more pronounced in the ICM than in the
TE. Closer examination showed that the percentage of frag¬
mented ICM nuclei was increased to 8.4±1.4% in high D-
glucose versus 1.6±0.4% in control culture medium (P<0.01)
whereas exposure to TNF-a alone did not induce any signifi¬
cant difference. Combining high D-glucose and TNF-a miscd
the nuclear fragmentation index in the ICM to 9.5±1.8%
(P^O.Ol). None of the treatments tested increased nuclear frag¬
mentation in the TE. At the start of the incubation period,
average frequencies of disintegrating nuclei were below 1.0%
in both ICM and TE lineages. In additional experiments, blas¬
tocysts were incubated in control medium or in high D-glucose
or L-glucose for 24 hours and directly transferred into a
solution of HO and PI. The incidence of HO-stained frag¬
mented nuclei remained below 0.5% in the peripheral TE layer
of all the blastocysts examined. The frequencies of Pl-stained
intact and fragmented nuclei remained also at a very low level
(0.1%). Omission of enzymatic digestion allowed for the
observation of extruded cells in the perivitelline space ol about
15% of the blastocysts exposed to high D-glucose (Fig. 2).
Most of these cells contained HO-stained nuclear fragments.
TUNEL-positive nuclei in blastocysts in vivo
The occurrence of cell death was further analyzed using a
technique that allowed for the simultaneous detection of frag¬
mented nuclei in u.v. light and nuclei with abundant free DNA
3'-OH ends (TUNEL-positive nuclei) in visible light (Fig. 5).
A comparison between blastocysts from control and diabetic
rats on day 5 confirmed that the mean total cell number was
decreased in the diabetic group (P<0.01) (Fig. 6). In these blas¬
tocysts, the F-index and T-index were both increased (P<0.01)
whereas the presence of nuclei combining signs of fragmenta¬
tion with TUNEL-staining was not detected (below 0.1%).
Only 21.4% of the blastocysts collected from diabetic rats
showed no signs of cell death against 73.2% in the control
group. The frequency of nuclei in metaphase was not statisti¬
cally different in embryos from the control and diabetic groups
(1.5±0.3% versus 1.2±0.3%). Close examination of 12 blasto¬
cysts from diabetic rats in which the blastocoele was clearly
delineated showed that 82% of the TUNEL-positive nuclei
detected in these embryos were localized in the ICM region.
Blastocysts recovered on day 6 were examined using the same
technique. All the three nuclear labeling indexes were
increased in blastocysts in the diabetic group (P<0.01) (Fig. 6).
Only 13.2% of the blastocysts from diabetic rats were without
signs of nuclear damage, relative to 42.2% in the control group.
The percentage of nuclei in metaphase was low (<0.3%) and
Fig. 5. TUNEL staining in blastocysts. HO staining coupled with
TUNEL staining were used to visualize different types of nuclear
degradation. Damaged nuclei were classified in three categories
according to their labeling pattern: HO-stained fragmented nucleus
without TUNEL signal (F-labeling) (A,B; arrow), HO-stained intact
nucleus with TUNEL signal (T-labeling) (C; arrow, D) or HO-stained
fragmented nucleus with TUNEL signal (F+T labeling) (E,F; arrow).
Blastocysts shown were from control (A,B and C,D) and diabetic
(E,F) rats. The scale bar in F represents 15 pm.
4832 S. Pampfer and others
Fig. 6. TUNEL staining in blastocysts exposed to maternal diabetes.
Embryos were recovered from control (CTR) and diabetic (DIAB)
rats on day 5 (upper panels) or day 6 (lower panels) and counted for
the total number of cells per embryo (A.C) and for the frequencies of
fragmented nuclei (F), TUNEL-positive nuclei (T) and nuclei
displaying both nuclear labels (F+T). More than 40 embryos were
examined in each group on day 5 and more than 30 embryos on day
6. (**) indicates statistically significant difference from
corresponding control value (,P<0.01).
identical in the two groups. Because the blastocoele had
collapsed in almost all the blastocysts recovered on day 6. it
was more difficult to confirm that TUNEL-positive nuclei were
still predominantly located in the 1CM at that later stage.
TUNEL-positive nuclei in blastocysts in vitro
Normal blastocysts cultured in the presence of either 17 mM
D-glucose, 3000 U/ml TNF-a or high D-glucose and TNF-a
combined for 24 hours contained fewer cells than blastocysts
in control medium (P<0.05) (Fig. 7). Compared with control
embryos, F-index and T-index were both increased in embryos
exposed to high D-glucose (P<0.()l) although there was no dif¬
ference in the F+T index. Both T-index and F+T-index, but not
nuclear fragmentation alone, were increased in embryos
exposed to TNF-a (P<0.05). Exposure to high D-glucose and
TNF-a simultaneously resulted in an increase in all three
nuclear labeling indexes (P<0.05). The percentage of blasto¬
cysts showing no signs of cell death was 12.5% in the control
group versus 12.1% in high D-glucose, 2.9% in TNF-a and
2.3% in high D-glucose combined with TNF-a. The frequency
of metaphasic nuclei (<1.0%) was not influenced by the culture
conditions. Careful examination of 19 blastocysts exposed to
high D-glucose and 18 blastocysts treated with TNF-a in
which the limits of the blastocoele were clearly
visible showed that, respectively, 81% and 73% of
the TUNEL-positive nuclei detected in these
embryos were localized in the ICM region. In 16
control blastocysts, 77% of the TUNEL-positive
nuclei were found in the ICM. Addition of 11 mM
L-glucose to the control medium did not influence
the mean total number of cells per embryo nor the
percentages of nuclei showing signs of fragmenta¬
tion and/or TUNEL-staining (Fig. 7). Preincubation
of a culture medium containing 3000 U/ml TNF-a
Fig. 7. TUNEL staining in blastocysts exposed to high
glucose and TNF-a. Embryos were recovered from
normal rats and incubated in control medium (CTR, ;;=48
embryos) or in high D-glucose (HIGH GLUCOSE, n=33),
TNF-a (TNF, «=35) or a combination of high D-glucose
and TNF-a (TNF+H1GH GLUCOSE, /?=42) (upper
panels) or in 6 mM D-glucose with 1 1 mM L-glucose (L-
GLUC, /r=23), TNF-a"plus normal IgG (TNF+IgG. n=21)
or TNF-a neutralized with blocking anti-TNF-a
antibodies (TNF+NAb. n=29) before examination for the
total number of cells per embryo (A.C) and for the
frequencies of fragmented nuclei (F), TUNEL-positive
nuclei (F+T) and nuclei displaying both nuclear labels
(F+T) (B.D). (*) and (**) indicate statistically significant
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with a 100-fold molar excess of neutralizing rabbit anti-rat
TNF-a antibody before embryo culture prevented the impact
of the cytokine on the mean number of cells and on the nuclear
labeling indexes. When an equivalent molar excess of normal
rabbit IgG was substituted for anti-TNF-a antibody, the mean
total number of cells per embryo as well as the average T-index
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and F+T-index were altered to the same extent as these values
were in the presence of TNF-a alone (P<0.05). In a series of
negative control reactions, blastocysts were incubated in 17
mM D-glucose for 24 hours and subjected to the TUNEL-
staining procedure without terminal transferase. Nine embryos,
with a mean total number of cells of 49.1 ±2.3 and an average
frequency of fragmented nuclei of 5.7±0.6%, were found com¬
pletely free of TUNEL staining. In a series of positive control
reactions, blastocysts were cultured in control medium for 24
hours and then treated with deoxyribonuclease 1 for 2 hours
before TUNEL staining. Examination of 5 blastocysts showed
that the proportion of TUNEL-positive nuclei was increased to
49.3±5.9%. The high embryotoxicity of the enzyme buffer
made it difficult to test whether a longer exposure time would
result in an even higher T-index.
Clusterin mRNA expression in blastocysts
Amplification of cDNA preparations from blastocysts
recovered from both control and diabetic rats with clusterin
primers SP1 and SP2 generated an amplicon of the expected
size (564 bp) (Fig. 8). Positive control amplifications
performed on cDNAs from either rat ovaries or limb buds
obtained from day 15 fetuses (a developing organ rich in
clusterin mRNA; Buttyan et al., 1989) produced the same
amplicon. In contrast, amplification of cDNA from morulae
was negative. When day 5 blastocysts from control or diabetic
rats were compared by means of a quantitative RT-PCR
method, the average level of clusterin mRNA was 57.7±9.1
arbitrary units in the control group versus 101.1 ±5.5 arbitrary
units in the diabetic group (P<0.01) (Fig. 9). In a second series
of experiments, the presence of clusterin transcripts was
analyzed in normal blastocysts incubated for 24 hours in either
17 mM D-glucose, 3000 U/ml TNF-a or a combination of high
D-glucose and TNF-a. Compared with embryos maintained in
control medium (50.6±2.5 arbitrary units), the average level of
clusterin mRNA was increased to 136.5±11.4 arbitrary units in
blastocysts exposed to high D-glucose alone and 158.2±14.1
arbitrary units in high D-glucose with TNF-a (P<0.01) (Fig.
9). Exposure to TNF-a alone did not influence clusterin mRNA
expression. In addition, there was no significant difference
between blastocysts treated with high D-glucose alone or with
high D-glucose and TNF-a combined.
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Fig. 8. Detection of clusterin transcripts in blastocysts by RT-PCR.
Total cDNA from rat fetal limb (LM), adult ovary (OV), morulae
(MC) and blastocysts (BC) from control rats as well as blastocysts
from diabetic rats (BD) were tested for clusterin/TRPM-2 mRNA
expression using specific primers expected to generate a 564 bp-long
amplicon (upper panel). The same cDNAs were amplified for |3-actin
in control reactions (lower panel). DNA size markers (MK) were run
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Fig. 9. Clusterin mRNA expression in blastocysts exposed to
maternal diabetes or to high glucose and TNF-a. Total cDNAs from
blastocysts collected from control (CTR. n=4 pools) and diabetic
(DIAB, n=3) rats on day 5 (A) or from normal rats and incubated in
control medium (CTR, n=3 pools), high D-glucose (HIGH
GLUCOSE, /i=5), TNF-a (TNF, n=2) or a combination of high D-
glucose and TNF-a (TNF+HIGH GLUCOSE, n=4) were analyzed
for clusterin expression by quantitative RT-PCR. Quantitative values
for individual blastocyst pools are represented (open circles) and the
average expression level in each group is indicated by a horizontal
bar.
Localization of clusterin mRNA expression
Control and diabetic blastocysts were collected on day 5 and
maintained overnight in normal culture medium before being
analyzed by ISH. Although 81% of the blastocysts from
diabetic rats were found to contain at least one clusterin
mRNA-positive cell, the frequency of these cells per embryo
was low (1.6±0.2 such cell per embryo). Simultaneous staining
with HO demonstrated that, in 46% of the clusterin mRNA-
positive cells, the ISH labeling in the cytoplasm correlated with
nuclear fragmentation (Fig. 10). The same pattern was found
in blastocysts incubated for 24 hours in high D-glucose, with
92% of the embryos containing at least one clusterin-express-
ing cell, an average of 1.5±0.2 such cell per embryo and 48%
of these cells displaying signs of nuclear disintegration. In
these two blastocyst groups, the incidence of clusterin-express-
ing cells was higher than in control embryos (F<0.01) (Table
2). In contrast, ISH analysis of blastocysts exposed to TNF-a
did not detect an increase in the proportion of clusterin-
expressing cells. About half the TNF-a-treated blastocysts
contained at least one clusterin mRNA-positive cell, with an
average of 0.6±0.2 such cell per embryo, and 49% of these cells
also displayed signs of nuclear fragmentation. Overall, the ISH
Table 2. In situ hybridization for clusterin mRNA
expression in blastocysts
Control Diabetic Incubation in Incubation




















Data are means ± s.e.m. with n representing the number of values. (**)
indicates P<0.0l.
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Fig. 10. Localization of
cells expressing clusterin
transcripts by ISH. HO
staining coupled with ISH
were used to identify the
cells overexpressing
clusterin in blastocysts. In
about half the cells found to





blastocyst from a diabetic
rat presented here (A,B;
arrows). Blastocysts
exposed to high D-glucose
and hybridized to the
control ISH probes did not
show any ISH signal (C).
The scale bar represents 10
pm in A,B and 30 pm in C.
data were consistent with the RT-PCR results. Experiments on
20 blastocysts exposed to high D-glucose and hybridized to the
control sense probes demonstrated the complete lack of non¬
specific signal (Fig. 10).
DISCUSSION
Cell death in blastocysts exposed to diabetes in
utero
Exposing blastocysts to the DNA fluorochromes HO and PI
following TE immunolysis showed that a high proportion of
cells identified as ICM cells showed signs of nuclear fragmen¬
tation in blastocysts from day 5 and day 6 diabetic rats. The fact
that these dying cells were stained only with HO indicated that
they were still delimited by intact membrane boundaries.
Although ICM cells in advanced degradation stages would take
PI when membrane integrity is lost and risk being miscounted
as TE cells, this possibility is considered as unlikely because
the proportion of cells with PI-stained nuclear fragments was
equally low in both embryo groups. Because cells in very early
stages of the suicidal process may already have subtle
chromatin alterations before nuclear fragmentation occurs, blas¬
tocysts were also examined using the TUNEL method coupled
with HO staining. This technique revealed the presence in blas¬
tocysts from day 5 diabetic rats of a population of dying cells
distinct from those identified on the basis of HO-stained nuclear
fragments. This distinction was confirmed when blastocysts
were investigated on day 6, with the additional observation of
yet another population of dying cells whose nuclei were dis¬
playing the two markers simultaneously (HO-stained DNA
particles within a TUNEL-positive nucleus). The observation
that not all TUNEL-positive nuclei were in the process of dis¬
integration, a phenomenon also recently described in mouse
blastocysts cultured under suboptimal conditions (Brison and
Schultz, 1997), is still unexplained, mostly because it is unclear
whether these two features form a directly coupled sequence of
nuclear events. Uncertainties as to the nature of the initial
event(s) leading to the DNA damages identified by the TUNEL
technique as well as the duration of fragmentation and TUNEL
detection in cells undergoing cell death also complicate the
interpretation (Gold et al., 1994; Didenko and Hornsby, 1996).
Although no attempt was made to combine TUNEL staining
with ICM-TE differential staining, it was clear that most of the
TUNEL-positive and/or fragmented nuclei were in cells
situated within the ICM region. To further describe the occur¬
rence of cell death in embryos, the mRNA expression of
clusterin was quantitated by RT-PCR and localized by ISH in
blastocysts from diabetic rats. Production of clusterin has been
associated with cell death in several systems (Buttyan et al.,
1989). One of its many proposed functions is the capture and
neutralization of cellular debris resulting from the degradation
of dying cells (Koch-Brandt and Morgans, 1996), a function
clusterin might perform for instance during the remodeling
process of blastocyst implantation (Brown et al., 1996).
According to the present study, control rat embryos were found
to start expressing clusterin mRNA at the blastocyst stage.
Previous studies have demonstrated that cells in the TE lineage
selectively expressed the gp330 clusterin receptor in the rat
(Sahali et al., 1993) as well as in the mouse (Guet-Hallonet et
al., 1994) blastocyst, findings that together with our data
support the concept that a clusterin / gp330-based system may
participate in the clearance of dead cell fragments inside
embryos. Compared with control blastocysts, the relative
amount of clusterin transcripts was increased two-fold in blas¬
tocysts from diabetic rats on day 5. Up-regulated clusterin
expression was confined to a very limited number of cells, many
of them displaying signs of nuclear fragmentation. Thus
analysis of clusterin expression on an individual basis revealed
a close correlation with the process of cell death in blastocysts.
Controversial results exist about whether cells accounting for
an elevation in clusterin expression within a site of cellular elim¬
ination are those undergoing cell death or neighboring cells
destined to survive. Studies aimed at identifying clusterin-
expressing cells and dying cells in the human thymus (French
et al., 1992) and in various lympho-hematopoietic cell lines
(French et al., 1994) support the idea that only viable cells
produce clusterin. In contrast, simultaneous display of nuclear
degradation and clusterin transcription has been reported in
individual glandular epithelial cells in the mouse uterus (Ahuja
et al., 1994). A reconciling view would be that, in certain situ¬
ations, such as in blastocysts, dying cells may engage into the
altruistic process of up-regulating their synthesis of clusterin in
order to facilitate the removal of their own debris by surround¬
ing clusterin receptor-expressing cells.
Cell death in blastocysts exposed to high glucose
Previous reports have shown that hyperglycemia per se is
directly toxic to certain cell populations, such as human endo¬
thelial cells (Lorenzi et al., 1985), and increases the expression
of several markers of active cell death (Baumgartner-Parzer et
al., 1995). Rat blastocysts incubated in high glucose were
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loss occurring mainly at the expense of the ICM. High glucose
also induced an five-fold increase of the proportion of ICM
cells displaying nuclear fragmentation within intact cell
membranes. When blastocysts were subjected to the TUNEL
technique paired with HO staining, both the F-labeling and T-
labeling indexes were found increased following culture in
high glucose. Substituting non-metabolizable L-glucose for D-
glucose in cultures demonstrated the specificity of the active
form of the nutrient. Additional experiments aimed at assessing
the expression of clusterin showed an increase in the relative
abundance of transcripts in blastocysts incubated in high
glucose. About half the cells expressing high levels of clusterin
transcripts also contain a fragmented nucleus, indicating again
a close relationship between individual cell death and clusterin
up-regulation. The mechanism by which moribund cells may
be cleared from within a blastocyst is not known. In contrast
with most situations where resident macrophages could rapidly
phagocytose cell fragments, the phagocytotic potential of
embryonic cells is probably limited (El-Shershaby and Hinch-
liffe, 1974). Embryonic dead cells that can not be phago-
cytosed by adjacent viable cells would therefore undergo in situ
degeneration or expulsion into the perivitelline space. Our
observations revealed the presence of such extruded cells (con¬
taining a fragmented nucleus within an intact cell membrane)
on the outer edge of several blastocysts. This was consistent
with a previous description of dead cell extrusion in blastocysts
from diabetic BB/E rats (Lea et al., 1996).
Cell death in blastocysts exposed to TNF-a
Previous studies have shown that the synthesis of TNF-a is up-
regulated in the uterus of the pregnant diabetic rat (Pampfer et
al., 1995a) as well as in primary cultures of rat uterine cells
incubated in high glucose (Pampfer et al., 1997). These data
suggest that blastocysts developing in diabetic rats may be
exposed to abnormally high concentrations of TNF-a. Cell
death induction is clearly one of the most prominent biologi¬
cal activities exerted by TNF-a (Nagata, 1997) and several
reproductive cell types, such as rat trophoblasts (Hunt et al.,
1989; Roby et al., 1994), have been shown to be sensitive to
the cytotoxic action of the cytokine. When rat recombinant
TNF-a was tested at a concentration about 5 times higher than
the circulating concentration of TNF-a in day 6 diabetic rats,
no significant increase was observed in the incidence of nuclear
fragmentation in blastocysts. These data confirmed earlier
results showing that mouse recombinant TNF-a could induce
a decrease in the total number of cells per rat blastocyst without
increasing the rate of nuclear fragmentation in these embryos
(Pampfer et al., 1994b) and were consistent with other obser¬
vations that DNA fragmentation is not always involved in the
cytotoxic process triggered by the cytokine (Mirkina et al.,
1996). This lack of nuclear fragmentation was tentatively
explained by the fact that rat blastocyst cells, like several other
cell types similarly resistant to TNF-a-induced DNA frag¬
mentation (Higuchi and Aggarwal, 1994), express only the p60
isoform of TNF-a receptor (Pampfer et al., 1995b). In contrast,
the cytokine was found to double the T-index and to triple the
F+T-index, thus confirming the ability of the cytokine to up-
regulate the expression of some markers of cell death in
embryos. The extent of the increase in T-index in rat blasto¬
cysts was consistent with the recently described 2.5-fold
increase in the proportion of TUNEL-positive cells among
TNF-a-treated human trophoblasts (Yui et al., 1994). Because
of previous indications that TNF-a can up-regulate clusterin
expression in mouse fibrosarcoma cells (Kyprianou et al.,
1991) and in human prostatic cells (Sensibar et al., 1995), it
was expected that TNF-a would increase the relative mRNA
level of clusterin in rat embryos. The data showed that the
cytokine did not influence the steady-state transcription level
of clusterin in blastocysts.
Cell death in blastocysts exposed to high glucose
and TNF-a
Co-exposure of the blastocysts to high glucose and TNF-a was
found to recapitulate the different effects observed in embryos
recovered from diabetic rats on day 6. Increases in all three
nuclear labeling indexes were detected after treatment with
high glucose and TNF-a. Clusterin mRNA expression was also
stimulated following this combined exposure. No additive
effect was seen in the frequency of TUNEL-positive nuclei, a
cell death parameter that was up-regulated by both glucose and
TNF-a, suggesting that the cell death mechanisms triggered by
the two effectors might converge at some limiting point.
CONCLUSION
Overall, the data demonstrate that several markers of active cell
death are increased in blastocysts exposed to maternal diabetes.
Excessive cell death occurred predominantly in the ICM. Incu¬
bation of normal blastocysts in high D-glucose, and to a lesser
extent in TNF-a, also increased the expression of these
markers. Because cell death is constitutively detected at a very
low level in control blastocysts, it is concluded that the del¬
eterious impact of maternal diabetes on embryo development
(Pampfer and De Hertogh, 1996) may be mediated by the inap¬
propriate up-regulation of this regular elimination process. The
observation of clusterin overexpression in blastocysts from
diabetic rats indicates that, in addition to suffering from a cell
deficiency in their vital ICM lineage, these embryos may be
affected by subtle disruptions in the expression pattern of
critical developmental genes.
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